Compositions and methods for crossing blood brain barrier
By combining targeted peptides with carbonic anhydrase IV, their activity is reduced, and the problem of insufficient permeability of the blood-brain barrier is solved, and efficient drug delivery to the central nervous system is achieved.
Patent Information
- Application Number
- CN202380035810.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-17
- Filing Date
- 2023-03-02
- Publication Date
- 2024-12-06
AI Technical Summary
The blood-brain barrier poses major challenges to central nervous system research and the delivery of therapy, mainly due to insufficient effective targets across the blood-brain barrier, which affects the efficiency of drug delivery.
By providing a targeted peptide capable of binding to carbonic anhydrase IV, increasing the permeability of the blood-brain barrier, the targeted peptide is used to bind to the zinc binding site and hydrophobic substrate binding site of carbonic anhydrase IV, reducing its activity, This improves the permeability of the blood-brain barrier and delivers the payload to the nervous system.
It significantly improves the permeability of the blood-brain barrier, increasing by at least 25%, 50%, 75% or more, greatly improving the efficiency of drug delivery to the central nervous system.
Smart Images

Figure CN119095865A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit under 35 USC §119(e) of U.S. Provisional Patent Application No. 63 / 316,298, filed on March 3, 2022, U.S. Provisional Patent Application No. 63 / 359,168, filed on July 7, 2022, and U.S. Provisional Patent Application No. 63 / 480,279, filed on January 17, 2023. The contents of these related applications are incorporated herein by reference in their entirety for all purposes.
[0003] Statement Regarding Federally Funded Research and Development
[0004] This invention was made with government support under Grant No. NS111369 awarded by the National Institutes of Health. The government has certain rights in this invention.
[0005] References to sequence listings
[0006] This application is submitted in electronic format along with a sequence listing. The sequence listing is provided as a file named 30KJ-302459-WO-SeqList with a size of 258 kilobytes created on March 2, 2023. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety. Technical Field
[0007] The present disclosure relates to methods and targeting peptides for crossing the blood-brain barrier. Background Art
[0008] The blood-brain barrier (BBB) is a fundamental bottleneck for the development of effective central nervous system (CNS) research tools and therapeutics. This structure consists primarily of brain endothelial cells, which require the delivery of macromolecules via invasive intracranial injections, technically challenging focused ultrasound, or receptor-mediated transcytosis. For a long time, the rational design of BBB-spanning macromolecules has been hampered by an incomplete understanding of the mechanisms involved in transcytosis, with only a few targets such as the transferrin receptor being validated for research and therapy.
[0009] Therefore, identification of targets, mechanisms, molecules, and methods for BBB crossing is needed to improve the efficiency of research tools and therapeutics for the CNS. Summary of the invention
[0010] Disclosed herein is a method for increasing the permeability of the blood-brain barrier. In some embodiments, the method includes providing a targeting peptide capable of binding to carbonic anhydrase IV, thereby increasing the permeability of the blood-brain barrier. In some embodiments, at least one activity of the carbonic anhydrase IV is reduced by binding to the targeting peptide. Also provided herein is a method for increasing the permeability of the blood-brain barrier. In some embodiments, the method includes reducing the activity of carbonic anhydrase IV, thereby increasing the permeability of the blood-brain barrier. In the methods disclosed herein, the targeting peptide can, for example, bind to the zinc binding site and / or hydrophobic substrate binding pocket of the carbonic anhydrase IV. In some embodiments, the permeability of the blood-brain barrier is increased by at least 25%, 50%, 75%, 100% or more, as compared to the absence of the target peptide or the reduction of carbonic anhydrase IV activity. Also provided herein is a method for delivering a payload to the nervous system. In some embodiments, the method includes providing a targeting peptide or a derivative thereof capable of binding to carbonic anhydrase IV, wherein the targeting peptide is part of a delivery system, and wherein the delivery system includes the payload to be delivered to the nervous system; and administering the delivery system to a subject.
[0011] As disclosed herein, the delivery system can, for example, include nanoparticles, nanotubes, nanowires, dendrimers, liposomes, ethosomes and aquasomes, polymer vesicles and nonionic surfactant vesicles (niosomes), foams, hydrogels, cubes, quantum dots, exosomes, macrophages and combinations thereof. In some embodiments, the delivery system includes a viral vector or a non-viral vector. The viral vector can, for example, include an adenoviral vector, an AAV vector, a lentiviral vector or a retroviral vector. In some embodiments, the target peptide is part of the capsid protein of the AAV vector. The AAV vector can be a vector selected from the following: AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-DJ, human isolate hu.31, human isolate hu.32, rhesus monkey isolate rh.8, rhesus monkey isolate rh.10 and variants thereof. In some embodiments, the AAV vector is AAV9. The non-viral vector can, for example, include lipid-based nanoparticles, polymer nanoparticles, inorganic nanoparticles, surfactant-based emulsions, nanowires, silica nanoparticles, peptide- or protein-based particles, lipid-polymer particles, nanolipoprotein particles, and combinations thereof.
[0012] In some embodiments, the payload to be delivered to the nervous system is a biological molecule, a non-biological molecule, or a combination thereof. The biological molecule may be a nucleic acid sequence, a protein, a peptide, a lipid, a polysaccharide, or a combination thereof. In some embodiments, the payload is a therapeutic molecule. In some embodiments, the nucleic acid sequence to be delivered to the nervous system includes one or more of the following: a) trophic factors, growth factors, or other soluble factors that may be released from transduced cells and affect the survival rate or function of the cell and / or surrounding cells; b) cDNAs that restore protein function to humans or animals carrying genetic mutations in genes; c) cDNAs encoding proteins that can be used to control or change the activity or state of cells; d) cDNAs encoding proteins or nucleic acids for assessing the state of cells; e) cDNAs and / or associated guide RNAs for genome engineering; f) sequences for genome editing by homologous recombination; g) DNA sequences encoding therapeutic RNAs; h) shRNA or artificial miRNA delivery systems; or i) DNA sequences that affect the splicing of endogenous genes.
[0013] In some embodiments, the carbonic anhydrase IV is a mouse carbonic anhydrase IV. In some embodiments, the carbonic anhydrase IV has an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the carbonic anhydrase IV is a human carbonic anhydrase IV. In some embodiments, the carbonic anhydrase IV has an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 180. In some embodiments, upon binding, the targeting peptide is capable of interacting with: (1) one or more positions functionally equivalent to S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 of the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV; or (2) one or more positions functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV. NO:180 of the amino acid sequence of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236. In some embodiments, the targeting peptide comprises (1) an amino acid sequence selected from the group consisting of SEQ ID NOs:70-174; or (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs:70-174. In some embodiments, the targeting peptide comprises an amino acid sequence selected from SEQ ID NOs:70-108. In some embodiments, the targeting peptide comprises an amino acid sequence selected from SEQ ID NOs:70-86. In some embodiments, the targeting peptide comprises (1) an amino acid sequence selected from the group consisting of AKPTPLLGLLQAQTG (SEQ ID NO: 70), AKPTPLLLLLQAQTG (SEQ ID NO: 71), AQPPLGGLLAQAQTG (SEQ ID NO: 72), AKPPGPWAEAQAQTG (SEQ ID NO: 73) and AQPPLLGGLAQAQTG (SEQ ID NO: 74); or (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 70-74. In some embodiments, the targeting peptide is inserted between two adjacent amino acids in AA587-594 of SEQ ID NO: 178 of the AAV9 vector, or between the functional equivalents of AA587-594 in an amino acid sequence at least 80% identical to SEQ ID NO: 178.In some embodiments, the targeting peptide is inserted between AA588-589 of SEQ ID NO: 178 of the AAV9 vector, or between the functional equivalents of AA588-589 in an amino acid sequence at least 80% identical to SEQ ID NO: 178. The AAV vector can be conjugated, for example, to a nanoparticle, a second molecule, or a combination thereof.
[0014] The administration can be systemic administration. In some embodiments, the administration is intravenous administration. In some embodiments, the administration is intrathecal administration. The subject can be, for example, a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a subject suffering from or at risk of suffering from one or more of the following: chronic pain, Friedreich's ataxia, Huntington's disease (Huntington's disease, HD), Alzheimer's disease (Alzheimer's disease, AD), Parkinson's disease (Parkinson's disease, PD), amyotrophic lateral sclerosis (ALS), type I and II spinal muscular atrophy (SMA I and II), Friedreich's ataxia (FA), spinocerebellar ataxia, multiple sclerosis (MS), chronic traumatic encephalopathy (CTE), HIV-1 related dementia or lysosomal storage diseases involving cells in the CNS. The lysosomal storage disease involving cells within the CNS can be, for example, Krabbe disease, Sandhoff disease, Tay-Sachs disease, Gaucher disease (type I, II or III), Niemann-Pick disease (NPC1 or NPC2 deficiency), Hurler syndrome, Pompe disease or Batten disease. In some embodiments, the subject is a subject who has, is at risk of, or has had a stroke, traumatic brain injury, epilepsy, or spinal cord injury.
[0015] Disclosed herein is an AAV capsid protein comprising a targeting peptide having binding specificity for carbonic anhydrase IV. In some embodiments, the targeting peptide is part of the capsid protein of the rAAV vector. In some embodiments, the targeting peptide is inserted between two adjacent amino acids in AA587-594 of SEQ ID NO: 178, or between the functional equivalents of AA587-594 in an amino acid sequence at least 80% identical to SEQ ID NO: 178. In some embodiments, the targeting peptide comprises (1) an amino acid sequence selected from the group consisting of SEQ ID NO: 70-174; (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 70-174. AAV can be, for example, AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-DJ, human isolate hu.31, human isolate hu.32, rhesus monkey isolate rh.8, rhesus monkey isolate rh.10, or a variant thereof. In some embodiments, the AAV vector is AAV9.
[0016] Disclosed herein is a recombinant adeno-associated virus (rAAV) comprising any one of the AAV capsid proteins disclosed herein. Disclosed herein is a rAAV comprising an AAV capsid protein comprising a targeting peptide having binding specificity to carbonic anhydrase IV, wherein the amino acid sequence of the targeting peptide is inserted between two adjacent amino acids in AA587-594 of the AAV capsid protein or their functional equivalents. In some embodiments, the two adjacent amino acids are AA588 and AA589. In some embodiments, the targeting peptide comprises (1) an amino acid sequence selected from SEQ ID NOs: 70-174; or (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from SEQ ID NOs: 70-174.
[0017] Disclosed herein is a composition comprising a drug for delivering a drug to the nervous system of a subject in need. In some embodiments, the composition includes an AAV comprising (1) any one of the AAV capsid proteins disclosed herein and (2) a drug to be delivered to the nervous system of the subject. In some embodiments, the nervous system is the central nervous system (CNS), the peripheral nervous system (PNS), or a combination thereof. The nervous system can be, for example, brain endothelial cells, neurons, capillaries in the brain, arterioles in the brain, arteries in the brain, or a combination thereof. In some embodiments, the composition is a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers. In some embodiments, the drug to be delivered includes a nucleic acid, a peptide, a small molecule, an aptamer, or a combination thereof.
[0018] Disclosed herein is an antibody or fragment thereof, wherein the antibody or fragment thereof comprises an amino acid sequence having binding specificity to carbonic anhydrase IV. In some embodiments, the antibody or fragment thereof comprises (1) an amino acid sequence selected from the group consisting of SEQ ID NO: 70-174; or (2) an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 70-174. In some embodiments, the antibody or fragment thereof is a bispecific antibody comprising at least one Fab having specificity to the carbonic anhydrase IV. Disclosed herein is an antibody conjugate comprising any one of the antibodies disclosed herein or a fragment thereof. In some embodiments, the antibody conjugate further comprises a therapeutic agent or a detectable label.
[0019] Disclosed herein is a peptide or a derivative or conjugate thereof that is specific for carbonic anhydrase IV. Disclosed herein is a nucleic acid that includes a sequence encoding any of the antibodies disclosed herein or a fragment thereof or any of the peptides disclosed herein or a derivative or conjugate thereof.
[0020] Disclosed herein is a delivery system comprising (1) a targeting peptide specific for carbonic anhydrase IV; and (2) an agent. In some embodiments, the targeting peptide (1) is displayed on the surface of the delivery system; or (2) is partially embedded in the delivery system. In some embodiments, the delivery system can be selected from nanoparticles, nanotubes, nanowires, dendrimers, liposomes, ethosomes and aquasomes, polymer vesicles and non-ionic surfactant vesicles, foams, hydrogels, cubes, quantum dots, exosomes, macrophages, and combinations thereof. In some embodiments, the delivery system comprises a viral vector or a non-viral vector. In some embodiments, the delivery system comprises a nanoparticle selected from the following: lipid-based nanoparticles, polymer nanoparticles, inorganic nanoparticles, surfactant-based emulsions, nanowires, silica nanoparticles, virus-like particles, peptide- or protein-based particles, lipid-polymer particles, nanolipoprotein particles, and combinations thereof.
[0021] Disclosed herein is a method for designing a targeting peptide specific for carbonic anhydrase IV. In some embodiments, the method comprises: generating one or more targeting peptides by computer simulation, each of which is capable of interacting with: (1) one or more positions functionally equivalent to S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 of the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV; or (2) one or more positions functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV. The position of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 of the amino acid sequence of NO:180. In some embodiments, generating the one or more targeting peptides by computer simulation comprises: generating a plurality of candidate peptides by computer simulation; performing a computer-assisted docking simulation on each of the plurality of candidate peptides bound to the carbonic anhydrase IV; and analyzing the structure of the carbonic anhydrase IV bound to one or more of the plurality of candidate peptides to identify one or more targeting peptides capable of interacting with: (1) one or more positions S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 that are functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV; or (2) one or more positions S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 that are functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV. NO:180 amino acid sequence S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 position. In certain embodiments, the method comprises: obtain the binding score of each candidate peptide in the multiple candidate peptides bound to the carbonic anhydrase IV; and select one or more candidate peptides with a binding score higher than a threshold value in the multiple candidate peptides as a targeting peptide specific to the carbonic anhydrase IV. In certain embodiments, the method comprises: compare the binding scores of two or more candidate peptides in the multiple candidate peptides to sort the candidate peptide sequence.In some embodiments, obtaining the binding score for each candidate peptide sequence in a plurality of candidate peptide sequences comprises (1) counting the total number of atoms in the interface between the candidate peptide and the carbonic anhydrase IV; (2) counting the total number of atoms in the candidate peptide that conflict with the carbonic anhydrase IV; (3) obtaining the binding angle of the candidate peptide; and (4) obtaining the binding depth of the candidate peptide.
[0022] Disclosed herein is a method for increasing the permeability of the blood-brain barrier of a murine species. In some embodiments, the method comprises: providing a targeting peptide capable of binding to Ly6c1, thereby increasing the permeability of the blood-brain barrier of these murine species. In some embodiments, the targeting peptide has 1) an amino acid sequence selected from the group consisting of AQRYQGDSVAQ (SEQ ID NO: 7), AQWSTNAGYAQ (SEQ ID NO: 8), AQERVGFAQAQ (SEQ ID NO: 9), AQWMTHGSAAQ (SEQ ID NO: 10), and SPRYKGDSVAQ (SEQ ID NO: 57); or (2) an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of AQRYQGDSVAQ (SEQ ID NO: 7), AQWSTNAGYAQ (SEQ ID NO: 8), AQERVGFAQAQ (SEQ ID NO: 9), AQWMTHGSAAQ (SEQ ID NO: 10), and SPRYKGDSVAQ (SEQ ID NO: 57). In some embodiments, the targeting peptide has the amino acid sequence of SPRYKGDSVAQ (SEQ ID NO: 57) or an amino acid sequence having at least 80% identity to SEQ ID NO: 57. In some embodiments, the targeting peptide is inserted between two adjacent amino acids in AA587-590 of SEQ ID NO:178, or between functional equivalents of AA587-590 in an amino acid sequence that is at least 80% identical to SEQ ID NO:178. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1A-Figure 1C Depicted are non-limiting exemplary embodiments and data related to the identification of engineered AAVs that do not utilize Ly6a for BBB crossing. Figure 1A It is depicted that AAV-PHP.eB can efficiently cross the BBB using membrane-localized Ly6a in C57BL / 6J mice but cannot use GPI-disrupted Ly6a in BALB / cJ mice. Figure 1BA cluster analysis of CNS-tropic engineered AAV insert sequences is depicted. The thickness of the connecting lines indicates the degree of correlation between nodes. The AAV in the upper left box shows a high correlation with PHP.eB. AAVs outside the box show little correlation with PHP.eB or with each other. The AA sequences inserted between positions 588-589 and 452-458 of the AAV9 capsid are shown for each variant. Figure 1C Depicted are surface plasmon resonance (SPR) of engineered AAV bound to Ly6a-Fc captured on a Protein A chip. Data are representative of 2 independent experiments.
[0024] Figure 2A-2C Depicted are non-limiting exemplary embodiments and data relating to the performance of Ly6a-independent AAV across mouse strains. Figure 2A Transduction by AAV-PHP.eB, AAV-PHP.N, AAV-PHP.C1-C4, and AAV-F in the thalamic region of 129S1 / SvlmJ (membrane-localized Ly6a), CBA / J (GPI-disrupted Ly6a), DBA / 2J (membrane-localized Ly6a), and NOD / ShiLtJ (GPI-disrupted Ly6a) mice is depicted as shown by sagittal brain sections. All images were acquired under the same image settings, except for the lower left quadrant of the cross-strain PHP.eB image optimized for DBA / 2J. The indicated capsids were used to package ssAAV:CAG-mNeonGreen and were administered to 6-8 week old adult mice (n=2 / group, 1×10 11 All images are from a single experiment where all viruses were freshly prepared and titrated in the same assay to ensure consistent dosing. Figure 2B A mouse phylogenetic tree including the strains used is depicted. Figure 2C Mean pixel intensity of thalamus across animals is depicted. Each data point represents one animal and the bar indicates the mean.
[0025] Figure 3A-3G Depicted are non-limiting exemplary embodiments and data related to novel receptors that enhance infectivity of engineered AAV in vitro. Figure 3A Depicts a plot of membrane protein differential expression scores in endothelial cells calculated in Scanpy relative to average transcript abundance in endothelial cells constructed from single-cell RNA sequencing of C57BL / 6J cortex. Proteins selected for cell culture screening are indicated by larger dots (Table 3), and hits are labeled and marked with a cross. Figure 3BDepicted is the screening of potential receptors in cell culture by comparing AAV fluorescent protein transgene levels at low multiplicity of infection (MOI) in mock-transfected cells and cells transfected with each potential receptor. Figure 3C The dose dependence of AAV9 and PHP.eB packaged with CAG-mNeonGreen in HEK293T cells in 96-well plates is shown. In Ly6a-transfected HEK293T cells, 1×10 9 At 1.34 vg / well, the potency of PHP.eB was significantly higher than that of AAV9. The scale shows the degree of infection (maximum: 0.75, minimum: 0.03) and the total brightness of each signal area (maximum: 0.79, minimum: 0.39). Figure 3D The efficacy of engineered AAV on HEK293T cells transfected with a panel of potential receptors is depicted. Infection degree (left, maximum: 0.33, minimum: 0.001; right, maximum: 0.55, minimum: 0.03). Total brightness of each signal area (left, maximum: 0.55, minimum: 0.06; right, maximum: 0.61, minimum: 0.11). Figure 3E Depicted are representative images of HEK cells cultured in 96-well plates that were mock-transfected (none) or transfected with potential receptors and cultured with 1 × 10 9 vg / well were infected with AAV packaged with CAG-mNeonGreen (left two columns are Ly6a-conjugated AAV) and imaged 24 hours after transduction. Overlays of brightfield and fluorescent images are presented. Scale bar = 200 μm. Figure 3F Depicted are the frequencies of amino acids by position in engineered AAVs found to have enhanced infectivity for Ly6a (6 viruses), Ly6c1 (SEQ ID NO:293; 9 viruses), and Car4 (SEQ ID NO:179; 2 viruses). Figure 3G The efficacy of engineered AAV on HEK293T cells transfected with Ly6 and potential receptors of the CAR family is depicted. Infection degree (left, maximum: 0.51, minimum: 0.03; right, maximum: 0.52, minimum: 0.05). The total brightness of each signal area (left, maximum: 0.75, minimum: 0.13; right, maximum: 0.79, minimum: 0.34).
[0026] Figure 4A-4C Depicted are non-limiting exemplary embodiments and data related to the role of carbonic anhydrase IV in the CNS efficacy of Car4-dependent AAV. Figure 4A Immunostaining of Car4 in the brain of WT / WT and KO / KO Car4 mice is depicted. Magnified regions of WT / WT show endothelial expression across different brain regions. Figure 4BDepicted are fluorescent images of transgene expression assays in whole brain and liver of WT / WT Car4 mice administered AAV-PHP.eB, 9P31, and 9P36. AAV-PHP.eB, 9P31, and 9P36 packaged with mNeonGreen were expressed at 3 × 10 11 Doses of vg / animal were intravenously administered to WT / WT Car4 mice (n=3 for each condition). Three weeks after administration, transgene expression in the whole brain and liver was determined by mNeonGreen fluorescence. Figure 4C Depicted are fluorescent images of transgene expression assays in whole brain and liver of KO / KO Car4 mice administered AAV-PHP.eB, 9P31, and 9P36. AAV-PHP.eB, 9P31, and 9P36 packaged with mNeonGreen were expressed at 3×10 11 Doses of vg / animal were intravenously administered to KO / KO Car4 mice (n=3 for each condition). Three weeks after administration, transgene expression in whole brain and liver was determined by mNeonGreen fluorescence. Scale bar=2 mm.
[0027] Figure 5A-5D Depicted are non-limiting exemplary embodiments and data related to the engineering of enhanced Ly6c1-dependency AAVs. Figure 5A AAV library design strategy is depicted. Scanning 3-mer libraries of PHP.C1-C4 were constructed as shown, where X indicates the position of NNK codons. AAVs were pooled and two rounds of M-CREATE selection were performed in Cre transgenic mice at 6-8 weeks of age. Figure 5B Depicts the second round of selection for brain enrichment in different Cre transgenic and wild-type mice administered with the selected control AAV and 20 capsid variants selected for further study. Yields were determined during small-scale production for final screening across strains. Figure 5C Depicts PHP.eB, PHP.C2, and PHP.eC ( Figure 5B The potency of variant 19 in a cell culture infectivity assay of HEK293T cells transfected with mock (none) or Ly6c1 receptor, thus indicating that PHP.eC retains Ly6c1 interaction. Degree of infection (maximum: 0.93, minimum: 0.02). Total brightness per signal area (maximum: 0.74, minimum: 0.16). Figure 5D Depicted are fluorescent images of transgene expression assays in whole brain and liver of NOD / ShiLtJ and BALB / cJ mice administered PHP.C2 and PHP.eC packaged with mNeonGreen under the control of the ubiquitous CAG promoter.11 Doses of vg / animal were intravenously administered to NOD / ShiLtJ and BALB / cJ mice (n=3 for each condition). Three weeks after administration, transgene expression in the whole brain and liver was measured by mNeonGreen fluorescence, indicating enhanced efficacy of PHP.eC. Sagittal images Scale bar = 2 mm. Brain region Scale bar = 250 μm.
[0028] Figure 6A-6G Depicted are non-limiting exemplary embodiments and data related to computer simulated predictions of the pose of the engineered AAV receptor and Ly6a interaction complex. Fig. 6A Depicted is an overview of the AlphaFold2-based in silico automated pairwise peptide-receptor analysis (APPRAISE-AAV) for screening engineered AAVs. Surface peptides of AAV variants are subjected to pairwise binding competition using AlphaFold2. Peptide competition metrics are calculated based on the interface energy, binding angle, and pocket depth of each peptide, which are then assembled into a more extensively ranked interaction probability matrix. Competition results reflect the relative peptide binding probabilities encoded in the AlphaFold2 neural network. Figure 6B Depicted is a table of engineered AAV capsids, their confirmed receptors, and capsid peptide sequences for APPRAISE-AAV. Figure 6C Depicted is a matrix ranking AAV peptides by their average competition metrics across ten replicate conditions for Ly6a, Ly6c1, and mouse Car4. Bold AAV peptide labels indicate experimentally identified AAV peptides that interact with the corresponding receptor. Metric values outside the range (-100-100) are clamped to the range limits. Fig.6D Depicted is the structure of the Ly6a-PHP.eB peptide complex predicted by AlphaFold2. The PHP.eB peptide is colored by the pLDDT (prediction local distance difference test) score, which is a per-residue estimate of model confidence. The highest confidence side chains P5' and F6' are shown as spheres. The Ly6a A58R mutation was selected to disrupt the predicted peptide interaction, resulting in reduced efficacy in the cell culture infectivity assay. Infection degree (maximum: 0.29, minimum: 0.03). The total brightness of each signal area (maximum: 0.61, minimum: 0.16). Fig. 6E The 5 angstrom of the modeled PHP.eB peptide is depicted. There are at least 2 Ly6a residues in the . Fig. 6F The complete model of the PHP.eB trimer and Ly6a complex is depicted. Fig.6D The AlphaFold2 structure prediction in was combined with the capsid monomer-receptor structure prediction and optimized using Rosetta Remodel in the context of AAV trimers ( Fig.13A ). Figure 6G Depicts the PHP.eB-Ly6a binding interface and the location of Ly6a in the modeled PHP.eB-Ly6a complex. Zoomed in view of PHP.eB residues with at least 2 atoms in between.
[0029] Figure 7A-7D Depicted are non-limiting exemplary embodiments and data related to the interaction of engineered AAV with carbonic anhydrase IV. Fig. 7A Depicted is the AlphaFold2 predicted structure of the mouse Car4-9P31 peptide complex. The 9P31 peptide is colored by the pLDDT score at each residue, with the highest confidence side chains shown as spheres. Figure 7B A cross-sectional view of the mouse Car4 catalytic pocket with the modeled 9P31 peptide binding pose (top left) and the crystallized brinzolamide binding pose (PDB ID: 3ZNC, top right) is depicted. Cell culture infectivity assay of the effect of brinzolamide on engineered AAV (bottom). Infection degree (maximum: 0.63, minimum: 0.04). Total brightness per signal area (maximum: 0.75, minimum: 0.18). Figure 7C Depicted is a view of the amino acid side chains that differ between mouse (PDB ID: 3ZNC) and human (PDB ID: 1ZNC) carbonic anhydrase IV in their brinzolamide and 9P31 peptide binding poses. Fig.7D Depicted are the potencies of 9P31 and 9P36 in cell culture infectivity assays of HEK293T cells transfected with mouse, rhesus or human carbonic anhydrase IV receptors and two chimeric receptors of the depicted loop sequences swapped for mouse and human carbonic anhydrase IV. Degree of infection (left, maximum: 0.52, minimum: 0.05, right, maximum: 0.65, minimum: 0.03). Total brightness per signal area (left, maximum: 0.78, minimum: 0.46, right, maximum: 0.75, minimum: 0.13).
[0030] Figure 8A-8C Depicted are non-limiting exemplary embodiments and data related to low-dose AAV performance across mouse strains. Fig. 8A Depicted with Figure 2A Mid-orbital injection 1×10 11 Sagittal sections of 129S1 / SvlmJ, CBA / J, DBA / 2J, and NOD / ShiLtJ mice with engineered AAV packaged with CAG-mNeonGreen vg / animal correspond to low-dose AAV performance across mouse strains (n=2). Mice were 6-8 weeks old at the time of injection, and tissues were collected 3 weeks after injection. Scale bar = 2 mm. Figure 8B Depicted is a retro-orbital injection of 1 × 10 11Quantification of mean fluorescence intensity in the thalamus region of male and female 129S1 / SvlmJ and CBA / J mice packaged with CAG-mNeonGreen PHP.C1 or PHP.C2 (n=2) of vg / animal. Mice were 6-8 weeks old at the time of injection. Tissues were collected 3 weeks after injection. Each data point represents one animal, and the bars indicate the mean. Figure 8C AAV-PHP.C3 efficacy in C57BL / 6J, CBA / J, and F1 hybrid mice is depicted. Animals were injected retro-orbitally at 6-8 weeks of age with 3 × 10 11 Vg was packaged with AAV-PHP.C3 containing CAG-mNeonGreen. Tissues were collected three weeks after injection. The thalamus was imaged to determine viral potency.
[0031] Figure 9A-9C Depicted are non-limiting exemplary embodiments and data associated with representative images from cell culture infectivity assays. Fig. 9A Depicted are fluorescent images showing the dose dependence of AAV9 and PHP.eB packaged with CAG-mNeonGreen in HEK293T cells in 96-well plates. In Ly6a-transfected HEK293T cells, 1×10 9 At 144 vg / well, the potency of PHP.eB was significantly higher than that of AAV9. Representative images are shown. Scale bar = 500 μm. Fig. 9B Depicted are representative images of HEK cells cultured in 96-well plates that were mock-transfected (none) or transfected with potential receptors and cultured with 1 × 10 9 vg / well were infected with PHP.B family AAV (labeled "Ly6a AAV" is Ly6a-binding) or Ly6a-independent AAV (labeled "Ly6a-independent AAV") packaged with CAG-mNeonGreen and imaged 24 hours after transduction. Overlays of brightfield and fluorescent images are presented. Scale bar = 200 μm. Fig. 9C Depicted are representative images of HEK cells cultured in 96-well plates that were mock transfected (None) or transfected with Ly6a or Slco1c1. Slco1c1-infected cells showed dim and diffuse fluorescence that extended beyond the cell borders for each AAV tested. Overlays of brightfield and fluorescence images are presented. Scale bar = 200 μm.
[0032] Fig. 10ADepicted are non-limiting exemplary embodiments and data related to the expression of selected membrane proteins from cell culture screening confirmed by immunofluorescence. DAPI and immunofluorescence (IF) overlays for untransfected and receptor-transfected HEK293T cells stained with the indicated antibodies, and separate IF channels (on the left) for receptor-transfected HEK293T cell images. Scale bar = 50 μm. Fig. 10B Depicted are non-limiting exemplary bright field (left side of each column) and fluorescence (right side of each column) images of PHP.eB, PHP.N and CAP-B10 packaged with CAG-mNeonGreen and CAP-B22 packaged with CAG-NLS-GFP in mock-transfected cells expressing Ly6a at two different doses. Ly6a-interacting AAVs engineered by PHP.eB showed the same degree of potency enhancement in cell culture. Scale bar = 100 μm. Fig. 10C Non-limiting exemplary embodiments and data related to the efficacy of CAP-B10 and CAP-B22 are depicted. CAP-B10 and CAP-B22 did not show enhanced efficacy against marmoset Ly6 protein. The efficacy of engineered AAV against HEK293T cells transfected with potential receptors is shown. Infection degree (maximum: 0.52, minimum: 0.05). Total brightness per signal area (maximum: 0.79, minimum: 0.17).
[0033] Fig.11A Non-limiting exemplary embodiments and data related to the performance of PHP.N, AAV9, and PHP.eB are depicted. At high doses, PHP.N outperformed AAV9 and PHP.eB in CBA / J mice. Animals were injected retro-orbitally with 1×10 12 vg was injected with AAV9, PHP.eB or PHP.N packaged with CAG-mNeonGreen (n=3). Four weeks after injection, tissues were collected and imaged to detect viral efficacy. Each data point in the quantification of mean pixel intensity of the thalamus represents one animal, and the bar indicates the mean. Fig. 11B Depicted are non-limiting exemplary embodiments and data related to the quantification of AAV potency in WT and Car4-KO mice. The mean pixel intensity of whole brain sagittal sections and liver sections was quantified. Each individual data point was then normalized to the mean PHP.eB intensity. Each data point represents one animal, and the bar indicates the mean.
[0034] Fig.12Depicted are non-limiting exemplary embodiments and data related to enriched capsid variants during M-CREATE selections. Capsids selected in rounds 1 and 2 were ranked according to their enrichment scores using either M-CREATE Cre-dependent or Cre-independent recovery. Sequence frequency plots represent the pattern of the most enriched variants in each round and each selection type.
[0035] Figures 13A-13D Depicted are non-limiting exemplary embodiments and data related to a snapshot of the PHP.eB-Ly6a interaction generated by an integrated structural modeling approach. Fig.13A Depicted is the workflow for modeling engineered AAV-receptor complex structures (PHP.eB: colored by pLDDT score, Ly6a: indicated by arrow). Fig. 13B Depicts a comparison between the computationally modeled PHP.eB-Ly6a and the CryoEM structure of unbound PHP.eB (PDB ID: 7WQO). All high confidence residues (pLDDT>45, see left inset arrow) inserted into the peptide show consistent conformations between the two models, except for F6' which has no clear side chain density in the CryoEM map. The F6' side chain predicted in the unbound PHP.eB model will cause steric clashes in the predicted complex model. Fig. 13C Depicted is the assembled PHP.eB capsid-Ly6a model, which, despite steric clashes, represents the ensemble of all Ly6a-bound states, as would occur in a cryo-EM particle reconstruction (PHP.eB: colored by pLDDT score, Ly6a: indicated by arrows). Top: Cross-section of the assembled capsid model. Middle: Zoomed-in 3-fold spike, highlighting steric clashes between the three different binding states. Fig.13D Depicted are superimposed structures of the CryoEM models of computationally modeled PHP.eB-Ly6a (PHP.eB: rainbow colors) and PHP.eB-AAVR PKD2 (PDB ID: 7WQP).
[0036] Figure 14A-14B Depicted are non-limiting exemplary embodiments and data related to modeling peptide complexes with Ly6c1 and mouse Car4. Fig.14A Depicted is a comparison between computationally modeled PHP.C2-Ly6c1 binding poses predicted by AlphaFold-Multimer v1 and v2. PHP.C2 peptides are colored by residues according to pLDDT scores. Ly6c1 residues selected for mutation are shown as spheres. Also shown is the potency of PHP.C2 against HEK293T cells transfected with wild-type or mutant Ly6c1 receptors ( Fig.14A(Continued)). Infection level (maximum: 0.67, minimum: 0.13). Total brightness of each signal area (maximum: 0.72, minimum: 0.31). Fig. 14B The top five AlphaFold2 predicted mouse CAR4-9P31 and CAR4-9P36 peptide complex structures are depicted, with the 9P31 and 9P36 peptides colored by the pLDDT score at each residue, and the potency of 9P31 and 9P36 against HEK293T cells transfected with wild-type or mutant CAR4 receptors aimed at disrupting putative site 2 binding. Degree of infection (top, maximum: 0.99, minimum: 0.12, bottom, maximum: 0.67, minimum: 0.13). The total brightness of each signal area (top, maximum: 0.89, minimum: 0.33, bottom, maximum: 0.72, minimum: 0.31). DETAILED DESCRIPTION
[0037] In the following detailed description, reference is made to the accompanying drawings which form a part of the detailed description. In the accompanying drawings, similar symbols generally identify similar components unless the context indicates otherwise. The illustrative embodiments described in the specific embodiments, drawings, and claims are not intended to be limiting. Other embodiments may be utilized and other changes may be made without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that, as generally described herein and as illustrated in the accompanying drawings, aspects of the present disclosure may be arranged, substituted, combined, separated, and designed into a variety of different configurations, all of which are expressly contemplated herein and are a part of the disclosure herein.
[0038] All patents, published patent applications, other publications, and sequences from GenBank, and other databases mentioned herein are incorporated by reference in their entirety with respect to the relevant art.
[0039] Disclosed herein are methods for increasing the permeability of the blood-brain barrier. In some embodiments, the method comprises providing a targeting peptide capable of binding to carbonic anhydrase IV, thereby increasing the permeability of the blood-brain barrier.
[0040] Disclosed herein are methods for increasing the permeability of the blood-brain barrier. In some embodiments, the method comprises reducing carbonic anhydrase IV activity, thereby increasing the permeability of the blood-brain barrier.
[0041] Disclosed herein are methods for delivering a payload to the nervous system. In some embodiments, the method comprises providing a targeting peptide or a derivative thereof capable of binding to carbonic anhydrase IV, wherein the targeting peptide is part of a delivery system, and wherein the delivery system comprises a nucleic acid sequence to be delivered to the nervous system; and administering the delivery system to a subject. In some embodiments, the delivery system is an AAV vector. Disclosed herein are also recombinant AAV (rAAV) vectors comprising a targeting peptide having binding specificity to carbonic anhydrase IV.
[0042] Disclosed herein include antibodies or fragments thereof. In some embodiments, antibodies or fragments thereof include peptides or portions thereof that are specific for carbonic anhydrase IV. Antibodies or fragments thereof may include (1) an amino acid sequence selected from SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174; (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174. Disclosed herein include antibody conjugates comprising antibodies or fragments thereof disclosed herein. In some embodiments, the antibody conjugates may further include a therapeutic agent or a detectable label. Disclosed herein include peptides or derivatives thereof or conjugates that are specific for carbonic anhydrase IV. Disclosed herein include nucleic acids that include sequences encoding antibodies or fragments thereof or peptides or derivatives thereof or conjugates disclosed herein.
[0043] Disclosed herein are delivery systems comprising (1) a targeting peptide specific for carbonic anhydrase IV; and (2) an agent.
[0044] Disclosed herein are methods for designing targeting peptides specific for carbonic anhydrase IV. In some embodiments, the method comprises: generating one or more targeting peptides by computer simulation, wherein the one or more targeting peptides are capable of interacting with: (1) one or more positions functionally equivalent to S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 of the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV; or (2) one or more positions functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV. The position of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 of the amino acid sequence of NO:180.
[0045] Disclosed herein are methods for increasing the permeability of the blood-brain barrier of murine species. In some embodiments, the method comprises: providing a targeting peptide capable of binding to Ly6c1, thereby increasing the permeability of the blood-brain barrier of these murine species.
[0046] definition
[0047] Unless otherwise defined, technical terms and scientific terms used herein all have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs.See, for example, Singleton et al., Dictionary of Microbiology and Molecular Biology, 2nd edition, J. Wiley & Sons (New York, NY, 1994); Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (Cold Spring Harbor, NY, 1989). For the purposes of the present disclosure, the following terms are defined below.
[0048] As used herein, the terms "nucleic acid" and "polynucleotide" are interchangeable and may refer to any nucleic acid, whether composed of phosphodiester bonds or modified bonds, such as phosphotriester bonds, phosphoamidate bonds, siloxane bonds, carbonate bonds, carboxymethyl ester bonds, acetamidate bonds, carbamate bonds, thioether bonds, bridged phosphoramidate bonds, bridged methylenephosphonate bonds, bridged phosphoramidate bonds, bridged phosphoramidate bonds, bridged methylenephosphonate bonds, phosphorothioate bonds, methylphosphonate bonds, phosphorodithioate bonds, bridged phosphorothioate bonds or sultone bonds and combinations of such bonds. The terms "nucleic acid" and "polynucleotide" also specifically include nucleic acids composed of bases other than the five biologically present bases (adenine, guanine, thymine, cytosine and uracil).
[0049] As used herein, the term "vector" may refer to a vehicle for carrying or transferring nucleic acid. Non-limiting examples of vectors include plasmids and viruses (eg, AAV viruses).
[0050] As used herein, the term "construct" may refer to a recombinant nucleic acid that has been generated for the purpose of expressing a specific nucleotide sequence, or a recombinant nucleic acid to be used to construct other recombinant nucleotide sequences.
[0051] As used herein, the term "plasmid" may refer to a nucleic acid that can be used to replicate a recombinant DNA sequence in a host organism. The sequence may be double-stranded DNA.
[0052] The term "viral genome" refers to a nucleic acid sequence flanked by cis-acting nucleic acid sequences that mediate the packaging of the nucleic acid into a viral capsid. For example, for AAV and parvovirus, the "inverted terminal repeats" (ITRs) located at the 5' and 3' ends of the viral genome are known to have this function, and the ITRs can mediate the packaging of heterologous viral genomes (e.g., non-wild-type viral genomes) into viral capsids.
[0053] The term "element" may refer to a separate or different part of something, such as a nucleotide sequence with a separate function in a longer nucleotide sequence. The terms "regulatory element" and "expression control element" are used interchangeably herein, and refer to nucleic acid molecules that can affect the expression of operably connected coding sequences in a specific host organism. These terms are widely used in and encompass all elements that promote or regulate transcription, including core elements, upstream elements, enhancers and response elements required for the basic interaction of promoters, RNA polymerases and transcription factors (see, for example, Lewin, "Genes V" (Oxford University Press, Oxford) 847-873 pages). Exemplary regulatory elements in prokaryotes include promoters, operator sequences and ribosome bind sites. Regulatory elements for eukaryotic cells may include, but are not limited to, transcription and translation control sequences, such as promoters, enhancers, splicing signals, polyadenylation signals, terminators, protein degradation signals, internal ribosome entry elements (IRES), 2A sequences, etc., which provide and / or regulate the expression of the coding sequence in the host cell and / or the generation of encoded polypeptides.
[0054] As used herein, the term "promoter" is a nucleotide sequence that allows RNA polymerase to bind and direct gene transcription. Typically, the promoter is located in the 5' non-coding region of the gene, close to the transcription start site of the gene. The sequence elements that initiate transcription in the promoter are generally characterized by a common nucleotide sequence. Examples of promoters include but are not limited to promoters from bacteria, yeast, plants, viruses, and mammals (including humans). Promoters can be inducible, repressible, and / or constitutive. Inducible promoters initiate transcription levels from DNA in response to some changes in culture conditions (such as temperature changes) under their control.
[0055] As used herein, the term "enhancer" refers to a regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the transcription start site.
[0056] As used herein, the term "operably connected" is used to describe the connection between a regulatory element and a gene or its coding region. Typically, gene expression is controlled by one or more regulatory elements, such as, but not limited to, constitutive or inducible promoters, tissue-specific regulatory elements, and enhancers. A gene or coding region is referred to as being "operably connected" or "operably connected" or "operably associated" with a regulatory element, which means that the gene or coding region is controlled or affected by the regulatory element. For example, if a promoter affects the transcription or expression of a coding sequence, the promoter is operably connected to the coding sequence.
[0057] As used herein, the term "polypeptide" is intended to encompass the singular "polypeptide" as well as the plural "polypeptide", and refers to a molecule consisting of monomers (amino acids) linearly connected by amide bonds (also referred to as peptide bonds). The term "polypeptide" refers to any one or more chains of two or more amino acids, and does not refer to the specific length of the product. Therefore, peptides, dipeptides, tripeptides, oligopeptides, "proteins", "amino acid chains" or any other terms used to refer to one or more chains of two or more amino acids are included in the definition of "polypeptide", and the term "polypeptide" can be used to replace any of these terms or to be used interchangeably with them. The term "polypeptide" is also intended to refer to the product of post-expression modification of the polypeptide, which post-expression modifications include but are not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization of known protection / blocking groups, proteolytic cleavage or modification of non-naturally occurring amino acids. The polypeptide can be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a specified nucleic acid sequence. The polypeptide can be generated in any manner, including by chemical synthesis.
[0058] As used herein, the term "variant" may refer to a polynucleotide or polypeptide having a sequence substantially similar to a reference polynucleotide or polypeptide. In the case of a polynucleotide, a variant may have a deletion, substitution and / or addition of one or more nucleotides at a 5' end, a 3' end and / or one or more internal sites compared to a reference polynucleotide. The similarity and / or diversity of sequences between a variant and a reference polynucleotide may be detected using conventional techniques known in the art, such as polymerase chain reaction (PCR) and hybridization techniques. Variant polynucleotides also include synthetically derived polynucleotides, such as polynucleotides generated by using site-directed mutagenesis. Typically, variants of polynucleotides, including but not limited to DNA, can have at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity with a reference polynucleotide, as determined by sequence alignment programs known to those skilled in the art. In the case of polypeptides, variants can have one or more amino acid deletions, substitutions, additions compared to a reference polypeptide. The similarity and / or differences in sequence between a variant and a reference polypeptide can be detected using conventional techniques known in the art, such as Western blots. Generally, variants of a polypeptide may have at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity to a reference polypeptide as determined by sequence alignment programs known to those of skill in the art.
[0059] As used herein, "sequence identity" or "identity" in the context of two nucleic acids or polypeptide sequences refers to the nucleotide bases or amino acid residues that are identical in the two sequences when aligned for maximum correspondence over a specified comparison window. When referring to percent sequence identity or similarity of proteins, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, in which an amino acid residue is substituted with a functionally equivalent residue having similar physiochemical properties and thus does not alter the functional properties of the molecule.
[0060] As used herein, the functional equivalent residue of amino acid can generally refer to other amino acid residues having substantially similar physiochemical and stereochemical properties to the original amino acid. Physiological chemical properties include water solubility (hydrophobicity or hydrophilicity), dielectric and electrochemical properties, physiological pH, partial charge (positive, negative or neutral) of the side chain, and other properties that can be identified by those skilled in the art. Stereochemical properties include the spatial and conformational arrangement of amino acids and their chirality. For example, in the sense of the present disclosure, glutamic acid is considered to be a functionally equivalent residue to aspartic acid. Tyrosine and tryptophan are considered to be functionally equivalent residues to phenylalanine. Arginine and lysine are considered to be functionally equivalent residues to histidine.
[0061] As used herein, the term "binding" refers to a non-covalent interaction between macromolecules (e.g., between two proteins and / or peptides). When in a non-covalent interaction state, the macromolecules are said to be "associated" or "interacting" or "bound" (e.g., when molecule X is said to interact with molecule Y, this means that molecule X binds to molecule Y in a non-covalent manner). The binding interaction can be characterized by a dissociation constant (Kd), for example, a Kd of or less than 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M, 10 -13 M, 10 -14 M, 10 -15 M or a value or range between any two of these values. Kd may depend on environmental conditions, such as pH and temperature. "Affinity" refers to the strength of binding, and increased binding affinity is associated with a lower Kd.
[0062] The words "specific", "specifically" or "specificity" used when referring to the combination of the first molecule and the second molecule herein refer to recognition, contact and formation of a stable complex between the first molecule and the second molecule, and substantially less recognition, contact or formation of a stable complex to no recognition, contact or formation of a stable complex between each molecule in the first molecule and the second molecule and other molecules that may exist. Exemplary specific binding is antibody-antigen interaction, cell receptor-ligand interaction, polynucleotide hybridization, enzyme substrate interaction, etc. The term "specificity" used when referring to the molecular components of the complex herein refers to the unique association of a component with a specific complex as a part of the component. The term "specificity" used when referring to the sequence of polynucleotides herein refers to the unique combination of a sequence with a single polynucleotide as a complementary sequence. "Stable complex" means a detectable complex, and does not require any arbitrary level of stability, although generally preferred is higher stability. The term "specific", "specifically" or "specificity" used when referring to the combination of the targeting peptide and carbonic anhydrase IV herein refers to the ability of the targeting peptide to form a stable complex with carbonic anhydrase IV, wherein the combination with the macromolecule except the carbonic anhydrase IV that may exist is significantly less to no combination. The terms "specific," "specifically," or "specificity" as used herein in reference to the binding of a targeting peptide to carbonic anhydrase IV also refer to the ability of carbonic anhydrase IV to form a stable complex with the targeting peptide, wherein there is significantly less to no binding to candidate peptides other than the identified targeting peptide that may be present.
[0063] The term "AAV" or "adeno-associated virus" refers to a dependent parvovirus within the Parvovirus genus of viruses. For example, the AAV can be an AAV derived from a naturally occurring "wild-type" virus, an AAV derived from a rAAV genome packaged into a capsid derived from a capsid protein encoded by a naturally occurring cap gene, and / or an AAV packaged into a rAAV genome derived from a capsid protein encoded by a non-natural capsid cap gene. Non-limiting examples of AAV include AAV type 1 (AAV1), AAV type 2 (AAV2), AAV type 3 (AAV3), AAV type 4 (AAV4), AAV type 5 (AAV5), AAV type 6 (AAV6), AAV type 7 (AAV7), AAV type 8 (AAV8), AAV type 9 (AAV9), AAV type 10 (AAV10), AAV type 11 (AAV11), AAV type 12 (AAV12), AAV type DJ (AAV-DJ), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV. In some cases, AAV is described as "primate AAV", which refers to AAV that infects primates. Similarly, AAV can infect bovine animals (e.g., "bovine AAV", etc.). In some cases, AAV is wild-type or naturally occurring. In some cases, AAV is recombinant.
[0064] As used herein, the term "AAV capsid" refers to a capsid protein or peptide of an adeno-associated virus. In some cases, the AAV capsid protein is configured to encapsulate genetic information (e.g., heterologous nucleic acid, transgene, therapeutic nucleic acid, viral genome). In some cases, the AAV capsid of the present disclosure is a variant AAV capsid, which means that in some cases it is a parent or wild-type AAV capsid that has been modified in the amino acid sequence of the parent AAV capsid protein.
[0065] As used herein, the term "AAV genome" may refer to a nucleic acid polynucleotide encoding genetic information associated with a virus. In some cases, the genome includes a nucleic acid sequence flanked by AAV inverted terminal repeat (ITR) sequences. The AAV genome may be a rAAV genome generated using a recombinant genetics approach, and the rAAV genome may include and / or be flanked by an ITR sequence. A heterologous nucleic acid (e.g., a transgene) may be included and / or flanked by an ITR sequence.
[0066] The term "rAAV" refers to "recombinant AAV". In some embodiments, the recombinant AAV has an AAV genome in which some or all of the rep and cap genes have been replaced by heterologous sequences. As used interchangeably herein, the terms "AAV particle", "AAV nanoparticle" or "AAV vector" refer to an AAV virus or virion comprising an AAV capsid, within which is packaged a heterologous DNA polynucleotide or "genome" comprising a nucleic acid sequence flanked by AAV ITR sequences. In some cases, the AAV particle is modified relative to the parent AAV particle.
[0067] The term "cap gene" refers to a nucleic acid sequence encoding a capsid protein that forms or contributes to the formation of the capsid or protein coat of a virus. In the case of AAV, the capsid protein may be VP1, VP2, or VP3. For other parvoviruses, the names and numbers of the capsid proteins may be different.
[0068] The term "rep gene" refers to the nucleic acid sequence encoding the nonstructural proteins (rep78, rep68, rep52 and rep40) required for viral replication and production.
[0069] The terms "native" and "wild-type" are used interchangeably herein and may refer to a form of a polynucleotide, gene or polypeptide as found in nature with its own regulatory sequences, if any.
[0070] As used herein, "endogenous" refers to the native form of a polynucleotide, gene, or polypeptide in its natural location in an organism or in the genome of an organism. "Endogenous polynucleotides" include native polynucleotides in their natural location in the genome of an organism. "Endogenous genes" include native genes in their natural location in the genome of an organism. "Endogenous polypeptides" include native polypeptides in their natural location in an organism.
[0071] As used herein, "heterologous" refers to polynucleotides, genes or polypeptides that are not normally present in a host organism but are introduced into a host organism. "Heterologous polynucleotides" include natural coding regions or parts thereof that are reintroduced into a source organism in a form different from the corresponding natural polynucleotides. "Heterologous genes" include natural coding regions or parts thereof that are reintroduced into a source organism in a form different from the corresponding natural genes. For example, a heterologous gene may include a natural coding region that is a part of a chimeric gene that includes a non-natural regulatory region that is reintroduced into a natural host. "Heterologous polypeptides" include natural polypeptides that are reintroduced into a source organism in a form different from the corresponding natural polypeptides. Subject genes and proteins can be fused with other genes and proteins to produce chimeric or fusion proteins. According to embodiments disclosed in this theme, useful genes and proteins include not only the full-length sequences specifically exemplified, but also parts, segments and / or fragments (including continuous fragments and internal and / or terminal deletions compared to full-length molecules), variants, mutants, chimeras and fusions thereof of these sequences.
[0072] As used herein, the term "exogenous" gene is meant to encompass all genes that do not naturally occur within the genome of an individual. For example, miRNA can be introduced exogenously by a virus (e.g., AAV nanoparticles).
[0073] As used herein, "antibody" or "antigen-binding polypeptide" refers to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen. An antibody can be a whole antibody and any antigen-binding fragment or single chain thereof. Therefore, the term "antibody" includes any protein or peptide containing molecule that includes at least a portion of an immunoglobulin molecule with biological activity that binds to an antigen. Examples of this class include, but are not limited to, a heavy or light chain complementary determining region (CDR) or a ligand binding portion thereof, a heavy or light chain variable region, a heavy or light chain constant region, a framework (FR) region or any portion thereof, or at least a portion of a binding protein.
[0074] As used herein, the term "antibody fragment" or "antigen binding fragment" is a portion of an antibody, such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv, etc. Regardless of the structure, the antibody fragment will bind to the same antigen recognized by the intact antibody. The term "antibody fragment" includes aptamers, spirochetes, and diabodies. The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts as an antibody by binding to a specific antigen to form a complex.
[0075] As used herein, "subject" refers to an animal that is the object of treatment, observation or experiment. "Animal" includes cold-blooded and warm-blooded vertebrates and invertebrates, such as fish, crustaceans, reptiles and particularly mammals. As used herein, "mammal" refers to an individual belonging to the mammal class, and includes but is not limited to people, livestock animals and farm animals, zoo animals, sports animals and pet animals. Non-limiting examples of mammals include mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cattle, horses, primates, such as monkeys, chimpanzees and apes and particularly people. In certain embodiments, mammals are people. However, in certain embodiments, mammals are not people. In certain embodiments, subjects are rodents (e.g., rats or mice). In certain embodiments, subjects are primates (e.g., people or monkeys).
[0076] As used herein, the term "treatment" refers to an intervention made in response to a disease, illness or physiological condition exhibited by a patient. The goal of treatment may include but is not limited to one or more of the following: alleviating or preventing symptoms, slowing down or preventing the progression or deterioration of a disease, illness or condition, and alleviating diseases, illnesses and conditions. The term "treatment (treat and treatment)" includes, for example, therapeutic treatment, preventive treatment and one of the applications that reduces the risk of a subject having a disease or other risk factor. Treatment does not require a complete cure of the disease and encompasses one of the embodiments that reduces symptoms or potential risk factors. In certain embodiments, "treatment" refers to both therapeutic treatment and preventive or preventive measures. Subjects in need of treatment include subjects who have been affected by a disease or disease or an undesirable physiological condition, and subjects who want to prevent a disease, disease or an undesirable physiological condition. As used herein, the term "prevention" refers to any activity that alleviates the burden of those symptoms that an individual later exhibits. This can be done at the primary, secondary and / or tertiary prevention levels, where: a) primary prevention avoids the development of symptoms / disorders / conditions; b) secondary prevention activities are aimed at the early stages of treatment of conditions / disorders / symptoms, thereby increasing the chances of intervention to prevent the progression of conditions / disorders / symptoms and the onset of symptoms; and c) tertiary prevention reduces the negative impact of established conditions / disorders / symptoms by, for example, restoring function and / or reducing any conditions / disorders / symptoms or associated complications. The term "prevention" does not require 100% elimination of the likelihood of an event. Rather, it means that the likelihood of an event occurring has been reduced in the presence of a compound or method.
[0077] As used herein, the term "effective amount" refers to an amount sufficient to affect beneficial or desired biological and / or clinical outcomes.
[0078] As used herein, the term "pharmaceutically acceptable" carrier is a carrier that is non-toxic to cells or mammals exposed thereto at the doses and concentrations employed. A "pharmaceutically acceptable" carrier may be, but is not limited to, an organic or inorganic, solid or liquid excipient suitable for the selected mode of application (such as oral application or injection), and is administered in the form of a conventional pharmaceutical preparation, such as solids such as tablets, granules, powders, capsules, and liquids such as solutions, emulsions, and suspensions. Typically, a physiologically acceptable carrier is a pH buffered aqueous solution, such as a phosphate buffer or a citrate buffer. A physiologically acceptable carrier may also include one or more of the following: antioxidants, including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin; gelatin; immunoglobulins; hydrophilic polymers, such as polyvinyl pyrrolidone; amino acids; carbohydrates, including glucose, mannose or dextrin; chelating agents, such as EDTA; sugar alcohols, such as mannitol or sorbitol; salt-forming counterions, such as sodium; and nonionic surfactants, such as Tween TM , polyethylene glycol (PEG) and Pluronics TM Adjuvants, stabilizers, emulsifiers, lubricants, binders, pH adjusters, control agents, isotonicity agents and other conventional additives may also be added to the carrier.
[0079] The blood-brain barrier (BBB) presents a significant challenge for the delivery of large molecules to the central nervous system (CNS). This is in part due to the paucity of effective targets for BBB crossing, and the identification of these effective targets is a crucial first step in drug development.
[0080] Disclosed herein are novel receptors (e.g., carbonic anhydrase IV) on the BBB interface for enhancing BBB crossing, and related methods using them to increase the permeability of the BBB and deliver agents to the nervous system (e.g., CNS). Disclosed herein are also targeting peptides or derivatives thereof that can be combined with receptors (e.g., carbonic anhydrase IV) that the BBB crosses disclosed herein, and recombinant AAV vectors, antibodies or fragments thereof, peptides or derivatives thereof including targeting peptides or derivatives thereof. Disclosed herein are also methods for designing targeting peptides with binding specificity to carbonic anhydrase IV. The identification of carbonic anhydrase IV and structural insights based on computational modeling provide new paths for human brain permeability chemicals (drugs) and biologics (including gene delivery).
[0081] Receptors for enhanced blood-brain barrier crossing
[0082] The blood-brain barrier (BBB) has become a complex, dynamic, adaptable interface that controls the exchange of substances between the central nervous system (CNS) and the blood to prevent substances from leaking uncontrolled from the blood into the brain. The cells that constitute the BBB structure mainly include brain endothelial cells, which constantly communicate with other cells of the CNS (e.g., astrocytes, microglia, neurons, mast cells and pericytes, and circulating immune cells), thereby adjusting their behavior to meet the needs of the CNS, responding to pathological conditions, and participating in the onset, maintenance or progression of the disease in some cases. The complexity of BBB function explains most of the difficulties in developing drugs that can cross the BBB. Utilizing receptors on the BBB interface can provide a method for crossing the BBB.
[0083] Disclosed herein are novel receptors comprising novel receptors on the BBB interface and methods of using them to enhance BBB crossing and CNS efficacy, such as increasing the permeability of the BBB and delivering therapeutic agents across the BBB to the nervous system. In some embodiments, the receptor for enhancing BBB crossing is carbonic anhydrase IV. In some embodiments, the BBB crossing receptor is Ly6c1. Without being bound by any theory, the novel target receptors disclosed herein can promote enhanced BBB receptor-mediated transcytosis across various species (including mammals such as humans).
[0084] In some embodiments, the method of increasing the permeability of the BBB includes providing a targeting peptide that can bind to a BBB-spanning receptor (e.g., carbonic anhydrase IV or lymphocyte antigen 6 complex, locus C1 (Ly6c1)), thereby increasing the permeability of the BBB (e.g., by transcytosis). In some embodiments, at least one activity of a BBB-spanning receptor (e.g., carbonic anhydrase IV or Ly6c1) can be reduced by binding to a targeting peptide. Therefore, in some embodiments, the method of increasing the permeability of the BBB includes reducing the activity of carbonic anhydrase IV or Ly6c1, thereby increasing the permeability of the BBB. In some embodiments, the targeting peptide binds to one or more sites in the zinc binding site (e.g., catalytic pocket) and substrate binding site of carbonic anhydrase IV. Carbonic anhydrase IV can be a vertebrate carbonic anhydrase IV, including non-human primates and humans. In some embodiments, carbonic anhydrase IV is mouse carbonic anhydrase IV (Car4), human carbonic anhydrase IV (CA4) or a variant or homolog thereof. In some embodiments, the targeting peptide binds to Ly6c1 in a murine species, thereby increasing the permeability of the blood-brain barrier of the murine species.
[0085] Carbonic Anhydrase IV
[0086] In some embodiments, the BBB-spanning receptor disclosed herein that can facilitate delivery of an agent across the BBB is carbonic anhydrase IV. Carbonic anhydrase IV is an isozyme belonging to the carbonic anhydrase family, which is a family of zinc metalloenzymes that catalyzes the reversible reaction of CO2 hydration. Enables enzymes to regulate CO2, H + and HCO3 - concentration. Carbonic anhydrase is involved in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. Carbonic anhydrase shows a wide variety in terms of tissue distribution and its subcellular localization. Mammalian carbonic anhydrase has at least seven genetically distinct isozymes, referred to as I-VII, each of which catalyzes the reversible hydration of carbon dioxide by a zinc hydroxide mechanism. Physiological functions regulated by carbonic anhydrase include, for example, the removal of HCO in the lungs by respiration. 3- , HCO in the kidney 3- Carbonic anhydrase family members also play important roles in metabolic processes including ureagenesis, gluconeogenesis, and lipogenesis.
[0087] Unlike other carbonic anhydrases that are soluble or attached to the plasma membrane via a transmembrane domain, carbonic anhydrase IV is a glycosylphosphatidyl-inositol-anchored membrane isozyme. Carbonic anhydrase IV is widely conserved in vertebrates and has a similar CNS expression profile in humans, with recent single-cell analysis of the human brain vasculature confirming CA4 expression in the human BBB. Carbonic anhydrase IV has been shown to regulate pH, which is associated with neural firing and can affect neuronal function through ion-gated channels.
[0088] In some embodiments, the carbonic anhydrase IV disclosed herein is human carbonic anhydrase IV (CA4). CA4 is known to be localized on the luminal surface of brain endothelial cells throughout the cortex and cerebellum, where it enzymatically regulates carbon dioxide-bicarbonate balance. Human CA4 has previously been characterized as a 35-kDa protein that is "highly active" in CO2 hydration and is active in catalyzing HCO3 -It has higher activity than other isozymes in dehydration. Generally speaking, human CA4 contains a signal sequence of 18 amino acids at the N-terminus of the protein that translocates in the endoplasmic reticulum (ER), and a "CA domain" of 260 amino acids containing active site amino acid residues showing 30-36% homology with cytoplasmic CA. At the C-terminus, the front of the additional 27 amino acid residues containing a hydrophobic sequence of 21 amino acids sufficient to cross the membrane is a signal sequence of 6 amino acids for GPI anchoring. Amino acid residue Ser 266 was identified as the attachment site of the GPI anchor. Removal of the C-terminal hydrophobic domain present in the CA4 precursor has an important effect on GPI anchoring, cell surface expression and enzyme activity. Based on the amino acid sequence deduced from the nucleotide sequence, human CA4 does not contain the classical consensus site (Asn-Xxx-Ser / Thr) for N-glycosylation. Human CA4 also contains no oligosaccharide chains, whereas other mammalian carbonic anhydrase IVs (eg, mouse carbonic anhydrase IV (Car4)) are glycoproteins with one to several oligosaccharide side chains.
[0089] In some embodiments, carbonic anhydrase IV disclosed herein is mouse carbonic anhydrase IV (Car4). According to recent discoveries, Car4 is one of the mouse proteins with the strongest positive correlation with plasma-protein uptake in the brain (slightly stronger than the transferrin receptors commonly targeted). This property can be used to identify receptors for enhanced BBB crossing. Car4 is also expressed in the GI tract, kidney and lung, and taste receptor cells that make it sense carbonation. Mouse Car4 and human CA4 have a high degree of homology, containing the same amino acids at positions (e.g., histidine residue 64 (His 64)) that are critical for enzyme activity, with several differences including, for example, mouse Car4 is an N-linked glycoprotein, and compared with human CA4, the CO2 hydration rate catalyzed by mouse Car4 is much lower. Without being bound by any theory, the lower enzyme activity of mouse Car4 may be related to several other amino acid substitutions such as the replacement of Gly 63 in human CA4 by Gln 63. Another difference between mouse Car4 and human CA4 is the Val-131-Asp-136 segment (segment of 130), which forms an α-helix in mouse Car4 and an extended loop in human CA4.
[0090] In some embodiments, the carbonic anhydrase IV (CAR4) disclosed herein as a receptor for enhancing BBB crossing can be any carbonic anhydrase IV, such as mouse CAR4, human CA4, or a homologue or variant thereof. Carbonic anhydrase IV homologues and / or variants can be derived from vertebrate species, including but not limited to mice, rats, humans, cattle, rabbits, monkeys, pigs, horses, rainbow trout, chimpanzees, squirrels, chickens, goats, and sheep. Carbonic anhydrase IV homologues from various species can be found in public databases identifiable by those skilled in the art, including, for example, UniProt, NCBI, and Swiss-Prot.
[0091] In some embodiments, mouse CA4 disclosed herein as a receptor for enhancing BBB crossing comprises a sequence having SEQ ID NO: 179. In some embodiments, human CA4 disclosed herein as a receptor for enhancing BBB crossing comprises a sequence having SEQ ID NO: 180. In some embodiments, a receptor disclosed herein for enhancing BBB crossing is a carbonic anhydrase IV homolog or variant of human CA4 (e.g., SEQ ID NO: 180) or mouse CA4 (SEQ ID NO: 179). Carbonic anhydrase IV homologs and variants are SEQ ID NO: 179 or SEQ ID NO: 180. %, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) are identical.
[0092] In some embodiments, the targeting peptide can be combined with carbonic anhydrase IV disclosed herein (e.g., mouse CA4, human CA4, or its homologue or variant), thereby increasing the permeability of the BBB (e.g., by transcytosis). In some embodiments, the increase in the permeability of the BBB is achieved by changing (e.g., increasing or decreasing) carbonic anhydrase IV activity, such as reducing its activity.
[0093] In some embodiments, the change in carbonic anhydrase IV activity is achieved by combining a targeting peptide with one or more active sites of carbonic anhydrase IV (comprising a zinc binding site and a hydrophobic substrate binding pocket). For example, a targeting peptide can be combined with a zinc binding site, a hydrophobic substrate binding pocket, or both.
[0094] The zinc binding site in carbonic anhydrase IV has a conserved structure dominated by a β-sheet superstructure, with the metal binding site formed by at least three His residues. Without being bound by any theory, it is believed that the zinc binding site is located at The hydrophobic pocket is located on one face of the β-sheet at the bottom of a deep conical active site cleft, wherein zinc is coordinated by three His residues and a hydroxide ion with a tetrahedral geometry. The hydrophobic substrate binding pocket is adjacent to the zinc-bound hydroxide and is formed to a large extent by bulky residues such as Val at its base and Val, Trp and Leu at its neck. Based on phylogenetic comparisons, this pocket is highly conserved in all active isozymes. Without being bound by any theory, it is believed that the hydrophobic pocket has the minimum width and depth for efficient catalysis, and the linear free energy relationship shows that the volume of the amino acid residues at the base of the pocket and the hydrophobicity of the residues at the neck of the pocket are crucial for activity. Both the zinc binding site and the hydrophobic substrate binding pocket in the carbonic anhydrase isozyme are highly conserved.
[0095] The targeting peptide can bind to one or more conserved amino acid residues at the interaction site of carbonic anhydrase IV. In some embodiments, computational modeling methods (e.g., AlphaFolder2-multimer) can be used to predict peptide interaction sites on carbonic anhydrase IV (e.g., mouse CA4) (e.g., AAV interaction sites when the peptide is part of an AAV capsid). Table 1 provides a list of AAV interaction sites predicted by Alphafold2-multimer on corresponding residues in mouse carbonic anhydrase IV and human CA4.
[0096]
[0097] In some embodiments, the targeting peptide can interact with one or more positions functionally equivalent to S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223 or W228 in the carbonic anhydrase IV having an amino acid sequence of SEQ ID NO: 179. In some embodiments, the target peptide can interact with one or more positions functionally equivalent to S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 in the carbonic anhydrase IV having an amino acid sequence of SEQ ID NO: 180.
[0098] Lymphocyte antigen 6
[0099] In some embodiments, the BBB-spanning receptor disclosed herein that is capable of enhancing BBB crossing when bound to a targeting peptide in a murine species is lymphocyte antigen 6 complex locus C1 (Ly6c1). Ly6c1 is a glycosylphosphatidyl-inositol anchored (GPI-anchored) protein and belongs to the Ly6 family of GPI-anchored surface glycoproteins. Ly6, known as lymphocyte antigen 6 or urokinase-type plasminogen activator receptor, is a closely related family of murine glycoproteins that share a common structure but differ in tissue expression patterns and function. Ly6 family proteins are structurally related proteins characterized by the LU domain, an 80 amino acid domain containing ten cysteines arranged in a specific spacing pattern that allows for the generation of different disulfide bridges of a three-finger structural motif. Ly6c1 can be used as a novel receptor that serves as a powerful research tool in mice, including, for example, designing an enhanced AAV capsid for Ly6c1 using a combination of directed evolution and computer simulation design.
[0100] In some embodiments, the Ly6c1 receptor disclosed herein as a receptor for enhanced BBB crossing can be mouse Ly6c1 or a homolog or variant thereof. In some embodiments, the Ly6c1 receptor from house mouse (Mus musculus) has an amino acid sequence of SEQ ID NO: 293 (Uniprot accession number: P0CW02). In some embodiments, in some embodiments, the Ly6c1 receptor disclosed herein for enhancing BBB crossing is a homolog or variant thereof of SEQ ID NO: 293. %, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) are identical.
[0101] In some embodiments, the targeting peptide can bind to Ly6c1 disclosed herein, thereby increasing the permeability of the BBB in a murine species. The murine species can be a species selected from the family Muridae, the subfamily Murinae, the genus Murus, and / or the subgenus Murus.
[0102] Screening of targeting peptides and in silico simulations
[0103] Methods of using the receptors described herein to increase the permeability of the BBB and deliver agents to the nervous system across the BBB include providing a targeting peptide that is capable of binding to a BBB-spanning receptor disclosed herein (e.g., Ly6c1 or carbonic anhydrase IV) or has binding specificity for a BBB-spanning receptor (e.g., Ly6c1 or carbonic anhydrase IV, such as Car4 and CA4).
[0104] Targeting peptides against carbonic anhydrase IV
[0105] In some embodiments, the method comprises providing to the subject a targeting peptide capable of binding to carbonic anhydrase IV or a targeting peptide having binding specificity for carbonic anhydrase IV (eg, Car4 and CA4).
[0106] The targeting peptide can be combined with the zinc binding site and / or the hydrophobic substrate binding pocket of carbonic anhydrase IV as described above, thereby changing the activity of carbonic anhydrase IV (for example, reducing carbonic anhydrase IV activity). The length of the targeting peptide can be about, at least or at most 4-15 (for example, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15) amino acids.
[0107] The targeting peptide can include (1) an amino acid sequence selected from SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174; (2) an amino acid sequence having at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) sequence identity to an amino acid sequence selected from SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174.
[0108] The targeting peptide may include an amino acid sequence selected from SEQ ID NO: 70-108. The targeting peptide may include an amino acid sequence selected from SEQ ID NO: 70-86. The targeting peptide may include an amino acid sequence selected from AKPTPLLGLLQAQTG (SEQ ID NO: 70), AKPTPLLLLLQAQTG (SEQ ID NO: 71), AQPPLGGLLAQAQTG (SEQ ID NO: 72), AKPPGPWAEAQAQTG (SEQ ID NO: 73) or AQPPLLGGLAQAQTG (SEQ ID NO: 74). In some embodiments, the targeting peptide comprises an amino acid sequence having at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) sequence identity to an amino acid sequence selected from SEQ ID NOs: 70-74.
[0109] Targeting peptide can comprise at least 4 continuous amino acids from sequence AKPTPLLGLLQAQTG (SEQ ID NO:70).For example, targeting peptide can comprise the sequence of KPTP (SEQ ID NO:181), PTPL (SEQ ID NO:182), TPLL (SEQ ID NO:183), PLLG (SEQ ID NO:184), LLGL (SEQ ID NO:185), LGLL (SEQ ID NO:186) or GLLQ (SEQ ID NO:187).Targeting peptide can comprise at least 5 continuous amino acids from sequence AKPTPLLGLLQAQTG (SEQ ID NO:70).For example, targeting peptide can comprise the sequence of KPTPL (SEQ ID NO:188), PTPLL (SEQ ID NO:189), TPLLG (SEQ ID NO:190), PLLGL (SEQ ID NO:191), LLGLL (SEQ ID NO:192) or LGLLQ (SEQ ID NO:193). Targeting peptide can comprise at least 6 continuous amino acids from sequence AKPTPLLGLLQAQTG (SEQ ID NO:70).For example, targeting peptide can comprise the sequence of KPTPLL (SEQ ID NO:194), PTPLLG (SEQ ID NO:195), TPLLGL (SEQ ID NO:196), PLLGLL (SEQ ID NO:197) or LLGLLQ (SEQ ID NO:198).Targeting peptide can comprise at least 7 continuous amino acids from sequence AKPTPLLGLLQAQTG (SEQ ID NO:70).For example, targeting peptide can comprise the sequence of KPTPLLG (SEQ ID NO:199), PTPLLGL (SEQ ID NO:200), TPLLGLL (SEQ ID NO:201) or PLLGLLQ (SEQ ID NO:202).Targeting peptide can comprise at least 8 continuous amino acids from sequence AKPTPLLGLLQAQTG (SEQ ID NO:70). For example, the targeting peptide can include the sequence of KPTPLLGL (SEQ ID NO:203), PTPLLGLL (SEQ ID NO:204) or TPLLGLLQ (SEQ ID NO:205). The targeting peptide can include at least 9 continuous amino acids from the sequence AKPTPLLGLLQAQTG (SEQ ID NO:70). For example, the targeting peptide can include the sequence of KPTPLLGLL (SEQ ID NO:206) or PTPLLGLLQ (SEQ ID NO:207).In some embodiments, the targeting peptide comprises AKPTPLLGLLQAQTG (SEQ ID NO: 70).
[0110] Targeting peptide can comprise at least 4 continuous amino acids from sequence AKPTPLLLLLQAQTG (SEQ ID NO:71).For example, targeting peptide can comprise the sequence of KPTP (SEQ ID NO:181), PTPL (SEQ ID NO:182), TPLL (SEQ ID NO:183), PLLL (SEQ ID NO:208), LLLL (SEQ ID NO:209) or LLLQ (SEQ ID NO:210).Targeting peptide can comprise at least 5 continuous amino acids from sequence AKPTPLLLLLQAQTG (SEQ ID NO:71).For example, targeting peptide can comprise the sequence of KPTPL (SEQ ID NO:188), PTPLL (SEQ ID NO:189), TPLLL (SEQ ID NO:211), PLLLL (SEQ ID NO:212), LLLLL (SEQ ID NO:213) or LLLLQ (SEQ ID NO:214). Targeting peptide can include at least 6 continuous amino acids from sequence AKPTPLLLLLQAQTG (SEQ ID NO:71).For example, targeting peptide can include the sequence of KPTPLL (SEQ ID NO:194), PTPLLL (SEQ ID NO:215), TPLLLL (SEQ ID NO:216), PLLLLL (SEQ ID NO:217) or LLLLLQ (SEQ ID NO:218).Targeting peptide can include at least 7 continuous amino acids from sequence AKPTPLLLLLQAQTG (SEQ ID NO:71).For example, targeting peptide can include the sequence of KPTPLLL (SEQ ID NO:219), PTPLLLL (SEQ ID NO:220), TPLLLLL (SEQ ID NO:221) or PLLLLLQ (SEQ ID NO:222).Targeting peptide can include at least 8 continuous amino acids from sequence AKPTPLLLLLQAQTG (SEQ ID NO:71). For example, the targeting peptide can include the sequence of KPTPLLLLL (SEQ ID NO:223), PTPLLLLL (SEQ ID NO:224) or TPLLLLLQ (SEQ ID NO:225). The targeting peptide can include at least 9 continuous amino acids from the sequence AKPTPLLLLLQAQTG (SEQ ID NO:71). For example, the targeting peptide can include the sequence of KPTPLLLLL (SEQ ID NO:226) or PTPLLLLLQ (SEQ ID NO:227). In certain embodiments, the targeting peptide includes AKPTPLLLLLQAQTG (SEQ ID NO:71).
[0111] The targeting peptide can include at least 4 continuous amino acids from sequence AQPPLGGLLAQAQTG (SEQ ID NO:72). For example, the targeting peptide can include the sequence of PPLG (SEQ ID NO:228), PLGG (SEQ ID NO:229), LGGL (SEQ ID NO:230), GGLL (SEQ ID NO:231), GLLA (SEQ ID NO:232) or LLAQ (SEQ ID NO:233). The targeting peptide can include at least 5 continuous amino acids from sequence AQPPLGGLLAQAQTG (SEQ ID NO:72). For example, the targeting peptide can include the sequence of PPLGG (SEQ ID NO:234), PLGGL (SEQ ID NO:235), LGGLL (SEQ ID NO:236), GGLLA (SEQ ID NO:237) or GLLAQ (SEQ ID NO:238). The targeting peptide can include at least 6 continuous amino acids from sequence AQPPLGGLLAQAQTG (SEQ ID NO:72). For example, the targeting peptide can include the sequence of PPLGGL (SEQ ID NO:239), PLGGLL (SEQ ID NO:240), LGGLLA (SEQ ID NO:241) or GGLLAQ (SEQ ID NO:242). The targeting peptide can include at least 7 continuous amino acids from the sequence AQPPLGGLLAQAQTG (SEQ ID NO:72). For example, the targeting peptide can include the sequence of PPLGGLL (SEQ ID NO:243), PLGGLLA (SEQ ID NO:244) or LGGLLAQ (SEQ ID NO:245). The targeting peptide can include at least 8 continuous amino acids from the sequence AQPPLGGLLAQAQTG (SEQ ID NO:72). For example, the targeting peptide can include the sequence of PPLGGLLA (SEQ ID NO:246) or PLGGLLAQ (SEQ ID NO:247). In certain embodiments, the targeting peptide includes AQPPLGGLLAQAQTG (SEQ ID NO:72).
[0112] Targeting peptide can include at least 4 continuous amino acids from sequence AKPPGPWAEAQAQTG (SEQ ID NO:73). For example, targeting peptide can include the sequence of KPPG (SEQ ID NO:248), PPGP (SEQ ID NO:249), PGPW (SEQ ID NO:250), GPWA (SEQ ID NO:251), PWAE (SEQ ID NO:252), WAEA (SEQ ID NO:253) or AEAQ (SEQ ID NO:254). Targeting peptide can include at least 5 continuous amino acids from sequence AKPPGPWAEAQAQTG (SEQ ID NO:73). For example, targeting peptide can include the sequence of KPPGP (SEQ ID NO:255), PPGPW (SEQ ID NO:256), PGPWA (SEQ ID NO:257), GPWAE (SEQ ID NO:258), PWAEA (SEQ ID NO:259) or WAEAQ (SEQ ID NO:260). The targeting peptide can include at least 6 continuous amino acids from the sequence AKPPGPWAEAQAQTG (SEQ ID NO:73). For example, the targeting peptide can include the sequence of KPPGPW (SEQ ID NO:261), PPGPWA (SEQ ID NO:262), PGPWAE (SEQ ID NO:263), GPWAEA (SEQ ID NO:264) or PWAEAQ (SEQ ID NO:265). The targeting peptide can include at least 7 continuous amino acids from the sequence AKPPGPWAEAQAQTG (SEQ ID NO:73). For example, the targeting peptide can include the sequence of KPPGPWA (SEQ ID NO:266), PPGPWAE (SEQ ID NO:267), PGPWAEA (SEQ ID NO:268) or GPWAEAQ (SEQ ID NO:269). The targeting peptide can include at least 8 continuous amino acids from the sequence AKPPGPWAEAQAQTG (SEQ ID NO:73). For example, the targeting peptide can include the sequence of KPPGPWAE (SEQ ID NO:270), PPGPWAEA (SEQ ID NO:271) or PGPWAEAQ (SEQ ID NO:272). The targeting peptide can include at least 9 continuous amino acids from the sequence AKPPGPWAEAQAQTG (SEQ ID NO:73). For example, the targeting peptide can include the sequence of KPPGPWAEA (SEQ ID NO:273) or PPGPWAEAQ (SEQ ID NO:274).In some embodiments, the targeting peptide comprises AKPPGPWAEAQAQTG (SEQ ID NO: 73).
[0113] Targeting peptide can comprise at least 4 continuous amino acids from sequence AQPPLLGGLAQAQTG (SEQ ID NO:74).For example, targeting peptide can comprise the sequence of PPLL (SEQ ID NO:275), PLLG (SEQ ID NO:184), LLGG (SEQ ID NO:276), LGGL (SEQ ID NO:230), GGLA (SEQ ID NO:277) or GLAQ (SEQ ID NO:278).Targeting peptide can comprise at least 5 continuous amino acids from sequence AQPPLLGGLAQAQTG (SEQ ID NO:74).For example, targeting peptide can comprise the sequence of PPLLG (SEQ ID NO:279), PLLGG (SEQ ID NO:280), LLGGL (SEQ ID NO:281), LGGLA (SEQ ID NO:282) or GGLAQ (SEQ ID NO:283). Targeting peptide can include at least 6 continuous amino acids from sequence AQPPLLGGLAQAQTG (SEQ ID NO:74). For example, targeting peptide can include the sequence of PPLLGG (SEQ ID NO:284), PLLGGL (SEQ ID NO:285), LLGGLA (SEQ ID NO:286) or LGGLAQ (SEQ ID NO:287). Targeting peptide can include at least 7 continuous amino acids from sequence AQPPLLGGLAQAQTG (SEQ ID NO:74). For example, targeting peptide can include the sequence of PPLLGGL (SEQ ID NO:288), PLLGGLA (SEQ ID NO:289) or LLGGLAQ (SEQ ID NO:290). Targeting peptide can include at least 8 continuous amino acids from sequence AQPPLLGGLAQAQTG (SEQ ID NO:74). For example, targeting peptide can include the sequence of PPLLGGLA (SEQ ID NO:291) or PLLGGLAQ (SEQ ID NO:292). In some embodiments, the targeting peptide comprises AQPPLLGGLAQAQTG (SEQ ID NO: 74).
[0114] Targeting peptides against Ly6c1
[0115] In some embodiments, the method includes providing a targeting peptide capable of binding to Ly6c1 or a targeting peptide having binding specificity to Ly6c1 in a subject (eg, a mouse).
[0116] The targeting peptide may include 1) an amino acid sequence selected from the group consisting of AQFVVGQSYAQ (SEQ ID NO:6), AQRYQGDSVAQ (SEQ ID NO:7), AQWSTNAGYAQ (SEQ ID NO:8), AQERVGFAQAQ (SEQ ID NO:9), AQWMTHGSAAQ (SEQ ID NO:10), AQWPTSYDAAQ (SEQ ID NO:11), DGSSSYYDAAQ (SEQ ID NO:12), AQGENPGRWAQ (SEQ ID NO:13), DGTGQVTGWAQ (SEQ ID NO:14), DGTGSTTGWAQ (SEQ ID NO:15), and SPRYKGDSVAQ (SEQ ID NO:57); or (2) an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of AQFVVGQSYAQ (SEQ ID NO:6), AQRYQGDSVAQ (SEQ ID NO:7), AQWSTNAGYAQ (SEQ ID NO:8), AQERVGFAQAQ (SEQ ID NO:9), AQWMTHGSAAQ (SEQ ID NO:10), AQWPTSYDAAQ (SEQ ID NO:11), DGSSSYYDAAQ (SEQ ID NO:12), AQGENPGRWAQ (SEQ ID NO:13), DGTGQVTGWAQ (SEQ ID NO:14), DGTGSTTGWAQ (SEQ ID NO:15), and SPRYKGDSVAQ (SEQ ID NO:57). NO:7), AQWSTNAGYAQ (SEQ ID NO:8), AQERVGFAQAQ (SEQ ID NO:9), AQWMTHGSAAQ (SEQ ID NO:10), AQWPTSYDAAQ (SEQ ID NO:11), DGSSSYYDAAQ (SEQ ID NO:12), AQGENPGRWAQ (SEQ ID NO:13), DGTGQVTGWAQ (SEQ ID NO:14), DGTGSTTGWAQ (SEQ ID NO:15) and SPRYKGDSVAQ (SEQ ID NO:57).
[0117] In some embodiments, the targeting peptide comprises the amino acid sequence of SPRYKGDSVAQ (SEQ ID NO:57), or an amino acid sequence having at least (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) sequence identity to SPRYKGDSVAQ (SEQ ID NO:57).
[0118] In silico screening of targeting peptides
[0119] Disclosed herein are methods for designing targeting peptides with binding specificity to carbonic anhydrase IV. In some embodiments, the method comprises generating one or more targeting peptides by computer simulation, each of which is capable of interacting with: (1) one or more positions functionally equivalent to S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 of the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV; or (2) one or more positions functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV. The position of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 of the amino acid sequence of NO:180.
[0120] In some embodiments, generating the one or more targeting peptides by computer simulation may include: generating a plurality of candidate peptides by computer simulation; performing a computer-assisted docking simulation on each of the plurality of candidate peptides bound to the carbonic anhydrase IV; and analyzing the molecular structure of the carbonic anhydrase IV bound to one or more of the plurality of candidate peptides to identify one or more targeting peptides capable of interacting with: (1) one or more positions S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 that are functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV; or (2) one or more positions S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 that are functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV. The position of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 of the amino acid sequence of NO:180.
[0121] The computer simulation method can provide high throughput method for screening a large number of candidate peptides and identifying the targeting peptide with desired specificity. In certain embodiments, the candidate peptide can include a part of AAV capsid protein. In certain embodiments, the candidate peptide is a part of AAV capsid protein. The method can include building one or more peptide-receptor models (for example, performing computer-assisted docking simulation) for each candidate peptide compounded with carbonic anhydrase IV. The molecular model of peptide-protein complex can be built using any reasonable computational peptide design and docking method, database, program or algorithm described herein or known in the art. Exemplary computational modeling methods, public databases, and programs include, but are not limited to, AlphaFold (e.g., AlphaFold2 and AlphaFold-Multimer provided by DeepMind, available at github.com / deepmind / alphafold), RoseTTAFold (github.com / RosettaCommons / RoseTTAFold), AutoDock, DOCK, FlexX, GOLD, OSPREY, SCWRL, PyMol, SWISS-MODEL (academic.oup.com / nar / article / 46 / Wl / W296 / 5000024), Protein Data Bank (Protein Data Bank), and the like. Bank, PDB) (available through the member organizations' websites, e.g., PDBe - pdbe.org, PDBj - pdbj.org, RCSB - rcsb.org / pdb, and BMRB - bmrb.wisc.edu), Phyre2 (nature.com / articles / nprot.2015.053), and RaptorX (nature.com / articles / nprot.2012.085).
[0122] The method may further include using visualization software (such as PyMol, Qlucore Omics Explorer, WebMol, Insight II, Discovery Studio 2.1 and other software that can be identified by those skilled in the art) to assess the characteristics or parameters related to the interaction between the candidate peptide and the carbonic anhydrase IV. The characteristics or parameters assessed may include interfacial energy and physical and geometric scoring. The characteristics or parameters associated with the interaction between the candidate peptide and the carbonic anhydrase IV may include measuring surface complementarity, solvent accessible surface area, solvation free energy, electrostatic interaction energy, van der Waals energy and / or total molecular mechanics energy. The method may also include determining the total number of atoms in the interface, the total number of atoms in the peptide that conflict with carbonic anhydrase IV, the binding angle of the peptide and / or the binding depth of the peptide in each inferred peptide-receptor complex model. The method may also include identifying the minimum energy conformation of the peptide-carbonic anhydrase IV complex. The energy score of every kind of conformation may be determined by calculating the interaction energy between the peptide and the carbonic anhydrase IV, comprising electrostatic energy, desolvation energy, van der Waals energy, as those skilled in the art will appreciate.
[0123] In certain embodiments, the targeting peptide can be assigned with a binding score and sorted based on the binding score. A threshold value can be applied to identify the desired targeting peptide. The method can include obtaining a binding score for each candidate peptide in the multiple candidate peptides combined with carbonic anhydrase IV; and selecting one or more candidate peptides with a binding score higher than the threshold value as a targeting peptide with binding specificity (or high binding affinity) to carbonic anhydrase IV.
[0124] A combination of physical and geometric scoring parameters, including interface energy, binding angle, and binding pocket depth calculations can be used to generate a binding score. In some embodiments, the binding score for each candidate peptide sequence in the plurality of candidate peptide sequences can be obtained by: (1) counting the total number of atoms in the interface between the candidate peptide and carbonic anhydrase IV; (2) counting the total number of atoms in the candidate peptide that conflict with carbonic anhydrase IV; (3) obtaining the binding angle of the candidate peptide; and / or (4) obtaining the binding depth of the candidate peptide.
[0125] In some embodiments, the number of atoms in the interface of candidate peptide and carbonic anhydrase can be the total number of atoms in the cut-off distance between the intervening atoms of candidate peptide and carbonic anhydrase. In various embodiments, the cut-off distance can change. In certain embodiments, the cut-off distance is about, at most, at most about 5 dusts (for example, 2 dusts, 3 dusts, 4 dusts or 5 dusts). In various embodiments, the number of intervening atoms between candidate peptide and carbonic anhydrase IV can be different. For example, the number of intervening atoms can be about or can be at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or numerical value or scope between any value in these values.
[0126] The total number of atoms in the peptide that conflict with carbonic anhydrase IV can be the total number of atoms within the conflict distance. The conflict distance can be defined as the distance when a geometric conflict occurs between the peptide and the receptor atom. In some embodiments, the conflict distance can be about 1 angstrom.
[0127] The binding angle of the peptide can be defined as the angle between the center of gravity of the carbonic anhydrase IV to the carrier of the carbonic anhydrase IV anchor and the angle between the center of gravity of the carbonic anhydrase to the center of gravity of the peptide.
[0128] The binding depth can be defined as the difference between the distances of the point on the peptide closest to the center of carbonic anhydrase IV and the minor radius of the ellipsoidal shell of carbonic anhydrase IV normalized to the minor radius.
[0129] The binding score can be the sum of the contact score, binding angle, and binding depth (calculated based on the total number of atoms and the total number of conflicting atoms in the interface of the candidate peptide and carbonic anhydrase). In some embodiments, the binding score is equal to or greater than 0. For example, if the sum of the contact score, binding angle, and binding depth is negative, the binding score is defined as 0. 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, or a value or range between any two of these values.
[0130] In some embodiments, the binding score (B) of the candidate peptide 肽 ) can be defined as follows:
[0131]
[0132] The method may further include selecting one or more candidate peptides with a binding score higher than a threshold value as a targeting peptide with binding specificity to carbonic anhydrase IV. The threshold value may be an arbitrary value defined by a user. In certain embodiments, the threshold value may be a binding score of a targeting peptide known to have binding specificity to carbonic anhydrase IV. In certain embodiments, the result from individual paired competition (relative score between two competitor peptides) may be assembled into a peptide competition metric, which ranks the set of candidate peptides according to its receptor-binding probability encoded in the AlphaFold2 neural network.
[0133] Table 2 provides an exemplary list of targeting peptides ranked by Automated Pairwise Peptide Receptor Analysis for Screening Engineered AAV (APPRAISE-AAV), the details of which are described in Examples 1 and 3 of the present disclosure. The B_POI in Table 2 is the binding score for each peptide of interest. The peptide sequences in Table 2 are amino acid sequences starting with AAV9 residue A587 and ending with residue G594.
[0134]
[0135]
[0136]
[0137] Antibodies and peptide derivatives
[0138] Disclosed herein also include antibodies or fragments thereof comprising amino acid sequences with binding specificity to BBB-spanning receptors disclosed herein (e.g., carbonic anhydrase IV or Ly6c1). Disclosed herein also include peptide derivatives or conjugates thereof with specificity to BBB-spanning receptors disclosed herein (e.g., carbonic anhydrase IV or Ly6c1).
[0139] In some embodiments, the antibody or its fragment may further include an Fc domain. In some embodiments, the antibody or its fragment is a single chain variable fragment (scFv), a single domain antibody, an immunoglobulin molecule, a monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a disulfide-linked Fv, a scFv, a single domain antibody, a bifunctional antibody, a multispecific antibody, a bispecific antibody (dual specificantibody), an anti-idiotypic antibody, a bispecific antibody (bispecific antibody) or a functionally active epitope binding fragment thereof.
[0140] In some embodiments, the antibody or fragment thereof is a bispecific antibody comprising at least one Fab specific for carbonic anhydrase IV. The bispecific antibody may comprise a second binding site for a different antigen.
[0141] In some embodiments, the antibodies or fragments thereof disclosed herein may include an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174; or (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174. In some embodiments, the antibodies or fragments thereof disclosed herein may include an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-15 and 57; or (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-15 and 57.
[0142] In some embodiments, the antibody or fragment thereof is unable to induce a harmful immune response in the subject (e.g., human) to be treated. In some embodiments, the antibodies, fragments, variants, or derivatives thereof of the present disclosure are modified to reduce their immunogenicity using techniques recognized in the art. For example, the antibody can be a humanized antibody, a primed antibody, a deimmunized antibody, or a chimeric antibody.
[0143] In some embodiments, the antibody, its fragment, variant or derivative may further include a chemical moiety that is not naturally associated with the antibody. For example, the antibody or its fragment may include a flexible linker, or may be modified to add a functional moiety, such as a detectable label. The antibody, its fragment, variant or derivative may be modified such that the covalent or non-covalent connection of the chemical moiety to the antibody does not interfere with or prevent the antibody from binding to the epitope. In some embodiments, the chemical moiety may be conjugated to the antibody using any technique known in the art.
[0144] The present disclosure also provides isolated polynucleotides or nucleic acid molecules encoding peptides, antibodies, fragments, variants or derivatives of the present disclosure. For example, the polynucleotides of the present disclosure can encode the heavy chain and light chain variable regions of antibodies, fragments, variants or derivatives thereof on the same polynucleotide molecule or a separate polynucleotide molecule. In some embodiments, the polynucleotides of the present disclosure can encode the heavy chain and light chain variable regions (e.g., CDR regions) of antibodies, fragments, variants or derivatives thereof on the same polynucleotide molecule or a separate polynucleotide molecule.
[0145] Payload delivery across the BBB
[0146] Disclosed herein are methods and delivery systems for delivering a payload (e.g., a therapeutic agent) to the nervous system. In certain embodiments, the method includes providing a targeting peptide or a derivative thereof that can be combined with carbonic anhydrase IV. The targeting peptide can be a part of a delivery system, and the delivery system can include a payload to be delivered to the nervous system. The method can further include administering a delivery system to a subject.
[0147] In some embodiments, the delivery system comprises nanoparticles, nanotubes, nanowires, dendrimers, liposomes, ethosomes and aquasomes, polymer vesicles and non-ionic surfactant vesicles, foams, hydrogels, cubes, quantum dots, exosomes, macrophages, and combinations thereof. In some embodiments, the delivery system comprises nanoparticles selected from lipid-based nanoparticles, polymer nanoparticles, inorganic nanoparticles, surfactant-based emulsions, nanowires, silica nanoparticles, virus-like particles, peptide- or protein-based particles, lipid-polymer particles, nanolipoprotein particles, and combinations thereof.
[0148] In some embodiments, the delivery system includes a viral vector or a non-viral vector. For example, the viral vector may include an adenoviral vector, an adeno-associated virus (AAV) vector, a lentiviral vector, or a retroviral vector. In some embodiments, the viral vector is an AAV vector, and the target peptide may be a part of the capsid protein of the AAV vector.
[0149] Adeno-associated virus (AAV) and recombinant AAV (rAAV)
[0150] In certain embodiments, the delivery system for delivering a payload across the BBB is an AAV vector. AAV is a replication-deficient parvovirus, and the length of its single-stranded DNA genome is about 4.7kb, comprising 145 nucleotide reverse terminal repeats (ITRs). ITR plays an important role in the integration of AAV DNA into the host cell genome. When AAV infects host cells, the viral genome is integrated into the host's chromosome, thereby causing latent infection of the cell. In a natural system, a helper virus (e.g., adenovirus or herpes virus) provides genes that allow the production of AAV viruses in infected cells. In the case of adenovirus, genes E1A, E1B, E2A, E4 and VA provide auxiliary functions. After infection with a helper virus, rescue and amplify the AAV provirus, and produce both AAV and adenovirus. In the case of a recombinant AAV vector without Rep and / or Cap genes, AAV can be non-integrated.
[0151] In some embodiments, the AAV vector may include coding regions for one or more proteins of interest. The AAV vector may include a 5'AAV ITR, a 3'AAV ITR, a promoter, and a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more proteins of interest, wherein the promoter and the restriction site are located downstream of the 5'AAV ITR and upstream of the 3'AAV ITR. In some embodiments, the AAV vector includes a post-transcriptional regulatory factor-element downstream of the restriction site and upstream of the 3'AAV ITR.
[0152] The viral vector may contain additional sequences that make the vector suitable for replication and integration in eukaryotes. In other embodiments, the viral vector disclosed herein may contain a shuttle element that makes the vector suitable for replication and integration in both prokaryotes and eukaryotes. In some embodiments, the viral vector may contain additional transcription and translation initiation sequences, such as promoters and enhancers; and additional transcription and translation terminators, such as polyadenylation signals. Various regulatory elements that may be included in AAV vectors have been described in US2012 / 0232133, which is hereby incorporated by reference in its entirety.
[0153] The AAV serotype used to derive the AAV capsid protein can be different. The AAV capsid can be derived from AAV9 or a variant thereof. The AAV capsid can be derived from an AAV selected from the group consisting of AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, human isolate hu.31, human isolate hu.32, rhesus monkey isolate rh.8, and rhesus monkey isolate rh.10. In some embodiments, the AAV capsid protein can be derived from an AAV serotype selected from the group consisting of AAV9, AAV9 K449R (or K449RAAV9), AAV1, AAVrhlO, AAV-DJ, AAV-DJ8, AAV5, AAVPHP.B (PHP.B), AAVPHP.A (PHP.A), AAVG2B-26, AAVG2B-13, AAVTH1.1-32, AAVTH1.1-35, AAVPHP.B2 (PHP.B2), AAVPHP.B 3(PHP.B3), AAVPHP.N / PHP.B-DGT, AAVPHP.B-EST, AAVPHP.B-GGT, AAVPHP.B-ATP, AAVPHP.B-ATT-T, AAVPHP.B- DGT-T, AAVPHP.B-GGT-T, AAVPHP.B-SGS, AAVPHP.B-AQP, AAVPHP.B-QQP, AAVPHP.B-SNP(3), AAVPHP.B-SNP, AAVP HP.B-QGT, AAVPHP.B-NQT, AAVPHP.B-EGS, AAVPHP.B-SGN, AAVPHP.B-EGT, AAVPHP.B-DST, AAVPHP.B-DST, AAVPH P.B-STP, AAVPHP.B-PQP, AAVPHP.B-SQP, AAVPHP.B-QLP, AAVPHP.B-TMP, AAVPHP.B-TTP, AAVPHP.S / G2A12, AAVG2 Al5 / G2A3(G2A3), AAVG2B4(G2B4), AAVG2B5(G2B5), PHP.S, AAV2, AAV2G9, AAV3, AA V3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2 , AAV8, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.6 8. AAV9.84, AAV9.9, AAV10, AAV11, AAV12, AAV16.3, AAV24.1, AAV27.3, AAV42.12,AAV42-1b、AAV42-2、AAV42-3a、AAV42-3b、AAV42-4、AAV42-5a、AAV42-5b、AAV42-6b、AAV42-8、AAV42-10、AAV42-11、AA V42-12、AAV42-13、AAV42-15、AAV42-aa、AAV43-1、AAV43-12、AAV43-20、AAV43-21、AAV43-23、AAV43-25、AAV43-5、AAV 44.1、AAV44.2、AAV44.5、AAV223.1、AAV223.2、AAV223.4、AAV223.5、AAV223.6、AAV223.7、AAVl-7 / rh.48、AAVl-8 / rh.49、AAV2-l5 / rh.62、AAV2-3 / rh.6l、AAV2-4 / rh.50、AAV2-5 / rh.5l、AAV3.l / hu.6、AAV3.l / hu.9、AAV3-9 / rh.52、AAV3-1 l / rh.53、AAV4-8 / r11.64、AAV4-9 / rh.54、AAV4-l9 / rh.55、AAV5-3 / rh.57、AAV5-22 / rh.58、AAV7.3 / hu.7、AAVl6.8 / hu.10、AAVl6.l2 / hu.11、AAV29.3 / bb.1、AAV29.5 / bb.2、AAVl06.l / hu.37、AAV1 l4.3 / hu.40、AAVl27.2 / hu.4l、AAVl27.5 / hu.42、AAVl28.3 / hu.44、AAVl30.4 / hu.48、AAVl45.l / hu.53、AAVl45.5 / hu.54、AAVl45.6 / hu.55、AAVl6l.l0 / hu.60、AAVl6l.6 / hu.6l、AAV33.l2 / hu.l7、AAV33.4 / hu.l5、AAV33.8 / hu.l6、AAV52 / hu.l9、AAV52.l / hu.20、AAV58. 2 / hu.25、AAVA3.3、AAVA3.4、AAVA3.5、AAVA3.7、AAVC1、AAVC2、AAVC5、AAVF3、AAVF5、AAVH2、AAVrh.72、AAVhu.8、AAVrh.68、AAVrh.70、 AAVpi.1、AAVpi.3、AAVpi.2、AAVrh.60、AAVrh.44、AAVrh.65、AAVrh.55、AAVrh.47、AAVrh.69、AAVrh.45、AAVrh.59、AAVhu.12、AAVh6、AAVH-1 / hu.1, AAVH-5 / hu.3, AAVLG-l0 / rh.40, AAVLG-4 / rh.38, AAVLG-9 / hu.39, AAVN72l-8 / rh.43, AAVCh.5, AAVCh.5Rl, AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVCy.5R1, AAVCy.5R2, AAVCy.5R3, AAVCy.5R4, AAVcy.6, AAVhu.1, AAVhu.2, AAVhu.3, AAVhu.4, AAVhu.5, AAVhu.6, AAVhu.7, AAVhu.9, AAV hu.10、AAVhu.11、AAVhu.13、AAVhu.15、AAVhu.l6、AAVhu.17、AAVhu.18、AAVhu.20、AAVhu.21、AAVhu.22、AAVhu.23.2、AAVhu.24、AAVhu.25、AAVhu.27 、AAVhu.28、AAVhu.29、AAVhu.29R、AAVhu.31、AAVhu.32、AAVhu.34、AAVhu.35、AAVhu.37、AAVhu.39、AAVhu.40、AAVhu.41、AAVhu.42、AAVhu.43、AAVhu. .44、AAVhu.44Rl、AAVhu.44R2、AAVhu.44R3、AAVhu.45、AAVhu.46、AAVhu.47、AAVhu.48、AAVhu.48Rl、AAVhu.48R2、AAVhu.48R3、AAVhu.49、AAVhu.51、 AAVhu.52、AAVhu.54、AAVhu.55、AAVhu.56、AAVhu.57、AAVhu.58、AAVhu.60、AAVhu.61、AAVhu.63、AAVhu.64、AAVhu.66、AAVhu.67、AAVhu.14 / 9、AAVhu. .t19、AAVrh.2、AAVrh.2R、AAVrh.8、AAVrh.8R、AAVrh.10、AAVrh.12、AAVrh.13、AAVrh.13R、AAVrh.14、AAVrh.17、AAVrh.18、AAVrh.19、AAVrh.20、AAVrh. rh.21、AAVrh.22、AAVrh.23、AAVrh.24、AAVrh.25、AAVrh.31、AAVrh.32、AAVrh.33、AAVrh.34、AAVrh.35、AAVrh.36、AAVrh.37、AAVrh.37、AAVrh.38、AAVrh.38AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54, AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.6l, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74, AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, Caprine AAV, Bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhErl.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhERl.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV-LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV-LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-miRNA-101, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2, AAV Shuffled 100-1, AAV Shuffled 100-3, AAV Shuffled 100-7, AAV Shuffled 10-2, AAV Shuffled 10-6, AAV Shuffled 10-8, AAV Shuffled 100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.11, AAVhu.53,AAV4-8 / rh.64, AAVLG-9 / hu.39, AAV54.5 / hu.23, AAV54.2 / hu.22, AAV54.7 / hu.24, AAV54.1 / hu.21, AAV54.4R / hu.27, AAV46.2 / hu.28, AAV46.6 / hu.29, AAV128.1 / hu.43, Ideal AAV (true type AAV, ttAAV), EGRENN AAV 10, Japanese AAV 10 serotype, AAV CBr-7.1, AAV CBr-7.10, AAV CBr-7.2, AAV CBr-7.3, AAV CBr-7.4, AAV CBr-7.5, AAV CBr-7.7, AAV CBr-7.8, AAV CBr-B7.3, AAV CBr-B7.4, AAV CBr-El, AAV CBr-E2, AAV CBr-E3, AAV CBr-E4, AAVCBr-E5, AAV CBr-e5, AAV CBr-E6, AAV CBr-E7, AAV CBr-E8, AAV CHt-1, AAV CHt-2, AAVCHt-3, AAV CHt-6.1, AAV CHt-6.10, AAV CHt-6.5, AAV CHt-6.6, AAV CHt-6.7, AAV CHt-6.8, AAV CHt-P1, AAV CHt-P2, AAV CHt-P5, AAV CHt-P6, AAV CHt-P8, AAV CHt-P9, AAVCKd-1, AAV CKd-10, AAV CKd-2, AAV CKd-3, AAV CKd-4, AAV CKd-6, AAV CKd-7, AAV CKd-8, AAV CKd-Bl, AAV CKd-B2, AAV CKd-B3, AAV CKd-B4, AAV CKd-B5, AAV CKd-B6, AAV CKd-B7, AAV CKd-B8, AAV CKd-H1, AAV CKd-H2, AAV CKd-H3, AAV CKd-H4, AAV CKd-H5, AAV CKd-H6, AAV CKd-N3, AAV CKd-N4, AAV CKd-N9, AAV CLg-F1, AAV CLg-F2, AAV CLg-F3, AAV CLg-F4, AAV CLg-F5, AAV CLg-F6, AAV CLg-F7, AAV CLg-F8, AAV CLv-1, AAV CLvl-l, AAV Clvl-lO, AAV CLvl-2, AAV CLv-l2AAV CLvl-3, AAV CLvl-4, AAV Clvl-7, AAV Clvl-8, AAV Clvl-9, AAV CLv-2, AAV CLv-3, AAV CLv-4, AAV CLv-6, AAV CLv-8 CLv-D1、AAVCLv-D2、AAV CLv-D3、AAV CLv-D4、AAV CLv-D5、AAV CLv-D6、AAV CLv-D7、AAV CLv-D8、AAVCLv-El、AAV-CLv-KAV、AAV CLv-K3, AAV CLv-K6, AAV CLv-L4, AAV CLv-L5, AAV CLv-L6, AAVCLv-M1, AAV CLv-M11, AAV CLv-M2, AAV CLv-M1, AAV CLv-M2, AAV CLv-M5, AAV-CLv-AAV CLv-M7, AAV CLv-M8, AAVCLv-M9, AAV CLv-R1, AAV CLv-R2, AAV CLv-R3, AAV CLv-R4, AAV CLv-R5, AAV CLv-R6, RAVCLv-AAV CLv-R8, AAV CLv-R9, AAV CSp-l, AAV CSp-lO, AAV CSp-11, AAV CSp-2, AAVCSp-3, AAV CSp-4, AAV CSp-6, AAV Csp-7, AAV Cp-8 CSp-8.l0、AAV CSp-8.2、AAVCSp-8.4、AAV CSp-8.5、AAV CSp-8.6、AAV CSp-8.7、AAV CSp-8.8、AAV CSp-8.9、AAV CSp-9, AAV.hu.48R3, AAV.VR-355, AAV3B, AAV4, AAV5, AAVF1 / HSC1, AAVF11 / HSC1 1、AAVF12 / HSC12、AAVF13 / HSC13、AAVF14 / HSC14、AAVF15 / HSC15、AAVF16 / HSC16、 AAVF17 / HSC17,AAVF2 / HSC2,AAVF3 / HSC3,AAVF4 / HSC4,AAVF5 / HSC5,AAVF6 / HSC6 、AAVF7 / HSC7、AAVF8 / HSC8、AAVF9 / HSC9、 The AAV system is not available in the United States.
[0154] The AAV vector can be an AAV9 having the amino acid sequence of SEQ ID NO: 178 or an amino acid sequence having at least 70% sequence identity (e.g., at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence of SEQ ID NO: 178.
[0155] In some embodiments, the AAV vectors disclosed herein can be used as AAV transfer vectors carrying transgenic proteins encoding the protein of interest (e.g., targeting peptides) for producing recombinant AAV viruses that can express the protein of interest in host cells. Therefore, disclosed herein also includes recombinant AAV viruses (rAAV). rAAV can include the AAV capsid proteins described herein.
[0156] rAAV can include chimeric AAV capsids. "Chimeric" AAV capsids refer to capsids with exogenous amino acids or amino acid sequences. rAAV can include mosaic AAV capsids. "Mosaic" AAV capsids refer to capsids composed of two or more capsid proteins or polypeptides, each of which is derived from a different AAV serotype. rAAV can be the result of transcapsidation, and in some cases, the transcapsidation refers to packaging the inverted terminal repeat sequence (ITR) from the first serotype into the capsid of the second serotype, wherein the first serotype and the second serotype are not the same. In some cases, the capsid gene of the parent AAV serotype can be pseudotyped, which means that the ITR from the first AAV serotype (e.g., AAV1) is used in the capsid from the second AAV serotype (e.g., AAV9), wherein the first AAV serotype and the second AAV serotype are not the same. As a non-limiting example, the pseudotype AAV serotype including AAV1 ITR and AAV9 capsid protein can be expressed as AAV1 / 9. The rAAV may additionally or alternatively include a capsid that has been engineered to express an exogenous ligand binding moiety (eg, a receptor) or a modified native receptor.
[0157] In some embodiments, the rAAV capsid protein includes a substitution or insertion of one or more amino acids in the amino acid sequence of the AAV capsid protein. In some cases, the rAAV capsid protein described herein has an insertion or substitution of an amino acid heterologous to the wild-type AAV capsid protein, and the amino acid is at the amino acid position of the insertion or substitution. In some embodiments, at the amino acid position of the insertion or substitution, the amino acid is not endogenous to the wild-type AAV capsid protein. The amino acid can be a naturally occurring amino acid in the same or equivalent amino acid position as the insertion replaced in different AAV capsid proteins. The AAV capsid protein from which the engineered AAV capsid protein of the present disclosure is produced can be referred to as a "parent" or "wild-type" AAV capsid protein or a "corresponding unmodified capsid protein". In some cases, the parent AAV capsid protein has a serotype selected from the following: AAV1, AAV2, rAAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and AAV12. The complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and in Srivastava et al., J. Virol., 45:555-564 (1983); the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the complete genome of AAV-5 is provided in GenBank Accession No. AF085716; the complete genome of AAV-6 is provided in GenBank Accession No. NC_00 1862; at least portions of the AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively; the AAV-9 genome is provided in Gao et al., Journal of Virology, 78:6381-6388 (2004); the AAV-10 genome is provided in Mol. Ther., 13(1):67-76 (2006); the AAV-11 genome is provided in Virology, 330(2):375-383 (2004); portions of the AAV-12 genome are provided in Genbank Accession No. DQ813647; portions of the AAV-13 genome are provided in Genbank Accession No. EU285562. At least a portion of the AAV-DJ genome is provided in Grimm, D. et al., J. Virol. 82, 5887-5911 (2008).
[0158] In some embodiments, the rAAV vector disclosed herein can carry a transgene encoding a targeting peptide described herein that can bind to carbonic anhydrase IV or is specific to carbonic anhydrase IV (e.g., Car4 or CA4). The targeting peptide can be a part of the rAAV capsid. Also disclosed herein is an AAV capsid protein. The AAV capsid protein can include the targeting peptide disclosed herein.
[0159] The position of the targeting peptide in the capsid protein can vary. In certain embodiments, the targeting peptide can be inserted between two adjacent amino acids in AA586-595 of the AAV9 capsid protein (e.g., between AA586 and AA587, between AA587 and AA588, between AA588 and AA589, between AA589 and AA590, between AA590 and AA591, between AA591 and AA592, between AA592 and AA593, between AA593, AA594 and AA595) or between its functional equivalents in other AAV capsid proteins. The AAV vector can be a vector selected from the following: AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-DJ, human isolate hu.31, human isolate hu.32, rhesus monkey isolate rh.8, rhesus monkey isolate rh.10 or a variant thereof. In some embodiments, the AAV vector is AAV9 or a variant or derivative thereof. For example, the AAV capsid protein comprises or consists of SEQ ID NO: 178 or an amino acid sequence that is at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) identical to SEQ ID NO: 178.
[0160] The targeting peptide can be inserted between AA588-589 of the AAV9 capsid protein or between its functional equivalents in other AAV capsid proteins. The two adjacent amino acids can be AA588-589. In some embodiments, the targeting peptide is inserted between AA587-590 of the AAV9 capsid protein or between its functional equivalents in other AAV capsid proteins.
[0161] The targeting peptide can include (1) an amino acid sequence selected from SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174; (2) an amino acid sequence having at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) sequence identity to an amino acid sequence selected from SEQ ID NOs: 11-12 and SEQ ID NOs: 70-174.
[0162] The targeting peptide can include (1) an amino acid sequence selected from SEQ ID NOs:6-15 and 57; (2) an amino acid sequence having at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, or a number or range between any two of these values) sequence identity with an amino acid sequence selected from SEQ ID NOs:6-15 and 57.
[0163] The binding specificity between the targeting peptide carried by rAAV and carbonic anhydrase IV can be screened using the AAV targeted evolution (CREATE) method (M-CREATE) based on multiple Cre recombination. In M-CREATE, rAAV nucleic acid contains a marker sequence flanked by two lox sequences. rAAV is applied to animals (e.g., mice), wherein the gene encoding the Cre recombinase is expressed only in target cells (e.g., endothelial cells in the brain). The marker sequence of rAAV that can enter the target cell is reversed by the Cre recombinase expressed in the target cell. Since the nucleic acid of rAAV lacking specificity to the target cell cannot contact the Cre recombinase, its marker sequence will not be reversed. Therefore, after sequencing the nucleic acid of the rAAV recovered from the animal, the targeting peptide of the rAAV containing the reverse marker sequence is specific to the target cell. The M-CREATE method is described in detail in U.S. Patent Publication US20170166926A1, and the contents of the U.S. Patent Publication are incorporated herein by reference as a whole for all purposes.
[0164] The generation of viral vectors can be achieved using any suitable genetic engineering techniques well known in the art, including but not limited to standard techniques of restriction endonuclease digestion, ligation, transformation, plasmid purification and DNA sequencing, such as described in Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, NY (1989)). Viral vectors can incorporate sequences from the genome of any known organism. The sequences can be incorporated in their native form, or can be modified in any way to obtain the desired activity. For example, the sequences can include insertions, deletions, or substitutions.
[0165] Use of AAV vectors and rAAV for payload delivery
[0166] Also disclosed herein are compositions for delivering a payload (e.g., a pharmaceutical agent) to a target environment (e.g., the nervous system of a subject). The composition may include an AAV comprising (1) an AAV capsid protein disclosed herein, and (2) a pharmaceutical agent to be delivered to a target environment (e.g., the nervous system) of a subject.
[0167] The target environment can be the CNS, the peripheral nervous system (PNS), or a combination thereof. The target environment can be brain endothelial cells, neurons, capillaries in the brain, arterioles in the brain, arteries in the brain, or a combination thereof.
[0168] The agent to be delivered may include a nucleic acid, a peptide, a small molecule, an aptamer, or a combination thereof. The AAV vector disclosed herein can be effectively transduced into a target environment (e.g., CNS), for example, for delivery of nucleic acids. In some embodiments, a method for delivering a nucleic acid sequence to the nervous system is provided. The protein may be part of the capsid of the AAV. The AAV may include a nucleic acid sequence to be delivered to the nervous system. Then, the AAV may be administered to a subject.
[0169] In some embodiments, the nucleic acid sequence to be delivered to the target environment (e.g., the nervous system) includes one or more sequences that will have some use or benefit to the nervous system and / or local delivery or surrounding tissue or environment. In some embodiments, it can be a nucleic acid encoding a protein of interest. The nucleic acid may include one or more of the following: a) a DNA sequence encoding a trophic factor, a growth factor, or a soluble protein; b) a cDNA that restores protein function to a person or animal carrying a genetic mutation in a gene; c) a cDNA encoding a protein that can be used to control or change the activity or state of a cell; d) a cDNA encoding a protein or nucleic acid that can be used to assess the state of a cell; e) a cDNA or guide RNA encoding a protein for gene editing; f) a DNA sequence for genome editing by homologous recombination; g) a DNA sequence encoding a therapeutic RNA; h) a shRNA or artificial miRNA delivery system; and i) a DNA sequence that affects the splicing of an endogenous gene.
[0170] In some embodiments, the vector may further include regulatory control elements known to those skilled in the art to affect the expression of RNA and / or protein products encoded by the polynucleotide within the desired cells of the subject.
[0171] Functionally, the expression of a polynucleotide can be controlled at least in part by operably connected regulatory elements, so that these elements regulate the transcription of the polynucleotide, the transportation, processing and stability of the RNA encoded by the polynucleotide, and the translation of the regulatory transcript under appropriate circumstances. A specific example of an expression control element is a promoter that is usually located at the 5' place of the transcribed sequence. Another example of an expression control element is an enhancer that can be located at the 5' or 3' place of the transcribed sequence or within the transcribed sequence. Another example of a regulatory element is a recognition sequence for microRNA. Another example of a regulatory element is an intron and a splicing donor and splicing acceptor sequence that regulates the splicing of the intron. Another example of a regulatory element is a transcription termination signal and / or a polyadenylation sequence.
[0172] Expression control elements and promoters include those that are active in specific tissues or cell types, referred to herein as "tissue-specific expression control elements / promoters". Tissue-specific expression control elements are typically active in specific cells or tissues (e.g., in the liver, brain, central nervous system, spinal cord, eye, retina, or lung). Expression control elements are typically active in these cells, tissues, or organs because they are recognized by transcriptional activator proteins or other transcriptional regulatory factors that are unique to specific cell, tissue, or organ types.
[0173] Expression control elements also include ubiquitous or promiscuous promoters / enhancers that can drive the expression of polynucleotides in many different cell types. Such elements include, but are not limited to, cytomegalovirus (CMV) immediate early promoter / enhancer sequences, Rous sarcoma virus (RSV) promoter / enhancer sequences, CMV, chicken β-actin, rabbit β-globin (CAG) promoter / enhancer sequences, and other viral promoters / enhancers active in various mammalian cell types; promoter / enhancer sequences from ubiquitous or promiscuous mammalian genes, including, but not limited to, β-actin, ubiquitin, or EF1α; or synthetic elements that do not exist in nature.
[0174] Expression control elements can also confer expression in a controllable manner, i.e., a signal or stimulus increases or decreases the expression of an operably connected polynucleotide. A controllable element that increases the expression of an operably connected polynucleotide in response to a signal or stimulus is also referred to as an "inducible element" (i.e., it is induced by a signal). Specific examples include, but are not limited to, hormone (e.g., steroid) inducible promoters. A controllable element that reduces the expression of an operably connected polynucleotide in response to a signal or stimulus is referred to as an "inhibitory element" (i.e., the signal reduces expression so that expression increases when the signal is removed or does not exist). Typically, the amount of increase or decrease conferred by such elements is directly proportional to the amount of the signal or stimulus present: the greater the amount of the signal or stimulus, the greater the increase or decrease in expression.
[0175] The heterologous nucleic acid may include a 5'ITR and a 3'ITR. The agent may include a DNA sequence encoding a protein (e.g., a nutrient factor, a growth factor, or a soluble protein). The heterologous nucleic acid may include a promoter operably connected to a polynucleotide encoding, for example, a protein or RNA agent. The promoter may be able to induce transcription of the polynucleotide. The transcription of the polynucleotide may generate a transcript. The heterologous nucleic acid may include one or more of the following: a 5'UTR, a 3'UTR, a small promoter, an enhancer, a splicing signal, a polyadenylation signal, a terminator, one or more silencer effector binding sequences, a protein degradation signal, and an internal ribosome entry element (IRES). The silencer effector may include a microRNA (miRNA), a precursor microRNA (pre-miRNA), a small interfering RNA (siRNA), a short hairpin RNA (shRNA), a precursor thereof, a derivative thereof, or a combination thereof. The silencer effector may be able to bind to the one or more silencer effector binding sequences, thereby reducing the stability of the transcript and / or reducing the translation of the transcript. In some embodiments, the silencing effector includes one or more miRNA binding sites (e.g., miR-122 binding sites). MiRNA binding sites are operably linked regulatory elements that are typically located in the 3'UTR of the transcribed sequence. The binding of miRNA to the target transcript (complexed with the RNA-induced silencing complex RISC) can reduce the expression of the target transcript by translational inhibition and / or transcript degradation.
[0176] The polynucleotide may further include a transcript stabilizing element. The transcript stabilizing element may include a woodchuck hepatitis post-translational regulatory element (WPRE), a bovine growth hormone polyadenylation (bGH-polyA) signal sequence, a human growth hormone polyadenylation (hGH-polyA) signal sequence, or any combination thereof. The nucleic acid may be or may encode an RNA agent. The RNA agent may include one or more of: dsRNA, siRNA, shRNA, pre-miRNA, pri-miRNA, miRNA, stRNA, lncRNA, piRNA, and snoRNA. The RNA agent may inhibit or suppress the expression of the gene of interest in the cell. In certain embodiments, the gene of interest may be selected from SOD1, MAPT, APOE, HTT, C9ORF72, TDP-43, APP, BACE, SNCA, ATXN1, ATXN2, ATXN3, ATXN7, SCN1A-SCN5A, and SCN8A-SCN11A. The heterologous nucleic acid may further include a polynucleotide encoding one or more secondary proteins, and the protein and the one or more secondary proteins may include a synthetic protein circuit. The heterologous nucleic acid may include a single-stranded AAV (ssAAV) vector or a self-complementary AAV (scAAV) vector.
[0177] The promoter may include a ubiquitous promoter. The ubiquitous promoter may be selected from the group consisting of the cytomegalovirus (CMV) immediate early promoter; the CMV promoter; the viral simian virus 40 (SV40) (e.g., early or late); the Moloney murine leukemia virus (MoMLV) LTR promoter; the Rous sarcoma virus (RSV) LTR; the RSV promoter; the herpes simplex virus (HSV) (thymidine kinase) promoter; the H5, P7.5, and P11 promoters from vaccinia virus; the elongation factor 1-alpha (E F1a) promoter; early growth response 1 (EGR1); ferritin H (FerH); ferritin L (FerL); glyceraldehyde 3-phosphate dehydrogenase (GAPDH); eukaryotic translation initiation factor 4A1 (EIF4A1); heat shock 70kDa protein 5 (HSPA5); heat shock protein 90kDa beta member 1 (HSP90B1); heat shock protein 70kDa (HSP70); β-kinesin (β-KIN); human ROSA 26 locus; ubiquitin C promoter (UBC); phosphoglycerate kinase-1 (PGK) promoter; 3-phosphoglycerate kinase promoter; cytomegalovirus enhancer; human β-actin (HBA) promoter; chicken β-actin (CBA) promoter; CAG promoter; CBH promoter; or any combination thereof.
[0178] The promoter can be an inducible promoter, including but not limited to a tetracycline responsive promoter, a TRE promoter, a Tre3G promoter, an ecdysone responsive promoter, a cumate responsive promoter, a glucocorticoid responsive promoter, and an estrogen responsive promoter, a PPAR-γ promoter, a RU-486 responsive promoter, or a combination thereof.
[0179] Promoter can include tissue-specific promoter and / or pedigree-specific promoter.Tissue-specific promoter can be liver-specific thyroxine binding globulin (TBG) promoter, insulin promoter, glucagon promoter, somatostatin promoter, pancreatic polypeptide (PPY) promoter, synaptic protein -1 (Syn) promoter, creatine kinase (MCK) promoter, mammalian desmin (DES) promoter, alpha-myosin heavy chain (a-MHC) promoter or cardiac troponin T (cTnT) promoter.Tissue-specific promoter can be neuron-specific promoter, such as synaptic protein -1 (Syn) promoter, CaMKIIa promoter, calcium / calmodulin-dependent protein kinase II a promoter, tubulin αI promoter, neuron-specific enolase promoter, platelet-derived growth factor β chain promoter, TRPV1 promoter, Nav1.7 promoter, Nav1.8 promoter, Nav1.9 promoter or Advillin promoter. The tissue-specific promoter may be or include a muscle-specific promoter, such as the MCK promoter.
[0180] The promoter may include an intron sequence. The promoter may include a bidirectional promoter and / or an enhancer. In certain embodiments, the enhancer is a CMV enhancer. One or more cells of an experimenter may include an endogenous version (e.g., gene) of a nucleotide sequence, and the promoter may include or may be derived from an endogenous version of the promoter. In certain embodiments, one or more cells of an experimenter may include an endogenous version of a nucleotide sequence, and the sequence may not be truncated relative to the endogenous version.
[0181] The length of the promoter can vary, for example, less than 1 kb. In other embodiments, the promoter is greater than 1 kb. The length of the promoter can be 200 bp, 210 bp, 220 bp, 230 bp, 240 bp, 250 bp, 260 bp, 270 bp, 280 bp, 290 bp, 300 bp, 310 bp, 320 bp, 330 bp, 340 bp, 350 bp, 360 bp, 370 bp, 380 bp, 390 bp, 400 bp, 410 bp, 420 bp, 430 bp, 440 bp, 450 bp, 460 bp, 470 bp, 480 bp, 490 bp, 500 bp, 510 bp, 520 bp, 530 bp, 540 bp, 550 bp, 560 bp, 570 bp, 580 bp, 590 bp, 600 bp, 610 bp, 620 bp, 630 bp, 640 bp, 650 bp, 660 bp, 670 bp, 680 bp, 690 bp, 700 bp, 710 bp, 720 bp, 730 bp, 740 bp, 750 bp, 760 bp, 770 bp, 780 bp, 790 bp, 800 bp, bp, 20bp, 530bp, 540bp, 550bp, 560bp, 570bp, 580bp, 590bp, 600bp, 610bp, 620bp, 630bp, 640bp, 650bp, 660bp, 670bp, 680bp, 690bp, 700bp, 710bp, 720bp, 730bp, 740bp, 750bp, 760bp, 770bp, 780bp, 790bp, 800bp or a value or range between any two of these values or greater than 800bp. Promoters can provide expression of therapeutic gene expression products for a period of time in target tissues such as, but not limited to, CNS.Expression of the therapeutic gene expression product can continue for the following time periods: 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 1 hour, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 3 weeks, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months , 1 year, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 21 years, 22 years, 23 years, 24 years, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65 years, or a value or range between any two of these values or greater than 65 years.
[0182] As used herein, "protein of interest" can be any protein, including naturally occurring and non-naturally occurring proteins. In some embodiments, the polynucleotides encoding one or more proteins of interest can be present in one of the AAV vectors disclosed herein, wherein the polynucleotides are operably connected to a promoter. In some cases, the promoter can drive the expression of the protein of interest in a host cell (e.g., an endothelial cell). In some embodiments, the protein of interest is an anti-tau antibody, an anti-AB antibody, and / or an ApoE isotype.
[0183] The protein can include aromatic L-amino acid decarboxylase (AADC), survival motor neuron 1 (SMN1), frataxin (FXN), cystic fibrosis transmembrane conductance regulator (CFTR), factor X (FIX), RPE65, retinoid isomerohydrolase (RPE65), sarcoglycan alpha (SGCA) and sarcoplasmic reticulum / endoplasmic reticulum Ca2+-ATPase (SERCA2a), ApoE2, GBA1, GRN, ASP A, CLN2, GLB1, SGSH, NAGLU, IDS, NPC1, GAN, CFTR, GDE, OTOF, DYSF, MYO7A, ABCA4, F8, CEP290, CDH23, DMD, ALMS1, or any combination thereof.
[0184] Proteins may include disease-associated proteins. In some embodiments, the expression level of disease-associated proteins is associated with the occurrence and / or progression of the disease. Proteins may include methyl CpG binding protein 2 (MeCP2), DRK1A, KAT6A, NIPBL, HDAC4, UBE3A, EHMT1, one or more genes NPHP1, LIMK1 encoded on chromosome 9q34.3, one or more genes P53, TPI1, FGFR1 and related genes encoded on chromosome 7q11.23, RA1, SHANK3, CLN3, NF-1, TP53, PFK, CD40L, CYP19A1, PGRN, CHRNA7, PMP22, CD40LG, derivatives thereof, or any combination thereof.
[0185] In certain embodiments, nucleic acid can include the cDNA of protein encoding, to control or monitor the activity or state of cell, and / or for evaluating the state of cell.Protein can include fluorescence activity, polymerase activity, protease activity, phosphatase activity, kinase activity, SUMO activity, deSUMO activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity or any combination thereof.Protein can include nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity, glycosidase activity, acetyltransferase activity, deacetylase activity, adenylation activity, deadenylation activity or any combination thereof.Protein can include nuclear localization signal (NLS) or nuclear export signal (NES).
[0186] Protein can include CRE recombinase, GCaMP, cell therapy component, knockdown gene therapy component, cell surface exposed epitope or any combination thereof. Protein can include chimeric antigen receptor. Protein can include diagnostic agent (for example, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), blue fluorescent protein (BFP), red fluorescent protein (RFP), TagRFP, Dronpa, Padron, mApple, mCherry, mruby3, rsCherry, rsCherryRev, its derivative or any combination thereof).
[0187] In some embodiments, the nucleic acid may include a cDNA or guide RNA encoding a protein for gene editing; or a DNA sequence for genome editing by homologous recombination. The protein may include a programmable nuclease. In some embodiments, the programmable nuclease is selected from: SpCas9 or its derivatives; VRER, VQR, EQR SpCas9; xCas9-3.7; eSpCas9; Cas9-HF1; HypaCas9; evoCas9; HiFi Cas9; ScCas9; StCas9; NmCas9; SaCas9; CjCas9; CasX; Cas9 H940A nickase; Cas12 and its derivatives; dcas9-APOBEC1 fusion, BE3 and dcas9 deaminase fusion; dcas9-Krab, dCas9-VP64, dCas9-Tet1 and dcas9 transcriptional regulator fusion; Dcas9 fluorescent protein fusion; Cas13 fluorescent protein fusion; RCas9 fluorescent protein fusion; Cas13 adenosine deaminase fusion. Programmable nucleases can include zinc finger nucleases (ZFNs) and / or transcription activator-like effector nucleases (TALENs). Programmable nucleases can include Streptococcus pyogenes Cas9 (SpCas9), Staphylococcus aureus Cas9 (SaCas9), zinc finger nucleases, TAL effector nucleases, large-range nucleases, MegaTAL, Tev-m TALEN, MegaTev, homing endonucleases, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr 5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, Cpf1, C2c1, C2c3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, derivatives thereof, or any combination thereof. Heterologous nucleic acid and / or rAAV may include polynucleotides encoding (i) targeting molecules and / or (ii) donor nucleic acids. The targeting molecule may be associated with a programmable nuclease. The targeting molecule may include single-stranded DNA or single-stranded RNA. The targeting molecule may include single guide RNA (sgRNA).
[0188] The rAAV disclosed herein may include one or more heterologous nucleic acids in the heterologous nucleic acids disclosed herein. The heterologous nucleic acid may include a polynucleotide encoding a protein. The nucleic acid may be or may encode an RNA agent. The heterologous nucleic acid may include a promoter operably connected to a polynucleotide encoding a protein. As disclosed herein, in some embodiments, the gene is operably connected to a suitable regulatory element. The one or more genes of the heterologous nucleic acid may include siRNA, shRNA, antisense RNA oligonucleotides, antisense miRNA, trans-splicing RNA, guide RNA, single guide RNA, crRNA, tracrRNA, trans-splicing RNA, pre-mRNA, mRNA or any combination thereof. The one or more genes of the heterologous nucleic acid may include one or more synthetic protein circuit components. The one or more genes of the heterologous nucleic acid may include a whole synthetic protein circuit, which includes one or more synthetic protein circuit components. The one or more genes of the heterologous nucleic acid may include two or more synthetic protein circuits.
[0189] The protein can be any protein, including naturally occurring and non-naturally occurring proteins. Examples include, but are not limited to, luciferase; fluorescent protein (e.g., GFP); growth hormone (GH) and variants thereof; insulin-like growth factor (IGF) and variants thereof; granulocyte colony stimulating factor (G-CSF) and variants thereof; erythropoietin (EPO) and variants thereof; insulin, such as proinsulin, preproinsulin, insulin, insulin analogs, etc.; antibodies and variants thereof, such as hybrid antibodies, chimeric antibodies, humanized antibodies, monoclonal antibodies; antigen-binding fragments of antibodies (Fab fragments), single-chain variable fragments of antibodies (scFV fragments); dystrophin and variants thereof; coagulation factors and variants thereof; cystic fibrosis transmembrane conductance regulator (CFTR) and variants thereof; and interferons and variants thereof.
[0190] Examples of proteins of interest include, but are not limited to, luciferase; fluorescent proteins (e.g., GFP); growth hormone (GH) and variants thereof; insulin-like growth factor (IGF) and variants thereof; granulocyte colony stimulating factor (G-CSF) and variants thereof; erythropoietin (EPO) and variants thereof; insulin, such as proinsulin, preproinsulin, insulin, insulin analogs, etc.; antibodies and variants thereof, such as hybrid antibodies, chimeric antibodies, humanized antibodies, monoclonal antibodies; antigen-binding fragments of antibodies (Fab fragments), single-chain variable fragments of antibodies (scFV fragments); dystrophin and variants thereof; coagulation factors and variants thereof; CFTR and variants thereof; and interferons and variants thereof.
[0191] In some embodiments, the protein of interest is a therapeutic protein or a variant thereof. Non-limiting examples of therapeutic proteins include blood factors such as β-globin, hemoglobin, tissue plasminogen activator and coagulation factors; colony stimulating factor (CSF); interleukins such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, etc.; growth factors such as keratinocyte growth factor (GF), stem cell factor (SCF), fibroblast growth factor (FGF, such as basic FGF and acidic FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), bone morphogenetic protein (BMP), epidermal growth factor (EGF), growth differentiation factor-9 (GDF-9), hepatoma-derived growth factor (HDGF), myostatin (GDF-8), nerve growth factor (NGF), and fibroblast growth factor (GF). GF), neurotrophic factors, platelet-derived growth factor (PDGF), thrombopoietin (TPO), transforming growth factor α (TGF-α), transforming growth factor β (TGF-β), etc.; soluble receptors, such as soluble TNF-a receptor, soluble VEGF receptor, soluble interleukin receptor (e.g., soluble IL-1 receptor and soluble type II IL-1 receptor), soluble γ / δT cell receptor, ligand binding fragments of soluble receptors, etc.; enzymes, such as -glucosidase, imiglucerase, β-glucocerebrosidase and arabinocerebrosidase; enzyme activators, such as tissue plasminogen activator; chemokines, such as IP-10, monokine induced by interferon-γ (Mig), Groa / IL-S, RANTES, MlP-1 a, MIP-Ιβ, MCP-1, PF-4, etc.; angiogenic agents, such as vascular endothelial growth factor (VEGF, such as VEGF121, VEGF165, VEGF-C, VEGF-2), transforming growth factor-β, basic fibroblast growth factor, glioma-derived growth factor, angiopoietin, angiopoietin-2, etc.; anti-angiogenic agents, such as soluble VEGF receptor; protein vaccines; neuroactive peptides, such as nerve growth factor (NGF), bradykinin, cholecystokinin, gastrin, secretin, oxytocin, gonadotropin-releasing hormone, β-endorphin, enkephalin, substance P, Somatostatin, prolactin, galanin, growth hormone-releasing hormone, bombesin, dynorphin, warfarin, neurotensin, motilin, thyroid-stimulating hormone, neuropeptide Y, luteinizing hormone, calcitonin, insulin, glucagon, vasopressin, angiotensin II, thyrotropin-releasing hormone, vasoactive intestinal peptide, sleep peptide, etc.; thrombolytics; atrial natriuretic peptide; relaxin; glial fibrillary acid protein; follicle-stimulating hormone (FSH); human alpha-1 antitrypsin; leukemia inhibitory factor (LIF); transforming growth factor (TGF); tissue factor, luteinizing hormone; macrophage activating factor;Tumor necrosis factor (TNF); neutrophil chemoattractant factor (NCF); nerve growth factor; tissue inhibitor of metalloproteinases; vasoactive intestinal polypeptide; angiopoietin; angiotropin; fibrinogen; hirudin; IL-1 receptor antagonist; etc. Some other non-limiting examples of proteins of interest include ciliary neurotrophic factor (CNTF); brain-derived neurotrophic factor (BDNF); neurotrophins 3 and 4 / 5 (NT-3 and 4 / 5); glial cell line-derived neurotrophic factor (GDNF); aromatic amino acid decarboxylase (AADC); hemophilia-related coagulation proteins, such as factor IX or factor X; dystrophin or mini-dystrophin; lysosomal acid lipase; phenylalanine hydroxylase (PAH); glycogen storage disease-related enzymes, such as glucose-6-phosphatase, acid maltase, glycogen debranching enzyme, muscle glycogen phosphorylase, liver glycogen phosphorylase, muscle phosphofructokinase, phosphorylase kinase (e.g., PHKA2), glucose transporter (e.g., GLUT2), aldolase A, β-enolase, and glycogen synthase; lysosomal enzymes (e.g., β-N-acetylhexosaminidase A); and any variants thereof. ;
[0192] The protein of interest may be, for example, an active fragment of a protein, such as any of the aforementioned proteins, a fusion protein comprising some or all of two or more proteins, or a fusion protein comprising all or part of the aforementioned proteins.
[0193] In some embodiments, the viral vector comprises a polynucleotide comprising a coding region for two or more proteins of interest. The two or more proteins of interest may be the same or different from each other. In some embodiments, the two or more proteins of interest are related polypeptides, such as the light chain and heavy chain of the same antibody.
[0194] The protein of interest may be a multi-subunit protein. For example, the protein of interest may include two or more subunits or two or more independent polypeptide chains. In some embodiments, the protein of interest may be an antibody, including but not limited to antibodies of various isotypes (e.g., IgG1, IgG2, IgG3, IgG, IgA, IgD, IgE, and IgM); a monoclonal antibody produced by any means known to those skilled in the art, including an antigen-binding fragment of a monoclonal antibody; a humanized antibody; a chimeric antibody; a single-chain antibody; an antibody fragment, such as Fv, F(ab')2, Fab', Fab, Facb, scFv, etc.; provided that the antibody is able to bind to an antigen. In some embodiments, the antibody is a full-length antibody. In some embodiments, the protein of interest is not an immunoadhesin.
[0195] In some embodiments, the resulting targeting molecules can be used in methods and / or therapies related to in vivo gene transfer applications of long-lived cell populations. In some embodiments, these methods and / or therapies can be applied to any rAAV-based gene therapy, including, for example, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's ataxia, Pompe disease, Huntington's disease, Alzheimer's disease, Battens disease, lysosomal storage diseases, glioblastoma multiforme, Rett syndrome, Leber's congenital amaurosis, chronic pain, stroke, spinal cord injury, traumatic brain injury, and lysosomal storage diseases. In addition, rAAV can also be used for in vivo delivery of transgenes for non-therapeutic scientific studies (such as optogenetics), gene overexpression, gene knockdown with shRNA or miRNA, endogenous miRNA modulation using miRNA sponges or decoys, recombinase delivery for conditional gene deletion, conditional (recombinase-dependent) expression, or gene editing with CRISPR, TALEN, and zinc finger nucleases.
[0196] In some embodiments, the gene encoding can stimulate an immunogenic material of an immune response (e.g., an adaptive immune response), such as an antigenic peptide or protein from a pathogen. The expression of the antigen can stimulate the adaptive immune system of the body to provide an adaptive immune response. Therefore, it is contemplated that some embodiments of the heterologous nucleic acids provided herein can be used as a vaccine (e.g., as a vaccine) for preventing or treating infectious diseases.
[0197] As described herein, the nucleotide sequence encoding the protein can be modified to improve the expression efficiency of the protein. The methods that can be used to improve the transcription and / or translation of the gene herein are not particularly limited. For example, the nucleotide sequence can be modified to better reflect the use of the host codon to increase gene expression (e.g., protein production) in the host (e.g., mammal).
[0198] The gene expression degree in target cell can change.The amount of protein expressed in subject (for example, subject's CNS) can change.For example, in some embodiments, protein can be expressed in subject with following amount: at least about 9 μ g / ml, at least about 10 μ g / ml, at least about 50 μ g / ml, at least about 100 μ g / ml, at least about 200 μ g / ml, at least about 300 μ g / ml, at least about 400 μ g / ml, at least about 500 μ g / ml, at least about 600 μ g / ml, at least about 700 μ g / ml, at least about 800 μ g / ml, at least about 900 μ g / ml or at least about 1000 μ g / ml. In some embodiments, the protein is expressed in the subject in an amount of about 9 μg / ml, about 10 μg / ml, about 50 μg / ml, about 100 μg / ml, about 200 μg / ml, about 300 μg / ml, about 400 μg / ml, about 500 μg / ml, about 600 μg / ml, about 700 μg / ml, about 800 μg / ml, about 900 μg / ml, about 1000 μg / ml, about 1500 μg / ml, about 2000 μg / ml, about 2500 μg / ml, or a range between any two of these values. It will be appreciated by those skilled in the art that the method requires that the level of expression of the protein may vary depending on non-limiting factors, such as the specific protein and the subject being treated, and the effective amount of protein that can be readily determined by those skilled in the art using conventional methods known in the art without undue experimentation.
[0199] The agent can be an inducer of cell death. The agent can induce cell death through non-endogenous cell death pathways (e.g., bacterial pore-forming toxins). In some embodiments, the agent (e.g., a protein encoded by a nucleic acid) can be a pro-survival protein. In some embodiments, the agent is a regulator of the immune system. The agent can activate adaptive immune response and innate immune response or both. In some embodiments, nucleic acid encoding can stimulate immunogenic materials of immune response (e.g., adaptive immune response), such as antigenic peptides or proteins from pathogens. The expression of antigens can stimulate the adaptive immune system of the body to provide an adaptive immune response. Therefore, it is conceivable that some embodiments of the compositions provided herein can be used as vaccines (e.g., as vaccines) for preventing and treating infectious diseases. Proteins can include CRE recombinase, GCaMP, cell therapy components, knocking down gene therapy components, epitopes exposed on the cell surface, or any combination thereof. In some embodiments, proteins include CFTR, GDE, OTOF, DYSF, MYO7A, ABCA4, F8, CEP290, CDH23, DMD, and ALMS1.
[0200] The agent may include non-protein coding genes such as RNA agents, for example, sequences encoding antisense RNA, RNAi, shRNA and microRNA (miRNA), miRNA sponges or decoys, recombinase delivery for conditional gene deletion, conditional (recombinase-dependent) expression, including those required for gene editing components described herein. Non-protein coding genes may also encode tRNA, rRNA, tmRNA, piRNA, double-stranded RNA, snRNA, snoRNA and / or long non-coding RNA (IncRNA). In some embodiments, RNA agents may include non-natural or modified nucleotides (e.g., pseudouridine). In some embodiments, non-protein coding genes may regulate the expression or activity of target genes or gene expression products. For example, RNA described herein may be used to inhibit gene expression in target cells (e.g., cells in the central nervous system (CNS)). In some embodiments, inhibition of gene expression refers to inhibition of at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or 100%. In some embodiments, the protein product of the target gene is inhibited by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or 99%. The gene can be a wild-type gene or a gene with at least one mutation. The target protein can be a wild-type protein or a protein with at least one mutation.
[0201] Examples of genes encoding therapeutic proteins include sequences associated with signal transduction biochemical pathways, such as genes or polynucleotides (e.g., signal transducers) associated with signal transduction biochemical pathways. In some embodiments, the methods and compositions disclosed herein include knockdown of endogenous signal transducers, accompanied by the tuned expression of proteins including appropriate versions of signal transducers. Examples of DNA or RNA sequences contemplated herein include sequences of disease-associated genes or polynucleotides. "Disease-associated" genes or polynucleotides refer to any genes or polynucleotides that produce transcription or translation products at abnormal levels or in abnormal forms in cells derived from tissues affected by the disease, compared to tissues or cells of non-disease controls. It can be a gene expressed at an abnormally high level; it can be a gene that becomes expressed at an abnormally low level, wherein the altered expression is associated with the occurrence and / or progression of the disease. Disease-associated genes also refer to genes with mutations or genetic variations that directly result in or are in linkage disequilibrium with genes that cause the etiology of the disease. The transcribed or translated products can be known or unknown, and can be at normal or abnormal levels. Signal transducers can be associated with one or more diseases or conditions. In some embodiments, the disease or condition is characterized by abnormal signaling of one or more signal transducers disclosed herein. In some embodiments, the activation level of a signal transducer is associated with the occurrence and / or progression of a disease or condition. The activation level of a signal transducer can directly or indirectly lead to the cause of a disease or condition.
[0202] Many proteins (e.g., enzymes) are secreted and can play a cross-correction role. For these proteins, the AAV disclosed herein can be used to deliver genetic material into brain endothelial cells, thereby converting these cells into biofactories to produce therapeutic agents and distributing these therapeutic agents to other cell types. For example, the production of secreted Sparcl1 / Hevin proteins in brain endothelial cells can rescue the thalamocortical synaptic loss phenotype of Hevin KO mice (see Example 1 below). This proof of concept supports a brain endothelial cell biofactory model for the production of enzymes, antibodies, or other biotherapeutics, thereby providing a new type of treatment for diseases such as lysosomal storage diseases.
[0203] In some embodiments, rAAVs having a capsid protein comprising one or more targeting peptides disclosed herein can be used to deliver genes to specific cell types in a target environment of a subject. For example, rAAVs can be used to deliver genes to neurons and glia in the nervous system (including PNS, CNS, or both) of a subject (e.g., a mammal). The compositions and methods disclosed herein can be used, for example, to: (i) reduce expression of mutant huntingtin in patients with Huntington's disease by, for example, incorporating a huntingtin-specific microRNA expression cassette into the rAAV genome and packaging the rAAV genome into variant rAAV for delivery, for example, via the vasculature, (ii) deliver a functional copy of a frataxin gene to patients with Friedreich's ataxia, (iii) restore expression of an enzyme that is critical for normal lysosomal function in patients who lack enzyme expression due to a genetic mutation (e.g., patients with Neimann-Pick disease, mucopolysaccharidosis III, and / or Gaucher's disease), (iv) use rAAV to generate animal models of disease, or a combination thereof.
[0204] A subject in need may be a subject suffering from or at risk of suffering from one or more of the following: chronic pain, Friedreich's ataxia, Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy type I and II (SMA I and II), Friedreich's ataxia (FA), spinocerebellar ataxia, multiple sclerosis (MS), chronic traumatic encephalopathy (CTE), HIV-1 associated dementia, or a lysosomal storage disease involving cells within the CNS. The lysosomal storage disease may be Krabbe disease, Sandhoff disease, Tay-Sachs disease, Gaucher disease (type I, II, or III), Niemann-Pick disease (NPC1 or NPC2 deficiency), Hurler syndrome, Pompe disease, or Batten disease.
[0205] In some embodiments, the subject suffers from an acute condition or injury. A subject in need thereof may be a subject suffering from, at risk of suffering from, or having suffered from: a stroke, a traumatic brain injury, epilepsy, or a spinal cord injury.
[0206] Pharmaceutical compositions and methods of administration
[0207] Also disclosed herein are pharmaceutical compositions comprising one or more rAAV viruses disclosed herein and one or more pharmaceutically acceptable carriers. The composition may also include additional ingredients, such as diluents, stabilizers, excipients, and adjuvants. As used herein, a "pharmaceutically acceptable" carrier, excipient, diluent, adjuvant, or stabilizer is nontoxic (preferably inert) to cells or subjects exposed thereto at the dose and concentration employed, or has an acceptable toxicity level determined by a person skilled in the art. Carriers, diluents and adjuvants may include buffers such as phosphate, citrate or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides (e.g., less than about 10 residues); proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as Tween TM 、Pluronics TM Or polyethylene glycol (PEG). In some embodiments, the physiologically acceptable carrier is an aqueous pH buffered solution.
[0208] Disclosed herein are methods comprising delivering an agent to the nervous system of a subject. In some embodiments, the method comprises: providing an AAV vector comprising an AAV capsid protein disclosed herein. In some embodiments, the AAV vector comprises an agent to be delivered to the nervous system. In some embodiments, the method comprises administering the AAV vector to the subject. The composition can be used for intravenous administration. The composition can be used for systemic administration. The agent can be delivered to the intraventricular epithelial lining in the brain of the subject, the central canal of the spinal cord, the capillaries in the brain, the arterioles in the brain, the arteries in the brain, or a combination thereof. The subject can be an adult animal.
[0209] The titer of the rAAV to be administered will vary, for example, depending on the specific rAAV, mode of administration, therapeutic goal, individual and targeted cell type, and can be determined by standard methods in the art. As will be readily apparent to those skilled in the art, the useful in vivo dose of the recombinant virus to be administered and the specific mode of administration will vary according to age, weight, severity of pain and the animal species treated, the specific recombinant virus expressing the protein of interest used, and the specific use of the recombinant virus employed. The determination of the effective dose level, i.e., the dose level required to achieve the desired result, can be accomplished by those skilled in the art using routine pharmacological methods. Typically, human clinical use of the product begins with a lower dose level, with the dose level increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the methods of the present invention using established pharmacological methods.
[0210] The exact dosage can be determined on a drug-by-drug basis, and in most cases, some generalizations can be made regarding dosage. In some embodiments, rAAV for delivering an agent to a subject's nervous system (e.g., CNS) can be administered to a subject, for example, by injection, at a dose of between 1×10 10 The viral genomes (vg) of the recombinant virus / subject (kg) were compared with 2×10 l4 vg / kg, for example, between 5×10 11 vg / kg and 5×l0 12 In some embodiments, the dose of rAAV administered to a subject does not exceed 2×10 14 In some embodiments, the dose of rAAV administered to a subject does not exceed 5×10 12 vg / kg. In some embodiments, the dose of rAAV administered to a subject does not exceed 5×10 11 vg / kg.
[0211] The effective dose and dosage of the pharmaceutical composition for preventing or treating the disease or condition disclosed herein are defined by the observed beneficial response associated with the disease or condition or the symptom of the disease or condition. Beneficial responses include preventing, alleviating, stopping or curing the disease or condition or the symptom of the disease or condition. In some embodiments, beneficial responses can be measured by detecting the measurable improvement of the presence, level or activity of the subject's biomarkers, transcriptome risk profile or intestinal microbiome. As used herein, "improvement" refers to the presence, level or activity to the presence, level or activity observed in normal individuals (e.g., individuals not suffering from the disease or condition). In the case where the therapeutic rAAV composition is ineffective or does not fully alleviate the disease or condition or the symptoms of the disease or condition, the dosage and / or route of administration can be changed, or another agent can be applied to the subject together with the therapeutic rAAV composition. In some embodiments, when the patient begins the regimen of the therapeutic rAAV composition, the patient also gradually stops (e.g., the dose is gradually reduced) the second treatment regimen.
[0212] In some embodiments, the pharmaceutical composition according to the present disclosure is administered at a dosage level sufficient to deliver the following daily, once or multiple times a day to obtain the desired treatment, diagnosis or prevention and treatment effect: about 0.0001 mg / kg to about 100 mg / kg, about 0.001 mg / kg to about 0.05 mg / kg, about 0.005 mg / kg to about 0.05 mg / kg, about 0.001 mg / kg to about 0.005 mg / kg, about 0.05 mg / kg to about 0.5 mg / kg, about 0.01 mg / kg to about 50 mg / kg, about 0.1 mg / kg to about 40 mg / kg, about 0.5 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.1 mg / kg to about 10 mg / kg or about 1 mg / kg to about 25 mg / kg of subject body weight. It should be understood that those skilled in the art can convert the above dosage concentrations into vg per kg or viral genome or into total viral genomes.
[0213] In some embodiments, the concentration of infectious particles in a dose of the pharmaceutical composition is at least or about 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 , 10 16 or 10 17 In some cases, the concentration of infectious particles was 2 × 10 7, 2×10 8 , 2×10 9 , 2×10 10 , 2×10 11 , 2×10 12 , 2×10 13 , 2×10 14 , 2×10 15 , 2×10 16 , 2×10 17 or a range between any two of these values. In some cases, the concentration of infectious particles is 3 × 10 7 , 3×10 8 , 3×10 9 , 3×10 10 , 3×10 11 , 3×10 12 , 3×10 13 , 3×10 14 , 3×10 15 , 3×10 16 , 3×10 17 or a range between any two of these values. In some cases, the concentration of infectious particles is 4 × 10 7 , 4×10 8 , 4×10 9 , 4×10 10 , 4×10 1 , 4×10 12 , 4×10 13 , 4×10 14 , 4×10 15 , 4×10 16 , 4×10 17 or a range between any two of these values. In some cases, the concentration of infectious particles is 5×10 7 , 5×10 8 , 5×10 9 , 5×10 10 , 5×10 11 , 5×10 12 , 5×10 13 , 5×10 14 , 5×10 15 , 5×10 16 , 5×10 17 or a range between any two of these values. In some cases, the concentration of infectious particles is 6 × 10 7 , 6×10 8 , 6×10 9 , 6×10 10 , 6×10 11, 6×10 12 , 6×10 13 , 6×10 14 , 6×10 15 , 6×10 16 , 6×10 17 or a range between any two of these values. In some cases, the concentration of infectious particles is 7 × 10 7 ,7×10 8 ,7×10 9 ,7×10 10 ,7×10 11 ,7×10 12 ,7×10 13 ,7×10 14 ,7×10 15 ,7×10 6 ,7×10 17 or a range between any two of these values. In some cases, the concentration of infectious particles is 8 × 10 7 , 8×10 8 , 8×10 9 , 8×10 10 , 8×10 11 , 8×10 12 , 8×10 13 , 8×10 14 , 8×10 15 , 8×10 16 , 8×10 17 or a range between any two of these values. In some cases, the concentration of infectious particles was 9 × 10 7 ,9×10 8 ,9×10 9 ,9×10 10 ,9×10 11 ,9×10 12 ,9×10 13 ,9×10 14 ,9×10 15 ,9×10 16 ,9×10 17 Or a range between any two of these values.
[0214] The recombinant viruses disclosed herein can be administered to a subject (e.g., a human) in need thereof. The route of administration is not particularly limited. For example, a therapeutically effective amount of the recombinant virus can be administered to a subject via a standard route in the art. Administration can be systemic administration. Administration can be intravenous administration.
[0215] The non-limiting examples of approach include intramuscular, intravaginal, intravenous, intraperitoneal, subcutaneous, epidermal, intradermal, rectal, intraocular, lung, intracranial, intraosseous, oral, cheek, whole body or nose. In certain embodiments, the recombinant virus is applied to the subject by systemic transduction. In certain embodiments, the recombinant virus is applied to the subject by intramuscular injection. In certain embodiments, rAAV is applied to the subject by parenteral route (for example, by intravenous, intramuscular or subcutaneous injection), by surface scratches or by being inoculated into the body cavity of the subject. The route of administration and serotype of the AAV component of rAAV virus can be easily determined by those skilled in the art in view of the infection and / or disease state treated and the target cell / tissue of the protein being paid attention to expressing. In certain embodiments, it can be advantageous to apply rAAV by intravenous administration. The variant AAV provided herein can advantageously provide the intravenous administration of the carrier with enhanced tropism to CNS.
[0216] In certain embodiments, the subject is a primate, and the medicament is delivered to the endothelial cells and / or neurons of the nervous system. The nervous system can be the central nervous system (CNS). The efficiency of the medicament delivered to the endothelial cells of the nervous system of the subject can be at least 1.5 times, 2 times or 3 times of the efficiency of the medicament delivered to the neurons of the nervous system. In certain embodiments, the efficiency of the medicament delivered to the endothelial cells of the nervous system of the subject is more than 3 times (for example, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or the number or scope between any value in these values) of the efficiency of the medicament delivered to the neurons of the nervous system.
[0217] Disclosed herein are methods for delivering an agent to a cell. In some embodiments, the method comprises: contacting an AAV vector comprising an AAV capsid protein disclosed herein with a cell. In some embodiments, the AAV vector comprises an agent to be delivered to the nervous system. In some embodiments, the cell is an endothelial cell or a neuron. In some embodiments, the AAV vector is contacted with the cell in vitro, in vivo, or ex vivo. The cell may be present in a tissue, an organ, or a subject. The cell may be a brain endothelial cell, a neuron, a cell in a capillary in the brain, a cell in an arteriolar in the brain, a cell in an artery in the brain, a cell in the brain vasculature, or a combination thereof.
[0218] The AAV vector may be an AAV9 vector or a variant thereof. In some embodiments, the AAV vector is a vector selected from the following: AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, human isolate hu.31, human isolate hu.32, rhesus monkey isolate rh.8, rhesus monkey isolate rh.10 or a variant thereof. The serotype of the AAV vector may be different from the serotype of the AAV capsid.
[0219] Variant AAV capsids may include tropism for tissues or cells of the central nervous system (CNS). Target cells may be neuronal cells, neural stem cells, astrocytes, or tumor cells. Target cells may be located in the brain or spinal cord. Target cells may include antigen presenting cells, dendritic cells, macrophages, neural cells, brain cells, astrocytes, microglia, and neurons. In some embodiments, the target cell is an endothelial cell.
[0220] The actual administration of rAAV can be accomplished by using any physical method for transporting rAAV into the nervous system of a subject. For example, the rAAV disclosed herein can be advantageously administered intravenously for delivery to the CNS. As disclosed herein, the capsid protein of rAAV can be modified so that rAAV targets a specific target environment of interest such as the central nervous system, and enhances tropism (e.g., CNS tropism) to the target environment of interest. The pharmaceutical composition can be prepared, for example, as an injectable formulation.
[0221] The recombinant virus to be used can be used in liquid or freeze-dried form (combined with one or more suitable preservatives and / or protectants to protect the virus during the freeze-drying process). For gene therapy (e.g., gene therapy for neurological disorders that can be alleviated by specific gene products), a therapeutically effective dose of a recombinant virus expressing a therapeutic protein is administered to a host in need of such treatment. The use of the recombinant virus disclosed herein in the preparation of a medicament for inducing immunity in a host or providing gene therapy to the host is within the scope of this application.
[0222] In cases where human dosages of rAAV have been established for at least some condition, those same dosages or dosages between about 0.1% and 500%, more preferably between about 25% and 250%, of the established human dosages may be used. In cases where human dosages have not been established, as would be the case with a newly discovered pharmaceutical composition, the dosages may be determined based on the ED. 50 or ID 50 Suitable human dosages can be extrapolated from values or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
[0223] The rAAV of therapeutically effective amount can be applied to the subject at different time points. For example, rAAV can be applied to the subject before, during or after the subject has suffered from a disease or illness. rAAV can also be applied to the subject before, during or after a disease or illness (for example, Huntington's disease (HD), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, spinal muscular atrophy (type I and type II), Friedreich's ataxia, spinocerebellar ataxia and any lysosomal storage disease involving CNS cells, these lysosomal storage diseases include but are not limited to Krabbe disease, Sandhoff disease, Tay-Sachs disease, Gaucher disease (type I, type II or type 111), Niemann-Pick disease (NPC1 or NPC2 deficiency), Hurler syndrome, Pompe disease, Batten disease or any combination thereof), chronic pain or its combination occurs. In some embodiments, rAAV is applied to the subject during the remission of the disease or illness. In some embodiments, rAAV is applied before the onset of the disease or illness of the subject. In some embodiments, rAAV is administered to a subject at risk for developing a disease or condition.
[0224] The disease or disorder may include a neurological disease or disorder. For example, the neurological disease or disorder may include epilepsy; Dravet Syndrome; Lennox Gastaut Syndrome; myoclonic seizures; juvenile myoclonic epilepsy; refractory epilepsy; schizophrenia; juvenile spasms; West syndrome; infantile spasms; refractory infantile spasms; Alzheimer's disease; Creutzfeld-Jakob's syndrome / disease; bovine spongiform encephalopathy (BSE); prion-related infections; diseases involving mitochondrial dysfunction; diseases involving beta-amyloid and / or tauopathy; Down's syndrome; hepatic encephalopathy; Huntington's disease; motor neuron disease; amyotrophic lateral sclerosis (ALS); olivopontocerebellar atrophy; postoperative cognitive deficit (POCD); systemic lupus erythematosus; systemic sclerosis; Sjogren's syndrome syndrome; neuronal ceroid lipofuscinosis; neurodegenerative cerebellar ataxia; Parkinson's disease; Parkinson's dementia; mild cognitive impairment; cognitive deficits in various forms of mild cognitive impairment; cognitive deficits in various forms of dementia; dementia pugilistica; vascular and prefrontal dementia; cognitive impairment; learning disabilities; eye injuries; eye diseases; eye disorders; glaucoma; retinopathy; macular degeneration; head, brain or spinal cord injury; head, brain or spinal cord trauma; convulsions; epileptic convulsions; epilepsy; temporal lobe epilepsy; myoclonic epilepsy; tinnitus; movement disorders; chorea; Huntington's chorea); athetosis; dystonia; repetitive movements; tics; tardive dyskinesia; tic disorders; spasmodic torticollis; blepharospasm; focal and generalized dystonia; nystagmus; hereditary cerebellar ataxia; corticobasal degeneration; tremor; essential tremor; addiction; anxiety disorders; panic disorder; social anxiety disorder (SAD); attention deficit hyperactivity disorder (ADHD); attention deficit syndrome (ADS); restless legs syndrome (RLS); childhood hyperactivity disorder; autism; dementia; Alzheimer's disease Dementia due to Alzheimer's disease; dementia due to Korsakoff syndrome; Korsakoff syndrome; vascular dementia; dementia associated with HIV infection; HIV-1 encephalopathy; AIDS encephalopathy; AIDS dementia complex; AIDS-related dementia; major depressive disorder; major depressive disorder; depression; memory loss; stress; bipolar manic-depressive disorder; medication tolerance; tolerance to opioids; movement disorders; fragile X syndrome; irritable bowel syndrome (IBS); migraine;Multiple sclerosis (MS); muscle spasms; pain; chronic pain; acute pain; inflammatory pain; neuropathic pain; post-traumatic stress disorder (PTSD); schizophrenia; spasticity; Tourette's syndrome; eating disorders; food addiction; bulimia; agoraphobia; generalized anxiety disorder; obsessive-compulsive disorder; panic disorder; social phobia; phobia; substance-induced anxiety disorder; delusional disorder; schizoaffective disorder; schizophreniform disorder; substance-induced psychotic disorder; hypertension; or any combination thereof. ;
[0225] In some embodiments, disclosed herein are formulations of pharmaceutically acceptable excipients and carrier solutions suitable for delivering rAAV compositions described herein, as well as suitable dosages and treatment regimens for using specific compositions described herein in a variety of treatment regimens. In some embodiments, the amount of therapeutic gene expression products in each therapeutically useful composition can be prepared in such a way that a suitable dosage is obtained in any given unit dose of the compound. Those skilled in the art of preparing such pharmaceutical formulations will consider factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, and other pharmacological considerations, and in this way, a variety of dosages and treatment regimens may be desired. In some cases, rAAV compositions are pharmaceutical compositions of suitable formulations disclosed herein, which are delivered intraocularly, intravitreally, parenterally, subcutaneously, intravenously, intracerebro-ventricularly, intramuscularly, intrathecally, orally, intraperitoneally, orally or nasally by inhalation or by direct injection to one or more cells, tissues or organs. In some embodiments, the rAAV disclosed herein may be advantageously administered intravenously for delivery to the CNS.
[0226] In some embodiments, the pharmaceutical form of the AAV-based virus composition suitable for injectable use comprises a sterile aqueous solution or dispersion and a sterile powder for the extemporaneous preparation of a sterile injectable solution or dispersion. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), a suitable mixture thereof, and / or a vegetable oil. Appropriate fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. The prevention of microbial action can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.). In many cases, it will be preferred to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of the injectable composition can be achieved by using an agent that delays absorption in the composition, such as aluminum monostearate and gelatin.
[0227] In certain embodiments, for the use of injectable aqueous solution, for example, if necessary, the solution can be suitably buffered, and the liquid diluent is first isotonic with enough saline or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. Depending on the condition of the experimenter being treated, some changes will inevitably occur in dosage. The personnel responsible for administration will determine the appropriate dosage for individual subjects under any circumstances. In addition, for people to use, the preparation should meet the sterility, pyrogenicity and general safety and purity standards required by the FDA Office of Biologics standards.
[0228] Disclosed herein are sterile injectable solutions comprising rAAV compositions disclosed herein, which are prepared by incorporating the rAAV compositions disclosed herein in the desired amount into an appropriate solvent together with several of the other ingredients enumerated above as needed, followed by filtration sterilization. Typically, dispersions are prepared by incorporating various sterile active ingredients into a sterile vehicle containing a base dispersion medium and other required ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying techniques, which produce powders of the active ingredient plus any additional desired ingredients from their previously sterile filtered solutions. Injectable solutions can be advantageous for systemic administration (e.g., by intravenous administration).
[0229] Also provided herein are formulations in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of proteins), and they are formed with inorganic acids such as hydrochloric acid or phosphoric acid or organic acids such as acetic acid, oxalic acid, tartaric acid, mandelic acid. Salts formed with free carboxyl groups can also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or ferric hydroxide and organic bases such as isopropylamine, trimethylamine, histidine, procaine, etc. After formulation, the solution will be administered in a manner compatible with the dosage formulation and in a therapeutically effective amount. The formulation is easily administered in a variety of dosage forms such as injectable solutions, drug release capsules, etc.
[0230] The formulation for intranasal administration can include a coarse powder including active ingredients and having an average particle size of about 0.2 μm to 500 μm. Such formulations are applied in the manner of snuff, for example, by rapidly inhaling into the nasal cavity from a powder container kept near the nose. The formulation suitable for nasal administration can, for example, include as little as about 0.1% (w / w) and as much as 100% (w / w) of active ingredients, and can include one or more additional ingredients in the additional ingredients described herein. The pharmaceutical composition can be prepared, packaged and / or sold in a formulation suitable for buccal administration. Such formulations can, for example, be in the form of tablets and / or lozenges made using conventional methods, and can, for example, include 0.1% to 20% (w / w) active ingredients, and the remaining amount includes an oral soluble and / or degradable composition and optionally one or more additional ingredients in the additional ingredients described herein. Alternatively, the formulation suitable for buccal administration can include a powdered and / or aerosolized and / or atomized solution and / or suspension containing the active ingredient. Such powdered, aerosolized and / or aerosolized formulations when dispersed may have an average particle and / or droplet size in the range of about 0.1 nm to about 200 nm, and may further include one or more of any additional ingredients described herein.
[0231] The appropriate dose and dosage for administration to a subject is determined by factors including, but not limited to, the particular therapeutic rAAV composition, the disease condition and its severity, the identity of the subject in need of treatment (e.g., weight, sex, age), and may be determined based on the specific circumstances surrounding the case including, for example, the particular agent being administered, the route of administration, the condition being treated, and the subject or host being treated.
[0232] The amount of AAV compositions and the timing of administration of such compositions will be within the capabilities of those skilled in the art having the benefit of the teachings of the present invention. However, in some embodiments, administration of a therapeutically effective amount of the disclosed compositions can be achieved by a single administration, e.g., a single injection of a sufficient number of infectious particles to provide a therapeutic benefit to a patient receiving such treatment. This is made possible at least in part by the fact that certain target cells (e.g., neurons) do not divide, thereby eliminating the need for multiple or chronic administration.
[0233] In some embodiments, it may be advantageous to provide multiple or sequential administrations of an AAV vector composition over a relatively short or relatively extended period of time (which may be determined by a medical practitioner overseeing the administration of such compositions). For example, the number of infectious particles administered to a mammal may be about 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 1012 , 10 13 Or even higher infectious particles / ml, given in a single dose or divided into two or more administrations, as may be required to achieve therapy for the particular disease or condition being treated. Indeed, in certain embodiments, it may be desirable to administer two or more different AAV vector compositions, alone or in combination with one or more other therapeutic agents, to achieve the desired effect of a particular therapeutic regimen. In various embodiments, the daily dose and unit dose vary depending on a number of variables, including, but not limited to, the activity of the therapeutic rAAV composition used, the disease or condition to be treated, the mode of administration, the needs of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
[0234] The targeting peptides described herein can be used to generate rAAV with enhanced CNS tropism, wherein the capsid proteins are derived from different AAV serotypes (e.g., AAV9 and AAV1). In some embodiments, this can advantageously provide for the administration of two or more different AAV vector compositions without inducing an immune response in a subject.
[0235] The frequency of administration of rAAV virus can vary. For example, rAAV virus can be administered to a subject about once a week, about once every two weeks, about once a month, about once every six months, about once a year, about once every two years, about once every three years, about once every four years, about once every five years, about once every six years, about once every seven years, about once every eight years, about once every nine years, about once every ten years, or about once every fifteen years. In some embodiments, rAAV virus is administered to a subject at most about once a week, at most about once every two weeks, at most about once a month, at most about once every six months, at most about once a year, at most about once every two years, at most about once every three years, at most about once every four years, at most about once every five years, at most about once every six years, at most about once every seven years, at most about once every eight years, at most about once every nine years, at most about once every ten years, or at most about once every fifteen years.
[0236] Disclosed herein are kits including compositions disclosed herein. Also disclosed herein are kits for treating or preventing diseases or conditions of CNS, PNS or target organs or environments (e.g., CNS). In some cases, the disease or condition is cancer, pathogen infection, nervous system disease, muscle disease or immune disorder, such as those described herein. In one embodiment, the kit may include a therapeutic or preventive composition, which contains an effective amount of a composition of rAAV particles, and the rAAV particles encapsulate heterologous nucleic acids provided herein and rAAV capsid proteins disclosed herein. In another embodiment, the kit may include a therapeutic or preventive composition, which contains an effective amount of cells modified by rAAV described herein in a unit dosage form expressing therapeutic nucleic acids ("modified cells"). In some embodiments, the kit includes a sterile container, which may contain a therapeutic composition; such containers may be boxes, ampoules, bottles, vials, tubes, bags, pouches, blister packs or other suitable container forms known in the art. Such containers may be made of plastic, glass, laminated paper, metal foil, or other materials suitable for containing medications.
[0237] In some embodiments, the rAAV is provided with instructions for administering the rAAV to a subject having or at risk of developing a disease or condition. The instructions generally can include information regarding the use of the composition for treating or preventing a disease or condition.
[0238] The kit may comprise allogeneic cells. In some embodiments, the kit comprises cells that may include genomic modifications. In some embodiments, the kit comprises "off-the-shelf" cells. In some embodiments, the kit comprises cells that can be expanded for clinical use. In some embodiments, the kit contains inclusions for research purposes.
[0239] In some embodiments, the instructions include at least one of the following: a description of the therapeutic rAAV composition; dosage schedules and administration for treating or preventing a disease or condition disclosed herein; precautions; warnings; indications; contraindications; overdose information; adverse reactions; animal pharmacology; clinical studies; and / or references. These instructions can be printed directly on the container (if present), or as a label applied to the container or as a separate sheet, brochure, card, or folder provided in or with the container. In some embodiments, the instructions provide a procedure for administering rAAV alone to a subject. In some embodiments, the instructions provide procedures for administering the rAAV to a subject at least about 1 hour (hr), 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, or up to 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after or before administration of an additional therapeutic agent disclosed herein. In some cases, the instructions provide that the rAAV is formulated for intravenous injection. In some cases, the instructions provide that the rAAV is formulated for intranasal administration.
[0240] Examples
[0241] Some aspects of the embodiments discussed above are disclosed in further detail in the following examples, which are not intended to limit the scope of the disclosure in any way.
[0242] Example 1
[0243] Materials and Methods
[0244] The following experimental materials and methods were used in Examples 2 and 3 described below.
[0245] Plasmids
[0246] AAV capsid variants were subcloned into the pUCmini-iCAP-PHP.B backbone (Addgene ID: 103002). The ssAAV genomes used were pAAV:CAG-mNeonGreen (Addgene ID: 99134) and pAAV:CAG-2xNLS-EGFP (version equivalent to one NLS: Addgene ID: 104061), as shown in the figure and legend. Receptor candidate plasmids were purchased from GenScript. All selected open reading frame (ORF) clones were introduced into the pcDNA3.1+ / C-(K)-DYK backbone, except Lynx1 in pcDNA3.1. The AAV capsid library was amplified from the pCRII-9Cap-XE plasmid and subcloned into the rAAV-DCap-in-cis-Lox2 plasmid for transfection with AAV2 / 9REP-AAP-DCap.
[0247] animal
[0248] All animal procedures were approved by the California Institute of Technology Institutional Animal Care and Use Committee (IACUC) and complied with all relevant ethical regulations. C57BL / 6J (000664), BALB / cJ (000651), 129S1 / SvlmJ (002448), CBA / J (000656), DBA / 2J (000671), NOD / ShiLtJ (001976), Syn1-Cre (3966), GFAP-Cre (012886), Tek-Cre (8863), and Olig2-Cre (025567) mouse strains were purchased from Jackson Laboratory (JAX). Heterozygous Car4 knockout mice (008217) were cryopreserved by JAX and bred at Caltech to generate homozygous WT / WT and KO / KO animals. Six to eight-week-old male mice were injected intravenously with rAAV into the retro-orbital sinus. During the transduction phenotype test, mice were randomly assigned to specific rAAVs. The experimenters were not blinded for any of the experiments performed.
[0249] AAV vector production
[0250] AAV packaging and purification were performed as previously described. Briefly, rAAV was produced by triple transfection of HEK293T cells (ATTC, CRL-3216) using polyethyleneimine. The culture medium was collected at 72 and 120 hours post-transfection. The virus was precipitated in 2.5 M NaCl containing 40% polyethylene glycol. The virus was resuspended and incubated at 37°C with the cell pellet 120 hours post-transfection in 500 mM NaCl, 40 mM Tris, 10 mM MgCl2, and 100 U mL -1 The virus was purified by PCR and then concentrated to 5% phosphate buffered saline (PBS). The virus was then purified by PCR and the lysate was extracted by iodixanol (Cosmo Bio USA, OptiPrep, AXS-1114542) step gradient. The virus was then purified by PCR and the buffer was exchanged with phosphate buffered saline (PBS) before titration.
[0251] AAV vector administration, tissue processing, and imaging
[0252] As indicated in the figures and legends, AAV vectors were injected retroorbitally at 1 × 10 11 or 3×10 11 The dose of vg was intravenously administered to adult male mice. After three weeks of expression, mice were anesthetized with Euthasol (pentobarbital sodium and phenytoin sodium solution, Virbac AH Company (Virbac Ah)), and transcardially perfused with approximately 50 mL of 0.1 M PBS at pH 7.4, and then perfused with another 50 mL of 0.1 M PBS containing 4% paraformaldehyde (PFA). Organs were then collected, and fixed with 4% PFA overnight at 4°C, then washed and stored in 0.1 M PBS and 0.05% sodium azide at 4°C. Finally, the brain was cut into 100 μm slices on a Leica VT1200 vibrating microtome. Images were acquired with a Zeiss LSM 880 confocal microscope using a ×10 0.45M27 plan-apochromat (working distance, 2.0 mm) objective and processed in Zen Black 2.3SP1 (Zeiss) and ImageJ software.
[0253] Single-cell RNA sequencing analysis
[0254] As previously described, using the custom forkoff of scVI v0.8.1 and Scanpy v1.6.0, a pre-existing C57BL / 6J cortical single-cell RNA sequencing data set was analyzed in Python 3.7.4 with a custom-written script. In short, the droplets that passed quality control were classified as "neurons" or "non-neurons" using the trained scANVI cell type classifier, thereby retaining only those cells above the 0.05 false discovery rate threshold after multiple comparison corrections. Non-neuronal cells were further subtyped using the trained scVI model, and clustered based on the learned potential space using the Leiden algorithm implemented in Scanpy. If the endothelial cell cluster is positive for all marker genes of the cell subtype, these endothelial cell clusters are assigned. Membrane proteins are filtered by the Uniprot keyword 'cell membrane'. Differential expression scores are calculated in Scanpy.
[0255] Immunofluorescence
[0256] HEK293T cells were subjected to immunofluorescence experiments to label transiently transfected receptors such as Ly6a (Abcam ab51317, 1:200 dilution), Ly6c1 (Abcam ab15627, 1:200 dilution) and Car4 (Invitrogen PA5-47312, 1:40 dilution). HEK293T cells were seeded in 6-well plates at 80% confluence and maintained at 37°C in 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% fetal bovine serum (FBS), 1% non-essential amino acids (NEAA) and 100U / mL penicillin-streptomycin. Membrane-associated receptor candidates were transfected with polyethyleneimine (PolySciences No. 23966). 24 hours after transfection, cells were seeded on sterile German glass coverslips (Fisher Scientific No. NC0343705) coated with poly-D-lysine from Neuvitro in 24-well plates and then fixed in 4% paraformaldehyde once attached. Coverslips were blocked with 1× tris-buffered saline (TBS) containing 3% bovine serum albumin (BSA) for 30 minutes and incubated in primary antibodies in 1×TBS, 3% BSA, and 0.05% Triton X-100 for 60 minutes at ambient temperature. Coverslips were washed three times in 1×TBS and then incubated with secondary antibodies (Ly6a and Ly6c1: Invitrogen A-21247, 1:1000 dilution; Car4: Invitrogen A-21432, 1:1000 dilution) for 60 minutes in the same medium. Coverslips were mounted on slides using Diamond Antifade Mountant with DAPI (Invitrogen P36931). Fluorescence microscopic images were captured on a confocal laser scanning microscope (LSM 880, Carl Zeiss, USA).
[0257] Cell culture characterization of rAAV vectors
[0258] HEK293T cells were seeded at 80% confluence in 6-well plates and incubated at 37°C in 5% CO2 in a 5% CO medium supplemented with 5% FBS, 1% NEAA, and 100 U mL -1Membrane-associated receptor candidates were transiently expressed in HEK293T cells by transfecting each well with 2.53 μg of plasmid DNA. Cells expressing the receptors were transferred to 96-well plates at 20% confluence and maintained at 37°C in 5% CO2 in FluoroBriteTM DMEM supplemented with 0.5% FBS, 1% NEAA, 100 U mL-1 penicillin-streptomycin, 1× GlutaMAX, and 15 μM HEPES. Cells expressing each receptor candidate were transfected with engineered AAV variants in 1E9 vg wells. -1 and 5E8v.g. hole -1 Transductions were performed in triplicate. 24 hours after transduction, plates were imaged with a Keyence BZ-X700 using a 4x objective and NucBlue™ Live ReadyProbes™ reagent (Hoechst 33342) with automatic focus on each well.
[0259] Fluorescence image quantification of cell culture
[0260] All image processing was performed using a custom Python image processing pipeline. In short, cell areas were determined in both bright field and signal images. The percentage of transduced cells and the brightness of each transduced area were determined from these images.
[0261] First, the bright field image is background subtracted by applying a Gaussian blur (skimage.filters.gaussian, Σ=30, truncation=0.35) and subtracting the product from the original bright field image. In the bright field image, the outline of the cell is shown by the lamp, resulting in both bright and dark edges. Histogram-based thresholding is applied to these images to determine the bright and dark areas of the bright field image, which can be combined to create a mask of the cell edges in the image. The cells can be filled by applying skimage.morphology.closing, which runs a template on the image to fill a continuous area (skimage.morphology.disk, radius=2). Then, by adding all the pixels in the mask, the total area of the cell in the bright field image can be determined.
[0262] On the signal image, background subtraction was performed by applying a Gaussian blur (skimage.filters.gaussian, Σ=100). Subtracting the product of the Gaussian blur from the original signal image produced an image with minimal background intensity fluctuations. Histogram-based thresholding was applied to these images to identify the background intensity in the bright field image, and a mask was created in the image that included the bright areas of the transduced cells. Noise was removed from the mask using skimage.morphology.remove_small_objects(min_size=5). From this, the total area of the transduced cells was determined by adding all the pixels in the mask.
[0263] After this segmentation, the percentage of transduced cells was determined by taking the ratio of the signal area to the total cell area. The total brightness of the transduced cells was determined by multiplying the mask by the original image and adding all pixel intensities in the product image. This value was then divided by the total area of the transduced cells to determine the brightness of each transduced area.
[0264] Receptor protein production
[0265] Ly6a-Fc was produced in Expi293F suspension cells grown in Expi293 expression medium (Thermo Fisher Scientific) at 37°C, 5% CO2 in an incubator with shaking at 130 rpm. Expifectamine was used for transfection according to the manufacturer's instructions (Thermo Fisher Scientific). After collecting the cell conditioned medium, 1M Tris at pH 8.0 was added to a final concentration of 20 mM. Ni-NTA agarose (QIAGEN) was added to about 5% of the volume of the conditioned medium. 1M sterile PBS at pH 7.2 (GIBCO) was added to about 3× the volume of the conditioned medium. The mixture was stirred overnight at 4°C. Ni-NTA agarose beads are collected in a Buchner funnel, and washed with approximately 300 mL protein wash buffer (30 mM HEPES, pH 7.2, 150 mM NaCl, 20 mM imidazoles). Beads are transferred to an Econo-Pak chromatographic column (Bio-Rad), and eluted protein in 15 mL elution buffer (30 mM HEPES, pH 7.2, 150 mM NaCl, 200 mM imidazoles). Amicon Ultracel 10K filter (Millipore) is used to concentrate protein. Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific) is used to measure the absorbance at 280 nm to determine protein concentration.
[0266] Surface plasmon resonance (SPR)
[0267] SPR was performed using Sierra SPR-32 (Bruker). Ly6a-Fc fusion protein in HBS-P+ buffer (GE Healthcare) was immobilized on a protein A sensor chip at a capture level of approximately 1200-1500 response units (RU). -1 The flow rate was 2 × 10 12 vgm -1 Initial rAAV with a contact time of 240 seconds and a dissociation time of 600 seconds. After each cycle, the Protein A sensor chip was regenerated with 10 mM glycine, pH 1.5. Kinetic data have been double referenced.
[0268] Automated Paired Peptide Receptor Assay for Screening Engineered AAVs (APPRAISE-AAV)
[0269] FASTA format files containing the target receptor amino acid sequence (mature protein only) and the peptide sequences corresponding to amino acids 587 to 594 (wild-type AAV9 VP1 index) from the two AAV capsids of interest were used for structure prediction using a batch version of ColabFold (alphafold-colabfold 2.1.14), a cloud-based multiple sequence alignment implementation, and AlphaFold2 Multimer. ColabFold Jupyter notebooks were run on a Google Colaboratory session using a GPU (NVIDIA Tesla V100SXM216GB; GPUs for the same model were found to produce the most consistent results). Unless otherwise stated, Alphafold2-multimer-v2 was used as the default AlphaFold version. Each model was re-cycled three times, and ten models were generated for each competition. Models were quantified using PyMol (version 2.3.3) using a custom script to count the total number of atoms in the interface of the peptide in each putative peptide-receptor complex model ( defined by a distance cutoff of 5 angstroms), the total number of atoms in the peptide that collide with the receptor ( Depend on The distance cutoff value was defined), the peptide binding angle (θ, defined as the angle between the vector from the receptor center of gravity to the receptor anchor and the vector from the receptor center of gravity to the peptide center of gravity), and the binding depth (d, defined as the difference between the distance between the point on the peptide closest to the receptor center and the minor radius of the receptor ellipsoid shell normalized to the minor radius). The minor radius of the receptor ellipsoid shell was measured using HullRad 8.1 (Ly6a: Ly6c1: Mouse CAR4: ). Finally, the metric ΔB for ranking receptor binding propensities was calculated by subtracting the corresponding scores of competitor peptides from the total binding score of the peptide of interest. POI,竞争者 :
[0270]
[0271] The definitions of the terms are as follows:
[0272]
[0273] The average of this metric across replicates was used to form a matrix and plot a heat map. The peptides in the heat map were ranked by the total number of competitions each peptide won minus the total number of competitions it lost (ΔB with a p-value greater than 0.05 in a single-sample Student's t-test was excluded). POI,竞争者 Rating competition).
[0274] Computational structural modeling of the receptor-AAV complex
[0275] The peptide-receptor structures were modeled using a procedure similar to that described in the APPRAISE-AAV section, but with only a single peptide of interest in the input file to achieve greater accuracy.
[0276] The AAV trimer-receptor complex model was generated using an integrated structural modeling approach ( Fig.13A). The trimer at the AAV three-fold symmetric interface was selected as the minimum complete binding interface with a putative receptor that could reproduce the entire virus particle while optimizing computational efficiency. First, as described above, a peptide-receptor model was generated by modeling a 15-mer peptide sequence between residues 587 and 594 (both in the wild-type AAV9 VP1 index) from the AAV variant of interest in complex with the target receptor. Then, the trimer model of the AAV variant of interest was modeled using AlphaFold2 Multimer. The two residues Pro5' and Phe6' with the highest confidence score (pLDDT score) in the 15-mer peptide of the peptide-receptor model were structurally aligned with the corresponding residues on the first chain of the trimer model. Then, a rough combined model was generated by combining the receptor and two high-confidence AAV residues in the peptide receptor model with the remaining AAV residues in the trimer model. The two loops between Pro5' and Phe6' and the high-confidence AAV9 backbone in the rough combined model (corresponding to residues 588-(588+)4' and residues (588+)7'-590, respectively) were then remodeled individually using RosettaRemodel in the Rosetta software package (version 2018.48.60516). Finally, these remodeled loops were merged to generate the final model. The pLDDT score for each residue in the original AlphaFold2 output was used to color the image of the final model.
[0277] PHP.eC's M-CREATE selection
[0278] AAV capsid libraries were generated in vivo, administered, and recovered after selection for next generation sequencing as previously described. Briefly, an initial library was generated by incorporating three amino acid NNK substitutions from a 7-mer insertion of AAV9 position 590 scanned from AAV9 587 to AAV-PHP.C1, C2, C3, and C4 ( Figure 5A ). Twist Biosciences synthesized a custom designed synthetic second-round library in equimolar ratios containing degenerate codon copies of 5515 capsid variants identified after selection from the first-round library and spike-in controls. To prevent capsid mosaicism, only 10 ng of the assembled library was transfected per 150 mm 293T producer cell culture dish, and assembled capsids were purified 60 hours after transfection. In Syn-Cre mice, the first-round library was transfected at 5 × 10 per mouse. 10vg were injected retro-orbitally, while the second round of libraries were injected at 5 × 10 per mouse in Syn-Cre, GFAP-Cre, Tek-Cre, Olig2-Cre, wild-type C57BL / 6J, and wild-type BALB / cJ mice. 11 vg was injected retro-orbitally.
[0279] Two weeks after injection, mice were euthanized, and all organs including brain were collected, snap frozen on dry ice, and stored at -80°C. Frozen tissues were homogenized using a Beadbug homogenizer (homogenizer, Benchmark Scientific, D1032-15, D1032-30, D1033-28), and rAAV genomes were extracted in Trizol mode. Purified rAAV DNA (Zymo DNA Cleaning and Concentrator Kit D4033) was amplified by PCR using Cre-dependent primers, thereby adding flow cell adapters around the diversified regions for next generation sequencing. As previously described, NGS data were aligned and processed to extract round 1 variant sequence counts and round 2 variant enrichment scores.
[0280] Example 2
[0281] Identification of carbonic anhydrase IV and murine restricted Ly6c1 as novel targets for crossing the blood-brain barrier
[0282] This example demonstrates the identification of carbonic anhydrase IV and murine restricted Ly6c1 as two new targets for crossing the blood-brain barrier. By screening a select pool of 40 candidate receptors selected for their CNS expression levels intersecting with endothelial cell specificity, Ly6c1 and carbonic anhydrase IV were identified as molecular receptors for enhanced BBB crossing of ten Ly6a-independent engineered AAVs (as well as Ly6a-dependent PHP.N). These findings allow for more efficient allocation of NHPs, provide information for future directed evolution library design, and enable receptor-guided engineering to be directly used for human protein interactions.
[0283] Identification of engineered AAVs that do not utilize Ly6a
[0284] Ly6a is the receptor responsible for the enhanced CNS tropism of PHP.B and PHP.eB in mice. A strain-specific SNP disrupts its GPI-anchored membrane localization ( Figure 1A ). Previously, the M-CREATE directed evolution selection platform was applied to a library of AAV9 variants (containing a seven-amino acid insertion at position 588 of capsid variable region VIII), leading to the identification of a family of engineered AAVs with distinct CNS tropisms and shared sequence motifs, represented by its founding member, AAV-PHP.B ( Figure 1B). The enhanced CNS potency of the variants was absent in BALB / cJ mice, a phenomenon that could be explained by their shared dependence on Ly6a for BBB crossing. Recently, multiple engineered AAVs outside the PHP.B sequence family were identified that retained their enhanced CNS tropism in BALB / cJ mice. Before attempting to de-orphanize these AAVs, their independence from Ly6a was first demonstrated.
[0285] To directly probe potential Ly6a binding interactions, surface plasmon resonance (SPR) was performed. To ensure that even weak interactions were detected, Ly6a was dimerized by fusion to Fc and immobilized at high density on a protein A chip. Each AAV analyte was tested over a range of concentrations ( Figure 1C ). As expected, AAV9 showed no evidence of binding at any concentration, and the PHP.B sequence family members all showed strong binding interactions with Ly6a. Although the exact affinity could not be determined due to avidity and mass transfer effects, the interaction profile was consistent with subnanomolar affinities. In contrast, all BALB / cJ-enhanced engineered AAVs were indistinguishable from AAV9 and thus did not show detectable interactions with Ly6a.
[0286] CNS efficacy of Ly6a-independent engineered AAV across genetically diverse mouse strains
[0287] To characterize strain-specific differences in the CNS potency of BALB / cJ-enhanced AAV, an exploratory evaluation of several genetically diverse mouse strains was performed ( Figure 2A-2C and Fig. 8A ssAAV (ss, single-stranded) containing CAG-mNeonGreen was used at 1×10 per animal. 11 vg was injected retro-orbitally. Tissue was collected and imaged 3 weeks after injection. The thalamus was chosen for comparison because all AAVs tested potently target this brain region. As expected, given their Ly6a interactions, PHP.eB and PHP.N showed enhanced efficacy in the 129S1 / SvlmJ and DBA / 2J mouse strains expressing membrane-localized Ly6a, and greatly reduced efficacy in the CBA / J and NOD / ShiLtJ mouse strains expressing GPI-disrupted Ly6a. However, Ly6a-independent AAVs showed different patterns of enhanced infectivity. Combinations of selective AAVs and mouse strains were explored in both sexes, with similar trends observed across strains ( Figure 8B The potentially higher potency observed in female mice could be due to AAV batch-to-batch differences or sex-related differences in AAV potency.
[0288] Previously, genetic techniques were used to identify the Ly6a receptor. Following this approach to identify the receptor responsible for enhanced CNS transduction of Ly6a-independent vectors, C57BL / 6J and CBA / J mice were crossed and the vector PHP.C3 was tested in their offspring (F1). If the receptor was inherited similarly to Ly6a, an intermediate phenotype would be expected. Both parental strains and F1 adults were injected retro-orbitally with 3×10 11 vg. After 3 weeks, tissues were harvested and imaged. Surprisingly, at this higher dose, PHP.C3 demonstrated robust CNS infectivity in all three populations ( Figure 8C ). This dose dependence suggests subtle mechanistic differences in the presence or absence of individual receptors, which led to the application of different approaches.
[0289] Construction of cell culture screens for putative receptors for engineered AAV
[0290] Receptors to which engineered AAVs can be assigned for efficient BBB crossing are likely to be both highly expressed and highly specific for endothelial cells of the brain. Therefore, single-cell RNA sequencing data previously collected from dissociated C57BL / 6J brain tissue were analyzed ( Figure 3A ). Gene expression levels and differential expression compared to all other CNS cell type clusters were studied in the CNS endothelial cell cluster. Before calculating the endothelial cell differential expression score of the gene in Scanpy, these genes were filtered to select only genes annotated as being located in the plasma membrane in Uniprot. Then, these scores were plotted for the average abundance of each transcript, thereby revealing a long tail of highly expressed and highly specific CNS endothelial membrane proteins. Encouragingly, Ly6a appears at the distal end of this tail. According to this analysis, a group of 40 abundant and specific candidate receptors (Table 3) were selected.
[0291] Table 3: Single-cell RNA sequencing profiles of C57bL / 6J brain endothelial cell membrane proteins included in the cell culture screen
[0292] name Accession Number Average expression Differential expression Abcb1a NM 011076.2 0.000688904 7.942371 Abcg2 NM 011920.3 0.000745241 5.5607147 Acvrl1 NM 009612.3 0.000485079 6.7861333 Adgrf5 NM_001357332.1 0.000546496 7.453164 Adgrl4 NM_133222.3 0.000763887 8.241394 App NM_001198823.1 0.000845707 0.04600084 Bsg NM_009768.2 0.013027801 4.6841507 Car4 NM_007607.2 0.000713242 3.7107854 Cd34 NM_133654.3 0.000467251 3.0983913 Cdh5 NM_009868.4 0.000332645 7.486805 Cldn5 NM_013805.4 0.005443705 9.174832 Clec2d NM_053109.3 0.000584914 6.370406 Clic1 NM_033444.2 0.000377934 2.6402416 Clic4 NM_013885.2 0.000408817 3.1440303 Eng NM_007932.2 0.000646813 5.9965453 Esam NM_027102.3 0.000660755 6.0463476 Fcg NM_010189.3 0.000503876 4.028085 Flt1 NM_010228.3 0.002267079 8.539886 Ifitm2 NM_030694.1 0.000314049 3.5160391 Ifitm3 NM_025378.2 0.001015794 5.313354 Igf1r NM_010513.2 0.000750016 3.374137 Itm2b NM_008410.2 0.001596154 -0.10450481 Kdr NM_010612.2 0.000304256 6.8344116 Kitl NM_013598.3 0.000382663 3.2804174 Ly6a NM_010738.3 0.002695857 8.700766 Ly6c1 NM_010741.3 0.00381227 8.841889 Ly6e NM_008529.3 0.001050145 2.9547617 Ocln NM_008756.2 0.000208863 6.836091 P5 NM_028748.2 0.000262998 7.7742887 Pecam1 NM_008816.3 0.000423881 7.1343536 Podxl NM_013723.3 0.000407256 6.3635473 Prom1 NM_001163577.1 0.000271125 5.4568763 Serinc3 NM_012032.4 0.000562215 1.2317827 Slc22a8 NM_001164634.1 0.000243451 5.054169 Slc2a1 NM_011400.3 0.001843255 5.4381437 Slc6a6 NM_009320.4 0.001148025 3.8466463 Slc7a1 NM_007513.4 0.000403344 4.1706085 Slco1A4 NM_030687.1 0.001701704 8.396132 Slco1c1 NM_021471.2 0.000828427 3.688315 Tek NM_013690.3 0.000224058 7.496325
[0293] It has been observed that at low multiplicity of infection (MOI), expression of membrane-localized Ly6a in HEK293 cells selectively enhanced the efficacy of PHP.eB infection compared to AAV9, with a significant increase in the extent of infection and brightness of infected cells ( Fig.9A This property is likely to be conserved among BBB-spanning receptors. Therefore, this behavior forms the basis for transient overexpression screening of receptors ( Figure 3B and Figure 3CThe C57BL / 6J coding sequence for each of the 40 candidate receptors was cloned into a mammalian expression plasmid and tested in triplicate against the engineered AAV at two different doses ( Figure 3A and Figure 3D ). PHP.eB was paired with Ly6a to serve as a positive control.
[0294] As expected, all members of the PHP.B sequence family showed a significant increase in infectivity in Ly6a-transfected cells compared to untransfected cells, whereas Ly6a-independent AAVs performed equally well in both conditions ( Figure 3D , Figure 3E and Fig. 9B Interestingly, the infectivity of all Ly6a-dependent capsids was enhanced to a similar extent ( Fig. 10B ).
[0295] Identification of Ly6c1 and Car4 as receptors for BBB crossing by Ly6a-independent engineered AAVs
[0296] Enhanced infectivity was observed for all tested Ly6a-independent AAVs harboring the novel receptor ( Figure 3D Surprisingly, given their diverse sequence families and strain-dependent patterns of CNS potency at low doses, all of the initial Ly6a-independent AAVs responded to the same candidate receptor, Ly6c1 ( Figure 3D-Figure 3G and Fig. 9B ). In addition, although the PHP.N cross-murine strain has a Ly6a-dependent CNS infectivity pattern, it also exhibits enhanced infectivity in Ly6c1-transfected cells. At higher doses, PHP.N outperformed both AAV9 and PHP.eB in CBA / J mice ( Fig.11A and Fig. 11B ), which expresses GPI-disrupted Ly6a. Although polymorphisms in Ly6c1 exist in mouse strains (as shown in a published analysis of 36 mouse strains for which the complete genomes are available), none of these polymorphisms correlated with the pattern of CNS potency of any of the eight Ly6c1-interacting AAVs. Additionally, unlike Ly6a, none of these polymorphisms were predicted to disrupt GPI anchoring of Ly6c1 to the plasma membrane using PredGPI. To determine the specificity of the Ly6c1 interaction, a subsequent screen was performed against additional closely related and CNS-expressed Ly6 superfamily members. No cross-reactivity of the Ly6c1-dependent AAVs with other Ly6 proteins was found ( Figure 3GCAP-B10 and CAP-B22, which have seven amino acid substitutions in the capsid variable region IV and showed enhanced potency in adult marmosets, did not show any additional receptor interactions in either the above screen or in a third screen with Ly6 family members expressed in the marmoset CNS ( Fig. 10C ), which would explain its NHP tropism. Furthermore, Ly6-interacting AAVs did not cross-react with the recently described human Ly6S, a close relative of murine Ly6a ( Figure 3G ).
[0297] Subsequent screening of Ly6 has been expanded to include a second panel of previously identified engineered AAVs (9P), which generated additional Ly6a- and Ly6c1-interacting AAVs ( Figure 3G ). However, 9P31 and 9P36 did not show enhanced infectivity to any Ly6 protein in the figure and were therefore tested in the complete receptor screen ( Figure 3D ). Both 9P31 and 9P36 showed enhanced infectivity of the GPI-linked enzyme Car4 ( Figure 3D and Fig. 9B This interaction is specific for Car4 in membrane-associated carbonic anhydrase ( Figure 3G ). As with Ly6c1, polymorphisms in Car4 across mouse strains are not predicted to affect GPI anchoring to the plasma membrane. Unlike Ly6a and Ly6c1, which are restricted to mice, Car4 is conserved throughout vertebrates, including nonhuman primates and humans. Therefore, Car4 knockout mice (B6.129S1-Car4 tm1Sly / J, Jackson Laboratory strain number 008217) confirmed the screening results in vivo. Immunofluorescence confirmed that Car4 was strongly expressed throughout the brain vasculature of homozygous WT / WT mice and was completely absent in KO / KO ( Figure 4A ). When each animal was given 3×10 11 vg, PHP.eB, 9P31, and 9P36 were strongly expressed in both the brain and liver of wild-type mice ( Figure 4B ). Under the same conditions in KO / KO mice, PHP.eB was unaffected, whereas both 9P31 and 9P36 completely lost their enhanced CNS tropism ( Figure 4C and Fig. 11B On the other hand, liver tropism was not associated with this effect, with all three viruses showing robust transduction in KO / KO mice. It is possible that any differences in the potency of 9P31 and 9P36 in the periphery of KO / KO mice may be due to pharmacokinetic effects that no longer efficiently enter the CNS.
[0298] Notably, each of the AAVs tested showed modest enhancement of infectivity in cells transfected with Slco1c1 (also known as Oatp1c1), an integral membrane anion transporter ( Figure 3D However, unlike cells transfected with other potential receptors, the mNeonGreen signal in cells transfected with Slco1c1 was weak and diffuse, extending beyond the cell borders ( Fig. 9C ), which is indicative of transgene export or cell health phenotype. The ubiquity of this effect and the specificity of Slco1c1 expression in the brain suggest that it may play a role in the poor BBB transcytosis of the parental AAV9. None of the other 36 candidate receptors produced meaningful enhancement of infectivity for any of the 16 engineered AAVs screened.
[0299] Example 3
[0300] Receptor-binding peptides and engineered AAVs for BBB crossing
[0301] This example demonstrates the design of receptor binding peptides and engineered AAVs comprising receptor binding peptides and demonstrates their enhanced efficacy at BBB crossing.
[0302] Directed evolution of improved Ly6c1-dependent capsids
[0303] Despite an incomplete understanding of the underlying biological systems, directed evolution is a powerful approach for generating biomolecules with enhanced fitness for desired properties. Importantly, the results of directed evolution libraries can in turn be used to unlock new biomolecules by probing the mechanisms of action of molecules with evolved properties. This reverse engineering-directed evolution paradigm has been applied to accumulate a large amount of data obtained by applying selective pressure to AAV libraries to enrich for the CNS after systemic administration.
[0304] Proof of concept for receptor-targeted directed evolution was demonstrated. For this purpose, the murine receptor Ly6c1 (vs. human Car4) was chosen due to (1) a strain with distinct BBB differences (e.g., Ly6a), and (2) the availability of distinct Cre transgenic animals for M-CREATE selection, which are not available for Car4 in other species. Additionally, given the mixed background of preclinical animal models, it remains important to have mechanistically distinct gene delivery vectors for rodents. Therefore, using the previously developed M-CREATE approach for directed evolution of AAV capsids, a single optimized capsid was engineered for widespread adoption as a research tool for the GPI-disrupted Ly6a mouse strain, an unmet need ( Figure 5A-5D). This approach uses Cre-dependent AAV genomes recovered from desired tissues and cell types following in vivo selection in Cre transgenic mice and allows for in-depth characterization of selected capsids across various cell types and tissues.
[0305] Using M-CREATE, scanning 3-mer replacement capsid libraries were constructed in chemically distinct Ly6c1 interacting variants PHP.C1, PHP.C2, PHP.C3, and PHP.C4. These libraries were combined for two rounds of selection in Syn-Cre mice ( Figure 5A In the second round of selection, Olig2-Cre, Tek-Cre, and GFAP-Cre mice were also included along with wild-type C57BL / 6J and BALB / cJ mice so that potential differences in enhancement between these strains or cell types could be detected during selection in the variants ( Figure 5B Interestingly, while the PHP.C2 variant dominated both rounds of selection (Cre-dependent or -independent) in the C57BL / 6J background, the PHP.C1 variant dominated the second round of Cre-independent selection in the BALB / cJ ( Fig.12 After selection, the best performing variants were generated and characterized. AAV-PHP.eC (variant 19), derived from PHP.C1, retained Ly6c1 interaction in cell culture ( Figure 5C ), and outperformed PHP.C2 in multiple mouse strains with membrane-disrupted Ly6a ( Figure 5D ). Thus, PHP.eC provides a powerful tool for transgene delivery in mouse strains lacking membrane-localized Ly6a.
[0306] Although the differences in their capsid insertion sequences and their CNS efficacy patterns across genetically diverse mouse strains at low doses indicate potential different mechanisms for crossing the BBB, nine capsids were found to interact with the same receptor Ly6c1. Efficacy differences across mouse strains can be highly dose-dependent, as shown in PHP.C3 and PHP.N. This suggests that, in some cases, cell culture screening can be sensitive to interactions that may only become functionally relevant in vivo at higher doses. Although there are several Ly6c1 polymorphisms across mouse strains, no obvious pattern appears between mutant variants and AAV strain efficacy, which is similar to the observations in Ly6a-dependent AAV. In addition, unlike Ly6a, sequence polymorphisms are not predicted to interfere with Ly6c1 GPI anchoring, and therefore interfere with membrane localization. Ly6c1 expression levels are also consistently high in inbred (in-bred) mouse strains, but are significantly lower in recent wild-derived mouse strains. This suggests that the low-dose efficacy pattern observed here may result from differences in how the individual Ly6c1 binding footprint of each AAV is affected by strain-dependent sequence polymorphisms or from unidentified off-target interactions.
[0307] AlphaFold2-based method identifies receptor-binding peptides and engineered AAV binding poses by computer simulation
[0308] After identifying a set of receptors and AAV capsid pairs, the binding poses of engineered AAV and its newly identified receptors were generated using protein structure prediction methods. The computational method based on AlphaFold2 was applied to perform APPRAISE-AAV. The APPRAISE-AAV computer simulation method can be applied to any existing engineered capsid library data set to mine capsid variants that may interact with selected target receptors (including carbonic anhydrase IV (e.g., Car4)). The modeling pipeline can also provide high-confidence binding models for AAV receptor complexes that have been proven difficult to distinguish structurally. AAV is used as an example to demonstrate the method of this computer simulation, however, the APPRAISE method is not limited to AAV. In addition, the pipeline for generating a complete AAV trimer complex structure can be easily used to guide the insertion and translation of engineered peptides identified by directed evolution in AAV into other protein forms.
[0309] Specifically, the APPRAISE-AAV in silico approach uses AlphaFold2 to allow surface-exposed peptides (AA587-594) from two different AAV variants to be inserted across mutagenesis to interact with potential receptors in competition ( Fig. 6A). This included minimal peptides to cover the solvent exposed residues of capsid variable region VIII. A combination of physical and geometric scoring parameters, including the results of interface energy, binding angle, and binding pocket depth calculations, were used to generate peptide competition metrics. The results of these individual pairwise competitions can be assembled into a larger matrix that ranks the set of AAV capsid insert peptides according to their receptor-binding probabilities encoded in the AlphaFold2 neural network. When applied to Ly6a and the newly identified receptors, the experimentally validated Ly6a, Ly6c1, and Car4 insert peptides rose to the top of their corresponding rankings ( Figure 6B-6C ). However, some false negatives were also observed, such as in 9P08 with Ly6a or 9P36 with Car4.
[0310] In addition to predicting whether a peptide binds to a receptor, the structural details of the binding interaction were computationally interrogated. Binding poses were generated by pairing the leading AAV insert peptide with its receptor. Each pair was validated by repeating the cell culture screen with receptors containing point mutations that were hypothesized to disrupt high-confidence regions of the binding interface in these predicted poses (as determined by the estimated per-residue model confidence pLDDT score and consistency between replicate models). The PHP.eB peptide was predicted to fit into the groove of Ly6a, resulting in a cleavage at Pro5' and Phe6' ( Fig.6D ) forms strong interactions with several Ly6a residues ( Fig. 6E ). Therefore, a point mutation Ly6a Ala58Arg was introduced in this groove and was found to abolish the enhanced infectivity of PHP.eB to the wild-type receptor. This experimental result further strengthened the confidence of the in silico APPRAISE-AAV sequencing.
[0311] To fully understand the AAV-receptor interaction, the PHP.eB inserted peptide and Ly6a receptor complex was modeled in the context of the AAV capsid three-fold symmetric spike. This structure is challenging for standard modeling tools because of the large size of the AAV capsid (~200 kDa per trimer) and the fact that the binding interactions between the engineered capsid and the receptor are typically weak and dynamic (μM affinity, possibly no avidity). AlphaFold2 failed to capture direct contacts of the full-length PHP.eB capsid with Ly6a in either the monomer-receptor or trimer-receptor configurations (data not shown). To address this challenge, an integrated structural modeling pipeline was developed. In this pipeline, the initial model of the AAV capsid trimer predicted using AlphaFold2-Multimer was structurally aligned with the peptide-receptor complex model predicted by AlphaFold2 in the context of the AAV capsid three-fold symmetric spike, with high-confidence Pro5' and Phe6' residues of the peptide insertion and Rosetta Remodel optimization of the connecting peptide residues. Fig.13A ). This complete binding model ( Fig. 6E ) provide a snapshot of dynamic interactions that have so far proven resistant to high-resolution structural characterization.
[0312] The PHP.eB-Ly6a model results are consistent with available experimental results. The root mean square deviation (RMSD) between the PHP.eB monomer model and the cryo-EM-based model (PDB ID: 7WQO) is 0.36 Å. The RMSD in the engineered loops of PHP.eB increases to 1.36 Å. The only high-confidence deviation from the cryo-EM structure of uncomplexed PHP.eB is the side chain of Phe6', which shows no significant electron density, indicating flexibility, but forms a stable interaction with Ly6a in the PHP.eB monomer model ( Fig. 13B , right). The high confidence predictions for Pro5' and Phe6' are consistent with recent evidence suggesting that insertion of the PFK 3-mer alone is sufficient to obtain Ly6a binding. Although Ly6a can bind to any of the inserted loops of the trimer, additional interactions induce steric clashes that favor a ratio of one Ly6a per capsid trimer. Interestingly, the assembly image of the PHP.eB-Ly6a complex forced to contain 60 bound copies of Ly6a resembles a recently reported cryoEM map whose analysis pipeline averages all 60 individually occupied binding sites to form a composite map ( Fig. 13C The PHP.eB-Ly6a complex model shows that single copies of both Ly6a and the AAVR PKD2 domain can bind to the same triple spike simultaneously without conflict ( Fig.13D), which is consistent with saturation binding experiments. Consistent with previous work showing that Ly6a SNP D63G does not affect PHP.eB binding, residues in the PHP.eB-Ly6a complex model are greater than 10 angstroms from PHP.eB peptide atoms. The PHP.eB-Ly6a complex model contains several interactions involving residues adjacent to the AAV insertion, which is consistent with previous reports ( Figure 6G ).
[0313] These structural modeling methods were then applied to the newly identified receptors. Interestingly, unlike Ly6a and Car4, the predicted binding pose of the PHP.C2 peptide to Ly6c1 was found to differ depending on the AlphaFold-Multimer version used, with the v1 predictions closely matching the mutational data from the cell culture infectivity assay ( Fig.14A ). This type of complementarity between versions has been reported previously. In mouse Car4, the 9P31 peptide invades the catalytic pocket of the enzyme ( Fig. 7A ). The tyrosine residue shared by 9P31 and 9P36 is close to the enzyme active site, and the divergent tryptophan of 9P31 is found in the auxiliary pocket ( Figure 7B ). This predicted binding pose competes with the binding site of brinzolamide (PDB ID 3NZC), a broad carbonic anhydrase inhibitor used in glaucoma medication. In a cell culture infectivity assay, brinzolamide showed dose-dependent inhibition of 9P31 and 9P36 potency, while PHP.eB was unaffected ( Figure 7B The smaller brinzolamide binds deep within the catalytic core of Car4, where the side chains are largely conserved between species ( Figure 7C ). However, the 9P31 peptide extends to the surface of the enzyme where there is considerable sequence divergence. Similarly, while brinzolamide binds to both mouse and human CAR4, 9P31 and 9P36 are specific for mouse CAR4 ( Fig.7D Chimeric receptors that swapped the highly divergent loops of the 9P31 binding site showed that this region is necessary but not sufficient to control the potency of 9P31 and 9P36. A second potential Car4 binding site was also proposed by lower-ranked positions of 9P31 and 9P36, but mutagenesis experiments showed inconsistent results ( Fig. 14B ). In the future, rational engineering of new AAVs targeting CA4 of the appropriate species with the help of the APPRAISE-AAV approach is a promising new approach to generate non-invasive vectors with enhanced CNS potency. Targeting CA4 may also find application in a variety of protein and chemical forms. In vivo experiments can be performed to further validate the engineering of human CA-binding AAVs with optimal BBB-crossing properties.
[0314] In at least some of the foregoing embodiments, one or more elements used in one embodiment may be used interchangeably in another embodiment, unless such replacement is technically infeasible. It should be understood by those skilled in the art that various other omissions, additions, and modifications may be made to the above methods and structures without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter defined by the appended claims.
[0315] With respect to the use of substantially any plural and / or singular terms herein, those skilled in the art may convert the plural to the singular and / or the singular to the plural where appropriate for the context and / or application. For clarity, various singular / plural arrangements may be explicitly listed herein. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly indicates otherwise. Unless otherwise indicated, any reference to "or" herein is intended to encompass "and / or".
[0316] One of ordinary skill in the art will understand that, in general, the terms used herein and particularly in the appended claims (e.g., the bodies of the appended claims) are generally intended to be "open" terms (e.g., the term "including" should be understood as "including but not limited to," the term "having" should be understood as "having at least," the term "includes" should be understood as "including but not limited to," etc.). One of ordinary skill in the art will further understand that if a specific number of an introduced claim recitation is intended, such intent will be expressly stated in the claim, and in the absence of such statement, no such intent is present. For example, to aid understanding, the following appended claims may contain the use of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be interpreted as implying that the introduction of a claim recitation by the indefinite article "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim contains the introductory phrase "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should be interpreted as meaning "at least one" or "one or more"); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly stated, one skilled in the art will recognize that such a statement should be interpreted as meaning at least the stated number (e.g., a direct statement of "two recitations" means at least two recitations or two or more recitations in the absence of other modifiers). Furthermore, in those cases where a convention similar to “at least one of A, B, and C, etc.” is used, generally speaking, such convention is intended to be used in the sense that one skilled in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include, but not be limited to, systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In those cases where a convention similar to “at least one of A, B, or C, etc.” is used, generally speaking, such convention is intended to be used in the sense that one skilled in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include, but not be limited to, systems having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). One skilled in the art would further understand that, in fact, any transitional word and / or phrase presenting two or more alternative terms, whether in the specification, claims, or drawings, should be understood to contemplate the possibility of including one, either, or both of the terms.
[0317] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0318] As will be understood by those skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily identified as fully describing and making the same range be decomposed into at least equal half, one-third, one-quarter, one-fifth, one-tenth, etc. As a non-limiting example, each range discussed herein can be easily decomposed into lower third, middle third, and upper third, etc. As will be understood by those skilled in the art, all languages such as "at most", "at least", "greater than", "less than", etc. contain the cited numbers and refer to the ranges that can be subsequently decomposed into the sub-ranges discussed above. Finally, as will be understood by those skilled in the art, the range includes each individual member. Therefore, for example, a group with 1-3 products refers to a group with 1, 2 or 3 products. Similarly, a group with 1-5 products refers to a group with 1, 2, 3, 4 or 5 products, etc.
[0319] While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.
Claims
1. A method for increasing the permeability of a blood-brain barrier, the method comprising: Targeting peptides are provided that are capable of binding to carbonic anhydrase IV, thereby increasing the permeability of the blood-brain barrier.
2. The method of claim 1, wherein at least one activity of the carbonic anhydrase IV is reduced by binding to a targeting peptide.
3. A method for increasing the permeability of a blood-brain barrier, the method comprising: Reduces carbonic anhydrase IV activity, thereby increasing the permeability of the blood-brain barrier.
4. A method according to any one of claims 1 to 3, wherein the targeting peptide binds to the zinc binding site and / or the hydrophobic substrate binding pocket of the carbonic anhydrase IV.
5. The method of any one of claims 1 to 4, wherein the permeability of the blood-brain barrier is increased by at least 25%, 50%, 75%, 100% or more as compared to the absence of the target peptide or the reduction of carbonic anhydrase IV activity.
6. A method of delivering a payload to a nervous system, the method comprising: Providing a targeting peptide or a derivative thereof capable of binding to carbonic anhydrase IV, wherein the targeting peptide is part of a delivery system, and wherein the delivery system comprises the payload to be delivered to the nervous system; and The delivery system is administered to a subject.
7. The method of claim 5, wherein the delivery system comprises nanoparticles, nanotubes, nanowires, dendrimers, liposomes, ethosomes and aquasomes, polymer vesicles and niosomes, foams, hydrogels, cubes, quantum dots, exosomes, macrophages, and combinations thereof.
8. The method of claim 5, wherein the delivery system comprises a viral vector or a non-viral vector.
9. The method of claim 8, wherein the viral vector comprises an adenoviral vector, an AAV vector, a lentiviral vector or a retroviral vector; and optionally wherein the target peptide is part of a capsid protein of an AAV vector.
10. The method of claim 9, wherein the AAV vector is a vector selected from the group consisting of AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-DJ, human isolate hu.31, human isolate hu.32, rhesus monkey isolate rh.8, rhesus monkey isolate rh.10, and variants thereof.
11. The method of claim 8, wherein the non-viral vector comprises lipid-based nanoparticles, polymer nanoparticles, inorganic nanoparticles, surfactant-based emulsions, nanowires, silica nanoparticles, peptide- or protein-based particles, lipid-polymer particles, nanolipoprotein particles, and combinations thereof.
12. The method of any one of claims 5 to 11, wherein the payload to be delivered to the nervous system is a biological molecule, a non-biological molecule, or a combination thereof; and optionally wherein the biological molecule is selected from the group consisting of: a nucleic acid sequence, a protein, a peptide, a lipid, a polysaccharide, and a combination thereof.
13. The method of any one of claims 5 to 12, wherein the payload is a therapeutic molecule.
14. The method of claim 12, wherein the nucleic acid sequence to be delivered to the nervous system comprises one or more of: a) trophic factors, growth factors or other soluble factors that may be released from the transduced cells and affect the survival or function of the cells and / or surrounding cells; b) cDNA to restore protein function to humans or animals carrying a genetic mutation in a gene; c) cDNA encoding a protein that can be used to control or change the activity or state of a cell; d) cDNA encoding a protein or nucleic acid used to assess the status of a cell; e) cDNA and / or related guide RNA for genome engineering; f) sequences for genome editing by homologous recombination; g) a DNA sequence encoding a therapeutic RNA; h) shRNA or artificial miRNA delivery system; or i) DNA sequences that affect the splicing of endogenous genes.
15. The method of any one of claims 1 to 14, wherein the carbonic anhydrase IV is mouse carbonic anhydrase IV; and optionally wherein the carbonic anhydrase IV has an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:
179.
16. The method of any one of claims 1 to 14, wherein the carbonic anhydrase IV is human carbonic anhydrase IV; and optionally wherein the carbonic anhydrase IV has an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:
180.
17. The method of any one of claims 1 to 16, wherein upon binding, the targeting peptide is capable of interacting with: (1) one or more positions functionally equivalent to S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 of the carbonic anhydrase IV having an amino acid sequence of SEQ ID NO: 179; or (2) one or more positions functionally equivalent to the carbonic anhydrase IV having an amino acid sequence of SEQ ID NO: The position of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 of the amino acid sequence of NO:
180.
18. according to the method described in any one of claims 1 to 17, wherein the targeting peptide comprises (1) an amino acid sequence selected from the group consisting of SEQ ID NO:70-174; or (2) an amino acid sequence having at least 80% sequence identity with the amino acid sequence selected from the group consisting of SEQ ID NO:70-174; optionally wherein the targeting peptide comprises an amino acid sequence selected from SEQ ID NO:70-108; and further optionally wherein the targeting peptide comprises an amino acid sequence selected from SEQ ID NO:70-86.
19. The method of any one of claims 1 to 18, wherein the targeting peptide comprises (1) an amino acid sequence selected from the group consisting of AKPTPLLGLLQAQTG (SEQ ID NO:70), AKPTPLLLLLQAQTG (SEQ ID NO:71), AQPPLGGLLAQAQTG (SEQ ID NO:72), AKPPGPWAEAQAQTG (SEQ ID NO:73), and AQPPLLGGLAQAQTG (SEQ ID NO:74); or (2) an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:70-74.
20. The method according to any one of claims 9 to 19, wherein the targeting peptide is inserted between two adjacent amino acids in AA587-594 of SEQ ID NO: 178 of the AAV9 vector, or between the functional equivalents of AA587-594 in an amino acid sequence that is at least 80% identical to SEQ ID NO:
178.
21. The method according to any one of claims 9 to 20, wherein the targeting peptide is inserted between AA588-589 of SEQ ID NO: 178 of the AAV9 vector, or between functional equivalents of AA588-589 in an amino acid sequence that is at least 80% identical to SEQ ID NO:
178.
22. The method of any one of claims 9 to 21, wherein the AAV vector is conjugated to a nanoparticle, a second molecule, or a combination thereof.
23. The method of any one of claims 5 to 22, wherein the administration is systemic administration; and optionally wherein the administration is intravenous administration or intrathecal administration.
24. The method of any one of claims 5 to 23, wherein the subject is a mammal; and optionally wherein the subject is a human.
25. The method of any one of claims 5 to 24, wherein the subject is a subject suffering from or at risk for one or more of: chronic pain, Friedreich's ataxia, Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy type I and II (SMA I and II), Friedreich's ataxia (FA), spinocerebellar ataxia, multiple sclerosis (MS), chronic traumatic encephalopathy (CTE), HIV-1 associated dementia, or a lysosomal storage disease involving cells within the CNS; and optionally wherein the lysosomal storage disease involving cells within the CNS is Krabbe disease, Sandhoff disease, Tay-Sachs disease, Gaucher disease, disease (type I, II, or III), Niemann-Pick disease (NPC1 or NPC2 deficiency), Hurler syndrome, Pompe disease, or Batten disease.
26. The method of any one of claims 5 to 24, wherein the subject is a subject suffering from, at risk of suffering from, or has suffered from stroke, traumatic brain injury, epilepsy, or spinal cord injury.
27. An adeno-associated virus (AAV) capsid protein comprising a targeting peptide having binding specificity for carbonic anhydrase IV.
28. The AAV capsid protein of claim 27, wherein the targeting peptide is a part of the capsid protein of the rAAV vector.
29. The AAV capsid protein of claim 27 or 28, wherein the targeting peptide is inserted between two adjacent amino acids in AA587-594 of SEQ ID NO: 178, or between functional equivalents of AA587-594 in an amino acid sequence that is at least 80% identical to SEQ ID NO:
178.
30. The AAV capsid protein of any one of claims 27 to 29, wherein the targeting peptide comprises (1) an amino acid sequence selected from the group consisting of SEQ ID NOs: 70-174; (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 70-174.
31. The AAV capsid protein of any one of claims 27 to 30, wherein AAV is a vector selected from the group consisting of AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-DJ, human isolate hu.31, human isolate hu.32, rhesus monkey isolate rh.8, rhesus monkey isolate rh.10, and variants thereof.
32. A recombinant adeno-associated virus (rAAV) comprising the AAV capsid protein according to any one of claims 27 to 31.
33. A recombinant adeno-associated virus (rAAV), comprising an AAV capsid protein, wherein the AAV capsid protein comprises a targeting peptide having binding specificity to carbonic anhydrase IV, wherein the amino acid sequence of the targeting peptide is inserted between two adjacent amino acids in AA587-594 of the AAV capsid protein or their functional equivalents.
34. The rAAV of claim 33, wherein the two adjacent amino acids are AA588 and AA589.
35. The rAAV of claim 33 or 34, wherein the targeting peptide comprises (1) an amino acid sequence selected from the group consisting of SEQ ID NOs: 70-174; or (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 70-174.
36. A composition for delivering an agent to the nervous system of a subject in need thereof, the composition comprising an AAV comprising (1) an AAV capsid protein according to any one of claims 27 to 31 and (2) an agent to be delivered to the nervous system of the subject; optionally wherein the nervous system is the central nervous system (CNS), the peripheral nervous system (PNS), or a combination thereof.
37. The composition of claim 36, wherein the nervous system is a brain endothelial cell, a neuron, a capillary in the brain, an arteriolar in the brain, an artery in the brain, or a combination thereof.
38. The composition according to any one of claims 36 to 37, wherein the composition is a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers.
39. The composition for use of any one of claims 36 to 38, wherein the agent to be delivered comprises a nucleic acid, a peptide, a small molecule, an aptamer, or a combination thereof.
40. An antibody or fragment thereof, wherein the antibody or fragment thereof comprises an amino acid sequence having binding specificity for carbonic anhydrase IV.
41. The antibody or fragment thereof of claim 40, comprising (1) an amino acid sequence selected from the group consisting of SEQ ID NOs: 70-174; or (2) an amino acid sequence having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 70-174.
42. The antibody or fragment thereof according to claim 40 or 41, wherein the antibody or fragment thereof is a bispecific antibody comprising at least one Fab specific for the carbonic anhydrase IV.
43. An antibody conjugate comprising the antibody or fragment thereof according to any one of claims 40 to 42, further comprising a therapeutic agent or a detectable label.
44. A peptide or derivative or conjugate thereof which is specific for carbonic anhydrase IV.
45. A nucleic acid comprising a sequence encoding the antibody or fragment thereof according to any one of claims 40 to 43 or the peptide or derivative or conjugate thereof according to claim 44.
46. A delivery system comprising (1) a targeting peptide specific for carbonic anhydrase IV; and (2) a pharmaceutical agent.
47. The delivery system of claim 46, wherein the targeting peptide is (1) displayed on the surface of the delivery system; or (2) partially embedded in the delivery system.
48. The delivery system of claim 46 or 47, wherein the delivery system is selected from the group consisting of nanoparticles, nanotubes, nanowires, dendrimers, liposomes, ethosomes and aquasomes, polymersomes and non-ionic surfactant vesicles, foams, hydrogels, cubes, quantum dots, exosomes, macrophages, and combinations thereof.
49. A delivery system according to any one of claims 46 to 48, wherein the delivery system comprises a viral vector or a non-viral vector.
50. according to the delivery system described in any one of claims 46 to 49, wherein said delivery system comprises nanoparticles selected from the group consisting of: lipid-based nanoparticles, polymer nanoparticles, inorganic nanoparticles, surfactant-based emulsions, nanowires, silica nanoparticles, virus-like particles, peptide- or protein-based particles, lipid-polymer particles, nanolipoprotein particles and combinations thereof.
51. A method for designing a targeting peptide specific for carbonic anhydrase IV, the method comprising: One or more targeting peptides are generated by computer simulation, and each of the one or more targeting peptides is capable of interacting with: (1) one or more positions S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223 or W228 of the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV; or (2) one or more positions functionally equivalent to the amino acid sequence of SEQ ID NO: 179 in the carbonic anhydrase IV. The position of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 of the amino acid sequence of NO:
180.
52. according to the method for claim 51, wherein generating described one or more targeting peptides by computer simulation comprises: Generate multiple candidate peptides through computer simulation; performing a computer-assisted docking simulation on each of the plurality of candidate peptides that bind to the carbonic anhydrase IV; as well as The structure of the carbonic anhydrase IV bound to one or more candidate peptides of the plurality of candidate peptides is analyzed to identify one or more targeting peptides capable of interacting with: (1) one or more positions S20, G21, W22, L36, W41, P42, E90, V111, Q112, H114, H139, V141, K143, F156, L217, T218, T219, P220, N221, D223, or W228 of the carbonic anhydrase IV having an amino acid sequence of SEQ ID NO: 179; or (2) one or more positions functionally equivalent to the carbonic anhydrase IV having an amino acid sequence of SEQ ID NO:
179. The position of S21, H22, W23, L37, W42, G43, M92, K113, Q114, H116, H141, V143, E145, Q158, L224, T225, T226, P227, T228, D231 or W236 of the amino acid sequence of NO:
180.
53. The method of claim 51 or 52, comprising: obtaining a binding score for each of the plurality of candidate peptides that binds to the carbonic anhydrase IV; as well as One or more candidate peptides having a binding score higher than a threshold value among the plurality of candidate peptides are selected as targeting peptides specific for the carbonic anhydrase IV.
54. The method of claim 53, comprising: The binding scores of two or more candidate peptides in the plurality of candidate peptides are compared to rank the candidate peptide sequences.
55. A method according to claim 53 or 54, wherein obtaining the binding score for each candidate peptide sequence in a plurality of candidate peptide sequences comprises (1) counting the total number of atoms in the interface between the candidate peptide and the carbonic anhydrase IV; (2) counting the total number of atoms in the candidate peptide where the atoms conflict with the carbonic anhydrase IV; (3) obtaining the binding angle of the candidate peptide; and (4) obtaining the binding depth of the candidate peptide.
56. A method of increasing the permeability of the blood-brain barrier of a murine species, the method comprising: Targeting peptides are provided that are capable of binding to Ly6c1, thereby increasing the permeability of the blood-brain barrier in said murine species.
57. The method of claim 56, wherein the targeting peptide has 1) an amino acid sequence selected from the group consisting of AQRYQGDSVAQ (SEQ ID NO:7), AQWSTNAGYAQ (SEQ ID NO:8), AQERVGFAQAQ (SEQ ID NO:9), AQWMTHGSAAQ (SEQ ID NO:10), and SPRYKGDSVAQ (SEQ ID NO:57); or (2) an amino acid sequence having at least 80% sequence identity to an amino acid sequence selected from the group consisting of AQRYQGDSVAQ (SEQ ID NO:7), AQWSTNAGYAQ (SEQ ID NO:8), AQERVGFAQAQ (SEQ ID NO:9), AQWMTHGSAAQ (SEQ ID NO:10), and SPRYKGDSVAQ (SEQ ID NO:57).
58. The method of claim 56, wherein the targeting peptide has an amino acid sequence of SPRYKGDSVAQ (SEQ ID NO: 57) or an amino acid sequence having at least 80% identity to SEQ ID NO:
57.
59. The method of claim 57 or 58, wherein the targeting peptide is inserted between two adjacent amino acids in AA587-590 of SEQ ID NO: 178, or between the functional equivalents of AA587-590 in an amino acid sequence that is at least 80% identical to SEQ ID NO: 178.
